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Summary/Zusammenfassung 
Summary 
Viral vectors are powerful tools for a steadily increasing number of applications in gene 
therapy and basic research. In recent years, many proof-of-concept studies and clinical trials 
resulted in important progress and benefit for patients. Strategies to customize viral vectors 
will be key to their future success. This thesis deals with viral vectors that were engineered to 
use a cell surface receptor of choice for cell entry. Such vectors can mediate a restricted gene 
delivery to a cell type defined by the targeted receptor. The first part of this thesis investigates 
lentiviral vectors (LVs) carrying engineered glycoproteins of measles virus (MV) to better 
understand the molecular events during particle cell entry that proceeds via membrane fusion. 
The second part focuses on adeno-associated viral vectors (AAV) which are non-enveloped 
particles. AAVs were engineered to assess their potential in detecting rare epithelial cell 
adhesion molecule (EpCAM)-positive tumor cells.  
The first step of MV infection is attachment mediated by the hemagglutinin (H) to one of its 
receptors which is thought to produce conformational changes in the membrane fusion protein 
(F) that trigger insertion of its fusion peptide into the target cell membrane. This fusion 
triggering model was challenged in this thesis by uncoupling the receptor attachment and the 
fusion-helper function of H by introducing mutations that made it blind to its normal 
receptors. An artificial receptor attachment protein specific for Her2/neu was incorporated 
into the membranes of pseudotyped lentiviral particles as a separate transmembrane protein 
along with H and F. Surprisingly, these particles entered efficiently into Her2/neu-positive 
SK-OV-3 as well as CHO-Her2 cells. Cell entry was pH-independent, required high-affinity 
receptor binding and was strictly dependent on the presence of H and F. H-specific 
monoclonal antibodies as well as mutations in H interfering with H/F interactions blocked cell 
entry. The vector particles mediated stable and specific transfer of reporter genes into 
Her2/neu-positive human tumor cells also in vivo, while exhibiting improved infectivity and 
higher titers as compared to conventional Her2/neu-targeted vectors displaying the targeting 
ligand on H. Additionally, several other targeting ligands were tested in this setting. 
Extending the current model of MV cell entry, the data suggest that receptor binding of H is 
not required for its fusion-helper function but particle-cell contact in general may be sufficient 
to induce the conformational changes in the H/F complex and to activate membrane fusion.   
Towards applying AAV targeting technology for the detection, modification or elimination of 
rare cells expressing EpCAM, which is a marker of circulating tumor cells (CTC), AAVs 
displaying designed ankyrin repeat proteins (DARPins) specific for EpCAM were generated. 
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The DARPin Ec1 was displayed on the particle surface and mediated EpCAM-specific gene 
transfer into receptor-positive cell lines which was further confirmed by competition 
experiments with the extracellular domain of EpCAM. Transduction was clearly receptor 
density-dependent and non-malignant EpCAM-positive primary cells were only poorly 
transducable ex vivo and in vivo. Performance of vector particles was further enhanced by ion 
metal affinity chromatography purification. To assess the potency of EpCAM-AAV in 
detecting rare EpCAM-positive tumor cells, low amounts of MDA-MB-453 tumor cells were 
mixed with isolated human PBMC. EpCAM-AAV tracked basically all of the tumor cells, 
even when these made up only 0.3% of the cell mixture. In a next step, the conditions of 
circulating tumor cells in whole blood were mimicked. As few as 150 tumor cells present in 
7.5 milliliters of human blood were readily detected by EpCAM-AAV suggesting that 
targeted AAVs form a new tool for the detection of rare tumor cells.  
The work of this thesis clearly demonstrates that receptor targeting of enveloped and non-
enveloped viral vectors is a flexible and versatile technique. Highlighting that both LVs and 
AAVs can be used not only as gene therapy vectors but also in virological research and 
diagnostics, these targeting systems open up new possibilities for a broad spectrum of 
applications.  
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Zusammenfassung 
Virale Vektoren haben sich als nützliche Hilfsmittel für eine immer größer werdende Zahl 
von Anwendungen in der Gentherapie aber auch in der Grundlagenforschung etabliert. In den 
letzten Jahren wurde die Weiterentwicklung dieser Vektoren von vielen Machbarkeits- und 
klinischen Studien vorangetrieben. Strategien um virale Vektoren so anzupassen, dass sie 
spezifische und individuelle Kriterien erfüllen, werden der Schlüssel zu ihrem weiteren Erfolg 
sein. Dies könnte zum Beispiel durch Ansteuern eines definierten Rezeptors und somit einen 
auf bestimmte Zelltypen begrenzten Gentransfer gewährleistet werden. Im ersten Teil dieser 
Dissertation wurden lentivirale Vektoren untersucht, die veränderte Glykoproteine des 
Masernvirus tragen, um die molekularen Ereignisse der Membranfusion während des 
Partikelzelleintritts besser zu verstehen. Im zweiten Teil stehen nicht-behüllte adeno-
assoziierte virale Vektoren (AAV) im Fokus. Diese wurden so modifiziert, dass sie seltene 
Tumorzellen, die das epitheliale Zelladhäsionsmolekül (EpCAM) exprimieren, detektieren 
können.   
Der erste Schritt einer Masernvirusinfektion besteht in der durch das Hämagglutinin (H) 
vermittelten Anbindung an einen der natürlichen Rezeptoren. Es wird angenommen, dass dies 
Konformationsänderungen im Fusionsprotein (F) hervorruft, die dann das Einlagern des 
Fusionspeptids in die Zielzellmembran einleiten. Dieses Fusionsmodell wurde in der 
vorliegenden Arbeit hinterfragt, indem die Rezeptoranbindung und die Fusionshelferfunktion 
des H voneinander entkoppelt wurden. Hierfür wurden Mutationen im H eingeführt, die zu 
einer Verblindung für die natürlichen Rezeptoren führte. Stattdessen wurde ein artifizielles 
Rezeptoranbindungsprotein, welches spezifisch für Her2/neu ist, zusammen mit H und F in 
die Membran von pseudotypisierten lentiviralen Vektoren eingebaut. Überraschenderweise 
waren diese Partikel in der Lage sowohl in Her2/neu-positive SK-OV-3 als auch in CHO-
Her2 Zellen einzudringen. Es konnte gezeigt werden, dass der Zelleintritt eine hoch-affine 
Rezeptoranbindung benötigte, pH unabhängig und grundsätzlich von der Anwesenheit von H 
und F abhängig war. H-spezifische monoklonale Antikörper so wie eine Mutation in H, 
welche die H/F Interaktion stört, blockierten den Zelleintritt. Die Vektorpartikel vermittelten 
stabilen und spezifischen Reportergentransfer in Her2/neu-positive humane Tumorzellen in 
vitro und in vivo und wiesen darüber hinaus eine erhöhte Infektiösität und höhere Titer als die 
konventionellen Her2/neu-Targetingvektoren auf. Zusätzlich wurden verschiedene andere 
Targetingliganden in diesem System getestet. Als Erweiterung des gegenwärtigen 
Masernviruszelleintrittmodells legen diese Daten nahe, dass Rezeptoranbindung des H für 
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dessen Fusionshelferfunktion nicht benötigt wird. Der Kontakt zwischen Partikel und Zelle 
könnte ausreichend sein, um die Konformationsänderungen im H/F-Komplex hervorzurufen 
und die Membranfusion auszulösen.  
Ein erster Schritt zur Anwendung von AAV-Vektoren für die Detektion, Modifikation oder 
Eliminierung von seltenen Zellen, die EpCAM, einen Marker für zirkulierende Tumorzellen 
(CTC), exprimieren, war die Generierung von AAVs, die EpCAM-spezifische „designed 
ankyrin repeat proteins“ (DARPin) einbauen. Das DARPin Ec1 wurde auf der 
Kapsidoberfläche des AAV präsentiert und vermittelte spezifischen Gentransfer in EpCAM-
positive Zelllinien, was durch Kompetitionsexperimente mit der extrazellulären Domäne von 
EpCAM bestätigt wurde. Die von EpCAM-AAV vermittelte Transduktion war eindeutig von 
der Rezeptordichte abhängig und außerdem in nicht-malignen, primären, EpCAM-positiven 
Zellen, sowohl ex vivo als auch in vivo, stark eingeschränkt. Des Weiteren konnte die 
Transduktionseffizienz von EpCAM-AAV durch die chromatographische Abtrennung von 
DARPin-defizienten AAV Partikeln, die bei der Vektorherstellung als Nebenprodukt 
entstehen, deutlich erhöht werden. Um das Potential von EpCAM-AAV zur Detektion von 
seltenen EpCAM-positiven Tumorzellen zu untersuchen, wurde eine geringe Anzahl von 
MDA-MB-453 Tumorzellen mit isolierten humanen „peripheral blood mononuclear cells“ 
(PBMCs) gemischt. Fast alle Tumorzellen wurden durch EpCAM-AAV transduziert, auch 
wenn sie nur 0.3% der Mischung ausmachten. Im nächsten Schritt wurde die Situation von 
CTCs im Vollblut nachgestellt. Auch wenn nur 150 Tumorzellen in 7.5 ml Blut vorhanden 
waren, konnten diese mit Hilfe von EpCAM-AAV nachgewiesen werden, was darauf 
schließen lässt, dass EpCAM-AAV zur Detektion von seltenen Tumorzellen verwendet 
werden kann.   
Die Ergebnisse dieser Arbeit demonstrieren die Flexibilität und Vielseitigkeit des 
Rezeptortargetings von behüllten und nicht-behüllten viralen Vektoren. Die Tatsache, dass 
sowohl LVs als auch AAVs nicht nur als Gentherapievektor sondern auch für virologische 
Fragestellungen und Diagnoseverfahren verwendet werden können, unterstreicht, dass die 
Targetingsysteme für ein breites Spektrum von Anwendungen neue Möglichkeiten eröffnen. 
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Introduction 
1 Introduction 
Over the past decades gene therapy has become a promising technique and a potential future 
treatment option for many diseases. Various approaches to replace a mutated gene with a 
healthy copy or to introduce a therapeutic gene are being developed and by June 2014 more 
than 2000 clinical gene therapy trials were approved worldwide 
(http://www.wiley.co.uk/genmed/clinical). The respective genetic information is delivered to 
a human cell using non-viral or viral vectors. Whereas non-viral vectors are considered as safe 
albeit rather inefficient alternatives (Schaffer et al, 2008), viruses have evolved to infect host 
cells and deliver their genomic payload. Engineering viral vectors with new properties to 
customize them for the respective indication is an emerging field of research. However, a 
deep understanding of virus biology and structure as well as rational design is required.   
This thesis describes the generation and characterization of cell surface receptor-targeted 
adeno-associated and measles virus-pseudotyped lentiviral vectors for applications in virology 
and medical research.  
1.1 Measles virus 
Measles virus (MV) is the causative agent of measles which is a highly contagious disease 
accompanied by high fever, cough and rash. It is one of the leading causes of death among 
young children and although a safe and cost-effective vaccine is available, 122.000 deaths 
were reported globally in 2012 (WHO Fact Sheet N°286). While collaborative efforts of the 
Measles & Rubella initiative (WHO, UNICEF, the American Red Cross, the United States 
Centers for Disease Control and Prevention and the United Nations Foundation) aim at 
controlling and eventually eradicating measles, the virus itself has attracted considerable 
interest in biomedical research due to its oncolytic properties in recent years. Reports of 
spontaneous regression of malignancies in children following measles infection have been 
around since as early as 1971 (Bluming & Ziegler, 1971; Zygiert, 1971; Gross, 1971). 
Infected tumor cells express the MV glycoproteins which mediate intercellular fusion leading 
to formation of multinucleated giant cells (syncytia) and apoptotic cell death. But it is only 
with the use of attenuated vaccine strains which are nonpathogenic to normal tissues, non-
persistent and genetically stable that the field of MV virotherapy has moved forward (Russell 
& Peng, 2009). The MV vaccine strains such as the Edmonston strain acquired CD46 tropism 
during tissue culture adaption and are known to enter cells predominantly via this receptor 
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(Dörig et al, 1993; Galanis et al, 2010). CD46, a complement regulatory protein, is expressed 
by all human nucleated cells but most importantly it is frequently overexpressed in tumor 
cells (Riley-Vargas et al, 2004; Russell & Peng, 2009). Key to the measles virus attractiveness 
as oncolytic agent is that cytopathic effects are only observed when CD46 expression level 
reaches a certain threshold leaving non-malignant tissues unaffected by the virus and leading 
to preferential killing of tumor cells (Anderson et al, 2004). Nowadays, these favorable 
characteristics are combined with engineering strategies to monitor virus replication, enhance 
systemic delivery and tumor specificity and improve efficacy (Miest & Cattaneo, 2014). 
Promising preclinical results have already led to the initiation of several clinical phase trials.  
In July 2014, Russel et al. reported complete remission of one patient with advanced incurable 
myeloma after systemic administration of a high dose recombinant MV engineered to express 
the human thyroidal sodiumiodide symporter (NIS) allowing noninvasive tumor imaging 
(Russell et al, 2014; Bell, 2014). Remarkably, this was the first case of intravenous 
virotherapy to completely eliminate disseminated malignancies.  
However, many aspects of MV biology have not yet been fully understood. For the future 
development and application of MV as biomedical agent as well as treatment and eradication 
of the measles disease, a detailed understanding and unraveling of viral mechanisms will be 
necessary. 
1.1.1 Virus structure 
As a member of the Morbillivirus genus in the family of Paramyxoviridae, measles virus is an 
enveloped, non-segmented negative-strand RNA virus (Moss & Griffin, 2006) (Figure 1A). 
Its single strand genomic RNA is approximately 16 kb in length and serves as template for 
synthesis of the positive RNA strand and of the mRNAs that are translated into eight viral 
proteins (Knipe & Fields, 2007) (Figure 1B). One of the encoded proteins, the large protein 
(L), is a viral RNA polymerase that is packaged in the virus and is responsible for synthesis of 
mRNAs once the virus has been uncoated in the cytoplasm of the infected cell. Instead of 
producing a long positive-strand copy, the polymerase stops at specific sites to release one of 
six mRNAs and then restarts again. In order to generate a full-length negative-strand RNA 
genome for new viruses, the same viral RNA polymerase complements the maternal strand 
but due to accumulation of viral proteins the signals that usually cause the polymerase to 
stutter are masked (Sompayrac, 2002). Together with the polymerase cofactor phosphoprotein 
(P) and the nucleoprotein (N), the L protein encloses the viral genome forming the 
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ribonucleocapsid. The matrix protein (M) is also packaged within the virions and is known to 
be a mediator between the nucleocapsid and the viral envelope. Interactions between M and 
the cellular membrane (Hirano et al, 1992; Riedl et al, 2002; Runkler et al, 2007), the N 
protein (Hirano et al, 1993; Iwasaki et al, 2009; Suryanarayana et al, 1994) and the viral 
envelope proteins (Cathomen et al, 1998a; Cathomen et al, 1998b; Tahara et al, 2007) are 
described. It is commonly assumed that M forms a thin layer covering the inner membrane, 
but recent electron cryotomography data argue that it forms helices coating the 
ribonucleocapsid to tightly package the genome and recruit it to the budding site (Liljeroos et 
al, 2011) (Figure 1A).  
 
Figure 1: Measles virus structure and genome organization. (A) Schematic representation of the measles virus particle. 
The pleomorphic enveloped virus contains RNA tightly encapsidated by the nucleoprotein (gray), large protein (green) and 
phosphoprotein (yellow). The matrix protein (orange) is shown in part as inner layer at the membrane and as layer coating the 
genome. The envelope glycoproteins hemagglutinin and fusion protein are shown in red and blue, respectively. (B) The non-
segmented genome encodes eight proteins, two of which (C and V) are non-structural proteins. Color code corresponds to A. 
In addition, two membrane spanning glycoproteins, the hemagglutinin (H) and the fusion 
protein (F), are transcribed from the viral RNA. They are organized on the viral surface in a 
hetero-oligomeric complex of F trimers and H tetramers which already forms in the 
endoplasmic reticulum (Plemper et al, 2001; Paal et al, 2009; Ader et al, 2012). Together, 
both proteins are the key players for membrane fusion and cell entry of the virus. While H 
mediates receptor binding and thereby determines the MV cellular tropism, F contains a 
hydrophobic stretch called fusion peptide that is inserted into the cellular membrane to initiate 
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virus-cell fusion (Navaratnarajah et al, 2009). Unlike other paramyxovirus attachment 
proteins, MV H has no neuraminidase activity since it does not bind sialic acid. It is a 617 
amino acid type II transmembrane protein which comprises a N-terminal cytoplasmic tail, an 
integral membrane part, an extracellular stalk region and a globular head domain 
(Navaratnarajah et al, 2009). The F protein is a highly conserved type I transmembrane 
protein which is synthesized as 553 amino acid F0 precursor protein. After cleavage by furin 
in the trans-Golgi network, the activated protein consists of disulfide-linked F1 and F2 
subunits (Knipe & Fields, 2007). Besides the six structural proteins N, P, M, F, H and L, two 
non-structural proteins called C and V are encoded by the viral genome. The basic protein C 
is alternatively translated in a different reading frame from the P gene using an initiator 
methionine codon downstream from that of P while V is a product of RNA editing of P 
mRNA (Knipe & Fields, 2007). Both proteins are described to interfere with the innate 
immune response by inhibiting interferon signaling and are suggested to modulate viral 
replication (Ito et al, 2013). 
1.1.2 Measles virus propagation and cell entry mechanism 
Like most paramyxoviruses, MV enters cells in a pH-independent manner and fuses directly 
with the plasma membrane (Iorio et al, 2009). However, in contrast to other family members, 
MV binds to the cell not via sialic acid residues but through direct protein-protein interaction. 
The wild-type MV clinical isolates enter cells via the signaling lymphocyte activation 
molecule (SLAM, also known as CD150) (Tatsuo et al, 2000; Erlenhoefer et al, 2001; Hsu et 
al, 2001) and the adherens junction protein nectin-4 (Mühlebach et al, 2011; Noyce et al, 
2011), whereas the vaccine strains additionally use CD46 as cellular receptor (Dörig et al, 
1993; Naniche et al, 1993) (Figure 2).  
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Figure 2: Measles virus receptors. (A) Structure of SLAM. The extracellular part is composed of a variable (V) and a 
constant (C2) Ig-like repeat. The major histocompatibility complex (MHC) presenting an antigen on dendritic cells as well as 
the T cell receptor (TCR) on a CD4+ T cell is shown. (B) Structure of nectin-4. Two nectin molecules form a dimer at the cell 
surface and are able to bind to another dimer on opposing cells. The extracellular domain consists of one V and two C2 Ig-
like repeats. (C) Structure of CD46. The third receptor that is exclusively used by laboratory-adapted MV strains has four 
short consensus repeats (SCR). Interaction of MV with the respective receptor domains are indicated by asterisks. Modified 
from (Sato et al, 2012). 
The use of different receptors with restricted expression in either lymphoid cells such as 
thymocytes, activated lymphocytes, mature dendritic cells, macrophages and platelets 
(SLAM) or in epithelial cells (nectin-4) explains the mode of transmission for MV in the 
human body. Current models postulate that macrophages and dendritic cells in the airway are 
the first target for the virus entering the respiratory tract (Figure 3). Then, these cells ferry the 
virus to the lymph nodes from where it spreads throughout the lymphatic organs. Eventually, 
the infected immune cells transmit the virus to epithelial cells expressing nectin-4 on their 
basolateral side. After infectious spread of the virus via tight junctions in the airway 
epithelium, progeny virus is released and expulsed by coughing and sneezing (Mühlebach et 
al, 2011; Sato et al, 2012). This way, the contagious viral particles can be transmitted to other 
hosts. 
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Figure 3: Transmission mode of MV. Infectious viral particles are shown as red spheres; viral glycoproteins are drawn as 
small spikes on the spheres in the inset close-up. Infected cells and organs are shown in red or pink at or after the peak of 
infection, respectively. (A) MV enters the human body through the respiratory tract and infects SLAM-positive macrophages 
and dendritic cells. These cells ferry the virus to the lymph nodes and (B) infection reaches thymus and spleen. (C) Infected 
immune cells expressing the viral glycoproteins transfer the virus to airway epithelial cells. Viral spread in epithelial cells is 
adherens junction (AJ, purple rectangles) protein nectin-4-dependent. Once epithelial cells are infected, the virus spreads via 
tight junctions (TJ, green rectangles). Finally, viral particles are released in the trachea and expulsed via coughing and 
sneezing. Modified from (Mühlebach et al, 2011). 
The first steps of the infectious life cycle depend on virus cell entry mediated by the concerted 
action of H and F. The structure of an H dimer is best described as a propeller with two 
cuboidal heads (Figure 4A), each composed of six β-blades (Figure 4B). Binding to the 
natural MV receptors SLAM and nectin-4 which both belong to the immunoglobulin 
superfamily is provided by attachment of the globular head to the respective V domains 
(Figure 2A+B). Residues involved in binding are well characterized and are mainly located in 
the β5-6 blades (SLAM) or in a hydrophobic groove between β4-5 (nectin-4) (Mateo et al, 
2014; Hashiguchi et al, 2011a). The H heads are situated on disulfide-linked long stalk 
regions, which interact with the globular head of F (Figure 4A) (Paal et al, 2009; Apte-
Sengupta et al, 2013). Receptor binding is believed to trigger rearrangements of H which are 
then transferred to F (fusion-helper function of H) to trigger conformational changes that 
ultimately expose its fusion peptide to become inserted into the cellular membrane (Plemper 
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et al, 2011). This H/F interplay is thought to depend on lowering the prefusion F activation 
energy barrier and thereby initiating the fusion process (Ader et al, 2012).  
 
Figure 4: Structure of the MV H and F proteins. (A) Sphere representation of the MV H dimer crystal structure shown in 
gray (Hashiguchi et al, 2007) and the F trimer of the paramyxovirus parainfluenza virus 5 shown in blue (Yin et al, 2006). 
The stalk, transmembrane, and cytoplasmic regions of H are depicted as vertical lines, with two horizontal lines indicating 
disulfide bonds. The residues most important for binding to SLAM (P191-R195, D530, R533), nectin-4 (L482) and CD46 
(Y481, L500) are shown in blue, orange and red, respectively. Residues involved in CD46 and nectin-4 binding (L464, F483, 
Y541, Y543) are colored yellow (Mateo et al, 2014). The virus membrane is illustrated as light gray box. (B) Top view of the 
six-bladed β-propeller sheet H protein head as cartoon representation. Each blade is represented in a different color. The C 
terminus is shown in black, the N terminus is shown in gray. The structures (Protein Data Bank [PDB] ID 2ZB5 and 2B9B) 
were modified using Pymol. 
How receptor binding alters the conformation of H and thus initiates the cascade of 
conformational changes is less well understood, especially when taking the unusual flexibility 
in using alternative receptors for cell entry into account. Besides the three identified MV 
receptors, the repertoire of entry receptors has been further extended by H protein 
engineering. Introducing mutations Y481A, R533A, S548L, and F549S makes the virus 
deficient for cell entry via its natural receptors (Nakamura et al, 2005; Vongpunsawad et al, 
2004). Specificity for a designated receptor was then achieved by fusing a targeting ligand 
such as a single chain antibody (scAb) or a designed ankyrin repeat protein (DARPin) to the 
C terminus of H.  In this way, a variety of tumor antigens have been shown to be functional as 
MV receptors (Msaouel et al, 2012).   
Contrary to current MV fusion mechanism models, data collected during my diploma thesis 
indicated that receptor attachment and fusion-helper function can possibly be separated 
without destroying the fusion competence of the glycoprotein complex (Rasbach, 2010). This 
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may be achieved by using lentiviral vectors pseudotyped with the MV F and blinded H and a 
third protein mediating receptor attachment.  
1.2 Lentiviral vectors 
Many diseases including immunodeficiency disorders, haemophilia or cystic fibrosis are 
caused by abnormalities in the genome. Patients suffering from one of these genetic 
conditions would greatly benefit from correction or transfer of the respective genes. Since the 
relationship between gene defects and diseases has been identified several decades ago, the 
idea of gene therapy is not very new. Already in 1972, Friedman & Roblin proposed the 
potential therapeutic use as well as scientific and ethical problems arising from gene therapy 
(Friedmann & Roblin, 1972). Nowadays, a lot of improvement in gene transfer techniques has 
been made and many promising gene therapy trials are ongoing. Among the gene delivery 
vehicles used, vectors derived from retroviruses are probably the most suitable tool for 
efficient gene transfer and stable integration of the transgene. Especially the development of 
lentiviral vectors (LV) has gained a lot of attention in the expanding and competitive field of 
vectorology (Naldini et al, 1996; Schambach et al, 2013). Compared to other retrovirus-
derived vectors, as for example γ-retroviral vectors, LVs stand out due to their capacity to 
transduce non-dividing cells and decreased genotoxicity. The potential of lentiviral vectors is 
also reflected by the fact that they are used in 4.2% of all vector gene therapy clinical trials 
(http://www.wiley.co.uk/genmed/clinical). Recently, two studies reported promising results 
from ex vivo clinical trials treating patients with rare hematopoietic diseases using improved 
lentiviral vectors. Remarkably, patients suffering from metachromatic leukodystrophy or 
Wiskott-Aldrich syndrome benefitted from treatment with gene-corrected hematopoietic stem 
cells without any signs of oncogene activation which was a major drawback of previous gene 
therapy trials using γ-retroviral vectors (Biffi et al, 2013; Aiuti et al, 2013).  
1.2.1 HIV-1 derived vectors 
Most LVs currently used in clinical trials are derived from the human immunodeficiency virus 
type I (HIV-1). This complex enveloped virus with a diameter of 100-120 nm and a cone-
shaped, cylindrical core is a major human pathogen causing the acquired immunodeficiency 
syndrome (AIDS) (Knipe & Fields, 2007) (Figure 5). As a member of the family 
Retroviridae, HIV-1 replicates through a unique life cycle. The genome of the virus is 
composed of two single-stranded RNA copies which are reverse transcribed to DNA upon cell 
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entry. The discovery of the viral enzyme which mediates this process called reverse 
transcriptase destroyed the dogma of molecular biology stating that genetic information can 
only be processed in one way from DNA to RNA to protein and earned David Baltimore, 
Howard Temin and Renato Dulbecco the Nobel Prize in 1975 (http://www.nobelprize.org). In 
a next step, the viral DNA is integrated into the host chromosomal DNA and this so-called 
provirus serves as template for viral genome replication and protein synthesis. The two key 
enzymes reverse transcriptase and integrase confer on the virus the outstanding ability to 
maintain a persistent infection and transfer its genetic information vertically.   
 
Figure 5: Structure of HIV-1. The enveloped virus has a cylindrical core (capsid) containing two single-stranded RNA 
genomes which are associated with the nucleocapsid proteins and viral enzymes (polymerase, integrase, reverse 
transcriptase). The matrix protein forms a thin layer covering the inner membrane. The viral glycoprotein consisting of gp120 
and gp41 are shown.  
The HIV-1 RNA genome codes for nine viral proteins (Figure 6A). The three main open-
reading frames gag, pol and env encode structural proteins and enzymes. While translation 
products of the gag gene are the viral core proteins matrix (MA), capsid (CA), nucleocapsid 
(NC) and p6 protein, the pol sequence provides the information for enzymes required for viral 
replication such as protease (PR), reverse transcriptase (RT) and integrase (IN). The viral 
surface glycoprotein gp160 which is eventually cleaved into the gp120 surface (SU) and gp41 
transmembrane (TM) protein is encoded by the env gene (Knipe & Fields, 2007). In addition, 
two regulatory proteins transactivating the transcription (Tat) from the viral long terminal 
repeats (LTR) flanking the genome and controlling splicing and nuclear export of the viral 
RNA (Rev) are synthesized (Sakuma et al, 2012). The remaining four genes code for the 
accessory proteins Vif, Vpr, Vpu and Nef that ensure viral survival by evasion of cell-
mediated antiviral responses (Malim & Emerman, 2008).   
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Figure 6: Schematic representation of the HIV-1 genome and HIV-1 vectors. (A) The viral genome encodes three 
structural (Gag, Pol, Env), two regulatory (Tat, Rev) and four accessory (Vif, Vpr, Vpu and Nef) proteins and is flanked by 
two long terminal repeats (LTRs). The ψ-signal which is required for packaging of the viral RNA into the virions is located 
close to the 5’-LTR. The Rev-responsive element (RRE) is also indicated. The Gag precursor protein consists of matrix 
(MA), nucleocapsid (NC) and p6 protein. The pol sequence provides the information for the enzymes protease (PR), reverse 
transcriptase (RT) and integrase (IN). The envelope protein is further processed into a surface (SU) and transmembrane (TM) 
protein. (B) First generation lentiviral vectors are produced by splitting the vector components into three separate plasmids. 
Only the transfer vector encoding the transgene under control of a strong viral promoter such as the spleen focus-forming 
virus (SFFV) promoter contains the ψ-signal. (C) In the second generation lentiviral vector system the accessory proteins are 
excluded to further enhance the safety profile of the vector. (D) The likelihood of recombination is decreased by deleting Tat 
and Rev from the packaging construct. While Rev is trans complemented with a fourth plasmid, Tat is not required due to 
replacement of the U3 promotor region in the transfer vector. Modified from (Sakuma et al, 2012) and (Abel, 2013). 
In order to develop a replication incompetent viral vector which enables safe and efficient 
transfer of a specific transgene, sophisticated constructs have been generated. The first 
generation of HIV-1-derived lentiviral vectors was produced by splitting the vector 
components into three separate plasmids: the packaging construct encoding Gag/Pol and the 
10 
 
Introduction 
accessory proteins, the Env plasmid, and the transfer vector coding for the transgene (Figure 
6B). Prerequisite for the delivery of the transgene without expression of viral proteins in the 
target cells was that only the transfer vector contained the ψ-signal which is responsible for 
packaging of the respective RNA into viral particles (Richardson et al, 1993). To further 
enhance safety, the sequences for the accessory proteins Vif, Vpu, Vpr and Nef counteracting 
the immune system and promoting HIV-1 propagation and virulence were deleted in the 
second lentiviral vector generation (Figure 6C) (Sakuma et al, 2012). Although the second 
generation vectors are often used in research, the third generation vector system is preferred 
for clinical applications. Here, the likelihood of recombination and thus production of 
replication competent particles is even more reduced by deleting tat and rev from the 
packaging construct. While rev is delivered on a separate plasmid, tat is not required anymore 
due to replacement of the U3 promoter region in the transfer vector (Figure 6D) (Sakuma et 
al, 2012).  
1.2.2 Retargeting lentiviral vectors using the measles virus envelope 
The cell tropism of a viral vector is determined by its envelope glycoproteins. The HIV-1 
gp120 protein uses CD4, a cell surface marker expressed in T-helper cells, monocytes, 
macrophages and dendritic cells, as its primary receptor (Knipe & Fields, 2007). In order to 
alter, restrict or expand the host range, envelope proteins derived from other viruses can be 
incorporated. This process known as pseudotyping enables the combination of unique 
lentiviral features with the tropism of an expanding list of viral glycoproteins (Cronin et al, 
2005). Probably the most popular protein for pseudotyping HIV-1-based vectors is the 
vesicular stomatitis virus glycoprotein (VSVG). First reported in 1996 by three independent 
groups (Akkina et al, 1996; Naldini et al, 1996; Reiser et al, 1996), VSVG pseudotypes are 
still widely used given that the glycoprotein is very stable, allows concentration to high titers 
and exhibits a broad tropism due to binding to the ubiquitously expressed LDL receptor 
family (Finkelshtein et al, 2013).   
But for some therapeutic applications a restricted gene transfer rather than a wide host range 
is required. Especially for in vivo applications where only one cell type needs to be modified, 
safety and efficacy can be improved by restricting cell entry of the viral vector (Buchholz et 
al, 2009). The glycoproteins of other RNA viruses such as Mokola virus or lymphocytic 
choriomeningitis virus have been exploited to achieve restriction to certain cell types as for 
example astrocytes or glioma cells (Sakuma et al, 2012). A major limitation is that viral 
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envelope proteins rarely mediate entry into only one single cell type. The HIV-1 gp120 is one 
of the few proteins that enable the virus to enter only CD4-positive lymphocytes, but most 
other viruses either bind to several different receptors or their binding partners are expressed 
in various cell types. Strikingly, the limited availability of natural envelope proteins can be 
overcome by engineering glycoproteins to retarget the vector to a cell surface molecule of 
choice. The measles virus F and H proteins already had been shown to be a powerful tool to 
redirect oncolytic viruses (chapter 1.1.2) and cytoplasmic tail truncated variants could be 
efficiently incorporated into lentiviral vectors (Funke et al, 2008; Frecha et al, 2008). An 
advantage of the measles virus pseudotype is that receptor attachment and fusion are mediated 
by two different proteins. Therefore, manipulation of the H protein does not interfere with the 
fusion capacity of F. The MV pseudotyped lentiviral targeting system relies on the same 
principles as targeted oncolytic viruses. The same four point mutations, namely Y481A, 
R533A, S548L and F549S, were introduced to ablate the natural tropism of H. Genetic fusion 
of a targeting ligand to the C terminus of H redirects the vector in cell entry to the receptor of 
choice. Funke et al. demonstrated the first set of MV pseudotyped lentiviral vectors that 
specifically targeted CD20 or the epidermal growth factor receptor (Funke et al, 2008), but 
since then the list of cell surface markers used has been further extended to proteins relevant 
in immunology, hematology, neurobiology and cancer research (Anliker et al, 2010; Ageichik 
et al, 2011; Zhou et al, 2012; Münch et al, 2011). 
1.3 Adeno-associated viral vectors 
Another promising viral vector system is based on the adeno-associated virus (AAV). 
Depending on the application, vectors constructed from AAVs are favorable due to features 
inherent to their viral biology. They are non-pathogenic, have low immunogenic potential, are 
capable of transducing dividing and non-dividing cells and although they usually do not insert 
genetic material into the host chromosomes, long-term gene expression can be sustained in 
non-dividing cells (Clark et al, 1997; Büning et al, 2008; Mingozzi & High, 2007). Many 
clinical trials using AAV gene therapy have achieved promising results in diseases such as 
congenital blindness and haemophilia (Mingozzi et al, 2013) and have led to the pioneering 
first market authorization of a gene therapy product in Europe. The product with the trade 
name Glybera is an AAV1 vector delivering an intact copy of the human lipoprotein lipase 
(LPL) gene to restore the enzyme’s activity in LPL deficiency patients suffering from severe 
or multiple pancreatitis attacks (Ylä-Herttuala, 2012; Flemming, 2012).    
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In combination with techniques to tackle the drawbacks of AAV vectors such as the presence 
of neutralizing antibodies in human serum or their limited cell specificity, AAV gene therapy 
is expected to progress even further and will have an impact on modern medicine.  
1.3.1 AAV biology 
AAV is a small, non-enveloped virus with an icosahedral shape of approximately 20-26 nm. 
The first human AAV was discovered in 1965 as contaminant in adenovirus preparations. 
Since it usually requires co-infection with a helper virus such as adenovirus or herpesvirus for 
productive infection, AAV is considered replication-deficient and is classified as member of 
the Dependovirus genus in the Parvoviridae family (Knipe & Fields, 2007). In the absence of 
a helper virus, AAV will integrate preferentially into the AAVS1 locus on chromosome 19 
(Kotin et al, 1990; Samulski et al, 1991) (Figure 7). This biphasic life cycle in combination 
with the ability for site-specific integration makes AAV unique among eukaryotic DNA 
viruses (Young et al, 2000).   
 
Figure 7: Biphasic life cycle of adeno-associated virus. In absence of helper virus, AAV integrates site-specifically into the 
human chromosome 19 (red) and persists in a latent form. If the cell is co-infected with adenovirus (Ad) or herpes simplex 
virus (HSV) the necessary factors for active AAV replication are provided. Modified from (Vasileva & Jessberger, 2005). 
The 4.7 kb single-stranded DNA genome can be of positive or negative polarity contains three 
open reading frames (ORF) flanked by two inverted terminal repeats (ITRs) (Berns, 1974) 
(Figure 8). The ITRs forming T-shaped hairpin structures are important for genome packaging 
and integration (Cao et al, 2002). Additionally, they contain Rep-binding elements and a 
terminal resolution site necessary for genome replication. Current models also propose that 
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the ITR is the origin of replication and serves as primer for second strand synthesis. The four 
non-structural AAV proteins Rep40, Rep52, Rep68 and Rep78 are encoded by the rep ORF 
and their expression is regulated by the viral promoters p5 and p19. The two overlapping 
mRNAs of Rep52 and Rep78 can be subject to splicing and give rise to Rep 40 and Rep68, 
respectively (Knipe & Fields, 2007). A common feature of all four proteins is their ATPase 
and helicase activity. The larger Rep proteins Rep68 and Rep78 are known to regulate viral 
replication and gene expression. In the presence of helper virus they transactivate 
transcription and contribute to the replication of the AAV genome whereas in the absence of 
helper virus they repress the promoters p5 and p19 and mediate site-specific integration 
(Pereira et al, 1997; Young et al, 2000). The small Rep proteins Rep40 and Rep52 are 
involved in viral assembly and packaging (King et al, 2001).   
 
Figure 8: Genome organization of AAV. The 4.7 kb single-stranded DNA genome is flanked by two T-hairpin shaped 
inverted terminal repeats (ITRs) and contains three open reading frames (ORFs). The rep ORF encodes the non-structural 
proteins Rep78, Rep68, Rep52 and Rep40. The cap ORF encodes the three structural proteins VP1, VP2 and VP3 that form 
the viral capsid with the aid of the assembly-activating protein (AAP) which is encoded by an alternative ORF within cap. 
The promoters p5, p19 and p40 drive expression of the viral proteins. The respective transcripts are shown below. Modified 
from (Kotterman & Schaffer, 2014). 
The cap gene encodes the three structural proteins VP1, VP2 and VP3 that form the viral 
capsid (Figure 8). They are produced from the p40 mRNA which is further processed using 
two different splice acceptors located in the intron between the rep and cap ORF. The longer 
splice variant contains the natural start codon and leads to the expression of VP1. In the 
second variant, this codon has been spliced out. An unusual ACG codon is used for the 
expression of VP2 and a conventional AUG further downstream is the initiator codon for VP3 
(Knipe & Fields, 2007). This regulation of gene expression leads to a common C-terminal end 
for all three structural proteins. The use of unusual start codons and splice variants results in a 
transcriptional gradient of 1:1:10 for VP1, VP2 and VP3. Assembly of the capsid is assisted 
by the assembly-activating protein (AAP) which is the gene product of a recently identified 
ORF within the cap gene (Sonntag et al, 2010).  
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The capsid comprises 60 VP monomers arranged with T=1 icosahedral symmetry. Several 
three-dimensional structures of different AAV serotypes have been determined by X-ray 
crystallography or cryo-electron microscopy reconstruction (Kronenberg et al, 2001; Xie et al, 
2002; Walters et al, 2004; Govindasamy et al, 2006; Nam et al, 2007; Lerch et al, 2010; Ng et 
al, 2010; Govindasamy et al, 2013). Common features to the capsid proteins of all serotypes 
are a small α-helix (αA) and an eight-stranded anti-parallel β-barrel (βB-βI) (Figure 9A). The 
large loops connecting the β-strands are divided in distinctive HI and DE loops as well as nine 
variable regions (VR-I to VR-IX) (Tseng & Agbandje-McKenna, 2014; Govindasamy et al, 
2006). These VRs form the exterior surface of the capsid and contribute to structural and 
functional differences between AAV serotypes, including receptor attachment, transduction 
efficiency and antigenic specificity (Drouin & Agbandje-McKenna, 2013).  
 
Figure 9: Capsid structure of adeno-associated virus. (A) Structure of the VP3 monomer of AAV2 as cartoon 
representation. The conserved αA helix (red), the β-barrel core motif (βB-βI, each strand in a different color according to 
(Govindasamy et al, 2006)), the DE and HI loops are indicated. (B) Sphere representation of the surface of the assembled 
AAV2 capsid radially colored (from capsid center to surface). The approximate two-, three- and five-fold symmetry axes are 
indicated. The structures (Protein Data Bank [PDB] ID 1LP3) (Xie et al, 2002) were modified using Pymol.  
Assembly of the capsid proteins is structured by two-, three- and five-fold symmetry-related 
interactions (Figure 9B). The two-fold axis formed by two monomers is marked by a 
depression while characteristic spiky protrusions arise at the three-fold axis. The latter is 
described to be important for receptor binding and to contain prominent antigenic epitopes 
(Gurda et al, 2013; Wu et al, 2000; Opie et al, 2003). The DE loops of five assembled 
monomers form the central pore complex at the five-fold axis which is surrounded by a 
canyon region. These cylindrical channels link the outside of the virus with the interior of the 
capsid. Mutational analyses revealed that this region is important for genome packaging and 
serves as portal for the VP1 and VP2 N-termini externalization (Bleker et al, 2005; Bleker et 
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al, 2006). The N-termini harbor a conserved catalytic phospholipase A2 domain and three 
clusters of basic amino acids which seem to be necessary for endosomal escape, nuclear 
import and virus infectivity (Girod et al, 2002; Grieger et al, 2006; Kronenberg et al, 2005; 
Popa-Wagner et al, 2012).   
To date, various AAV serotypes and variants have been isolated from humans and nonhuman 
primates but also horse, cow, chicken, snake and other tissues (Wu et al, 2006b; Asokan et al, 
2012). The most prevalent and best characterized strain found in the human population is the 
AAV2 serotype. Many AAV gene therapy approaches are based on AAV2 vectors which are 
described to transduce muscle, liver, brain, retina and lungs (Daya & Berns, 2008). They bind 
to heparan sulfate proteoglycan (HSPG) as primary receptor but internalization is enhanced 
by interaction with various co-receptors such as fibroblast/hepatocyte growth factor receptor, 
laminin receptor and integrin αVβ5/α5β1 (Summerford & Samulski, 1998; Qing et al, 1999; 
Akache et al, 2006; Kashiwakura et al, 2005; Summerford et al, 1999; Asokan et al, 2006). 
Other serotypes exhibit differences in tissue tropism, transduction efficiencies and prevalence 
of preexisting humoral immunity which enabled the rapid transition to potential candidates as 
gene therapy vectors depending on the medical indication.   
1.3.2 AAV vector engineering 
For gene transfer applications, AAV vectors are generated by modifying the viral genome and 
producing recombinant, replication-deficient AAV vector particles employing double or triple 
transfection of HEK293 cells (Figure 10). The gene of interest replaces both, rep and cap, and 
is inserted between the viral ITRs which are the only cis-acting elements necessary for 
packaging into the AAV capsid. The rep and cap genes are provided in trans on a second 
plasmid along with the adenoviral helper genes required for replication. Alternatively, the 
adenoviral helper proteins E2A, E4 and VA RNA are provided by transfection of a third 
plasmid. The resulting AAV vectors can then be purified by CsCl or iodixanol density 
gradient centrifugation and/or chromatography-based methods (Burova & Ioffe, 2005).    
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Figure 10: Generation of recombinant AAV vectors. To generate AAV vectors, a transgene of choice is inserted between 
the viral ITRs in the single-stranded or self-complementary conformation. The rep, cap and adenoviral helper genes E2A, E4 
and VA are provided in trans on separate plasmids. After triple transfection of HEK293 cells, the transfer vector is replicated 
and packaged into assembled capsids in the nucleus. Rep78, Rep68, Rep52 and Rep40 are non-structural proteins assisting 
replication and packaging. The capsid proteins VP1, VP2 and VP3 form the capsid with the help of the assembly-activating 
protein (AAP). Modified from (Kotterman & Schaffer, 2014). 
Because recombinant AAV vectors do not encode Rep proteins and lack a cis-acting element 
called integration efficiency element (IEE), the transgene persists primarily episomally 
(Philpott et al, 2002). One of the rate-limiting steps of transduction, besides trafficking and 
capsid uncoating, is the second strand DNA synthesis prior to gene expression which depends 
on the host cell replication machinery (Ferrari et al, 1996; Fisher et al, 1996). The 
development of self-complementary AAV (scAAV) genomes bypasses this natural barrier, 
shortens the lag time before transgene expression and improves efficiency in vitro and in vivo 
(McCarty et al, 2001; Wang et al, 2003; McCarty et al, 2003). This genome organization takes 
advantage of the preference for the formation of self-complementary DNA which was 
increased by deleting the terminal resolution site sequence from one ITR and thus preventing 
the Rep proteins from nicking at this position. The resulting dimeric genome in the inverted 
repeat configuration contains two wildtype ITRs at both ends and one mutated ITR in the 
middle (Figure 10) (McCarty, 2008). As consequence, the maximal transgene capacity is 
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reduced. Nevertheless, a scAAV2 construct of 3,300 bp  exceeded what was assumed 
originally for the maximal encapsidation of large genomes (Wu et al, 2007).    
1.3.2.1 Receptor-targeted AAV vectors 
The development of adeno-associated viral vectors targeting certain tissues or subtypes of 
cells has been driven by several different strategies. Among the most prominent ones is the 
so-called capsid shuffling followed by directed evolution. Here, capsid genes from different 
natural AAV isolates are fragmented, randomly reassembled for diversification and selected 
for desired properties (Kay, 2011). Another method relies on the use of chimeric capsids with 
inserted peptide sequences for retargeting (Choi et al, 2005). However, these methods are 
often labor-intensive and rarely result in vectors specific for only one cell type.  
Recently, clear-cut receptor specificity of an AAV vector targeting Her2/neu has been 
achieved by rational design. Natural receptor binding of the AAV2 vector to HSPG was 
ablated  by introduction of the two point mutations R585A and R588A in the capsid proteins 
(Kern et al, 2003; Opie et al, 2003; Boucas et al, 2009). Then, a DARPin specific for 
Her2/neu was fused to the N-terminus of the VP2 capsid protein conferring a redirected viral 
tropism (Münch et al, 2013). The specificity for tumor cells overexpressing the Her2/neu 
receptor was shown in vitro as well as in vivo and benefit of suicide gene transfer in a 
therapeutic xenograft setting was substantial. In order to prevent off-targeting in vivo which is 
caused by vector particles composed of only VP1 and VP3 and to enhance gene delivery 
efficiency, an additional purification step can be performed (Münch, 2013). Fusion of a His-
tag at the N-terminus of the DARPin-VP2 protein allows immobilized metal ion affinity 
chromatography and increases targeting vector quality.  
1.4 Objectives 
This thesis describes two different projects using receptor-targeted viral vectors. The aim of 
the first project was a better understanding of the molecular events during MV cell entry and 
to challenge the hypothesis that MV receptor contact triggers the conformational changes 
required for cell entry. The second project aimed at developing and characterizing an AAV 
vector targeting the human epithelial cell adhesion molecule (EpCAM) which is 
overexpressed in most epithelial malignancies and circulating tumor cells.  
To reach the first goal, lentiviral vectors pseudotyped with the measles virus glycoproteins 
could be used. In order to assess whether receptor attachment of H is required for fusion 
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triggering, a third protein mediating binding to the cellular receptor had to be incorporated 
into vector particles. Primary aim was to gain significance  for results obtained previously 
(Rasbach, 2010) and to further analyze vector particles for protein composition, surface 
presentation of envelope proteins and titers as well as cell entry characteristics. Several 
different targeting ligands should be assessed for their potential as attachment domains. 
Additionally, gene transfer efficiency of this new vector type should be evaluated in vitro and 
in vivo in a xenograft tumor model.    
For the generation of human EpCAM-specific AAV vectors, a recently established targeting 
system using high affinity binders should be employed (Münch et al, 2013). Therefore, highly 
specific DARPins had to be fused to the N-terminus of the VP2 protein for incorporation into 
the viral capsid. Generated vector particles had to be analyzed for their morphology, protein 
content, surface exposure of the DARPin, genomic titers and packaging efficiency. 
Furthermore, targeting specificity should be confirmed on different receptor-positive and 
receptor-negative cell lines as well as on primary cells and in a transgenic mouse model. 
Purity and efficiency of the vector particles should be further improved using affinity-
chromatography. Ultimately, the potential of EpCAM-AAV to detect and modify rare tumor 
cells in blood samples should be assessed.  
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2 Material and Methods 
2.1 Material 
2.1.1 Equipment  
Name Model Manufacturer  
Bacteria incubator shaker Innova™ 4200 New Brunswick Scientific 
Cell incubator BBD6220 Heraeus, Thermo Scientific 
Cell sorter MoFlo Beckman Coulter 
Centrifuge Multifuge X3, Multifuge 3 Heraeus, Thermo Scientific 
Chemiluminescence detection Fusion FX7 Vilber Lourmat 
Electron microscope EM 109 Zeiss 
Flowcytometer MACSQuant Analyzer Miltenyi Biotec 
Flowcytometer LSRII Becton Dickinson 
Fluorescence microscope Axiovert 200 Zeiss 
Gel documentation station Gel Imager Intas 
Gel electrophoresis system n/a Bio-Rad 
HPLC system Smartline Knauer 
In vivo imaging system IVIS Spectrum PerkinElmer 
Laminar Flow Cabinet Class II SterilGARD® III The Baker Company 
Laser scanning microscope LSM 510 Zeiss 
Light microscope Axiovert 25 Zeiss 
LightCycler LightCycler® Roche 
Micropipettes Research plus® Eppendorf 
Microplate reader THERMOmax Molecular Devices 
Multichannel pipettes Finnpipette F2 Thermo Scientific 
Pipetboy Accu-jet® Brand 
Spectrophotometer NanoDrop 2000c Thermo Scientific 
Table-top processor Curix 60™ Agfa 
Thermo cycler PTC 200 MJ Research 
Ultracentrifuge Optima™ L-70k Beckman Coulter 
20 
 
Material and Methods 
2.1.2 Kits 
Name Supplier 
GeneJET Plasmid Miniprep Kit Thermo Scientific 
EndoFree® Plasmid Maxi Kit QIAGEN 
JETStar NoEndo Jetfilter Giga Kit Genomed 
GeneJET Gel Extraction Kit Thermo Scientific 
Rapid DNA Ligation Kit Fermentas 
DNeasy® Blood & Tissue Kit QIAGEN 
FastStart DNA MasterPLUS SYBR Green I Roche 
RETROtek HIV-1 p24 Antigen ELISA ZeptoMetrix 
2.1.3 Enzymes 
Name Supplier 
Restriction endonucleases  New England Biolabs 
Trypsin 2.5% (Melnick) Paul-Ehrlich-Institut 
Phusion Hot Start II High Fidelity DNA Polymerase Thermo Scientific 
DreamTaq DNA Polymerase Thermo Scientific 
Benzonase® Nuclease Sigma-Aldrich 
2.1.4 Antibiotics 
Name Supplier 
Penicillin/Streptomycin  Paul-Ehrlich-Institut 
Geniticin Gibco 
Puromycin Sigma-Aldrich 
2.1.5 Buffers and chemicals 
Name Composition/Supplier 
AAV lysis buffer 50 mM Tris-HCl, 150 mM NaCl in PBS 
D-Luciferin Perkin Elmer 
DNA loading buffer 6x Thermo Scientific 
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Name Composition/Supplier 
ECL Plus Western Blotting 
detection reagent 
Amersham 
ELISA blocking buffer PBS, 0.05% Tween-20, 3% BSA, 5% sucrose 
ELISA washing buffer PBS, 0.05% Tween-20 
FACS washing buffer 2% FCS in PBS 
FACS fix 1% formaldehyde in PBS 
FACS sorting buffer 10 mM HEPES, 2% FCS, 0.5 mM EDTA in PBS 
Freezing medium 90% FCS, 10% DMSO 
Histopaque®-1077 Sigma-Aldrich 
IMAC binding buffer 20 mM imidazole, 20 mM sodium phosphate, 0.5 M NaCl 
IMAC elution buffer 300 mM imidazole, 20 mM sodium phosphate, 0.5 M NaCl 
OptiPrep™ Sigma-Aldrich 
PBS Lonza 
PBS M/K 2.5 mM KCl, 1 mM MgCl2 in PBS 
PEI 18 mM polyethylenimine in H2O 
S.O.C medium Sigma-Aldrich 
SDS running buffer 25 mM Tris, 192 mM Glycine, 1% SDS 
TAE 40 mM Tris, 20 mM Acetic acid, 1 mM EDTA 
TBS-T 10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Tween-20 
TMB liquid substrate Sigma-Aldrich 
TNE 25 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA 
Transfer buffer 48 mM Tris, 39 mM Glycine, 20% Methanol 
Triton X-100 Sigma-Aldrich 
Trypsin solution PBS, 2 mM EDTA, 0.25% Trypsin-Melnick 
Tween-20 Sigma-Aldrich 
 
2.1.6 Antibodies 
Name Application Dilution Supplier 
α-MV F, rabbit serum (F431) WB 1:4,000 R. Cattaneo 
α-MV H, rabbit serum (H606) WB 1:1,000 R. Cattaneo 
α-HIV-1 p24, mouse WB 1:1,000 Gentaur 
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Name Application Dilution Supplier 
α-HA tag, mouse (12CA5) WB 1:1,000 Roche 
α-AAV VP1/VP2/VP3, mouse (B1) WB 1:20 Progen 
α-rabbit-HRP, goat WB 1:2,000 DAKO 
α-mouse-HRP, rabbit WB 1:2,000 DAKO 
α-AAV intact particle, mouse (A20) ELISA 1:4 Progen 
α-myc tag, mouse ELISA 1:1,000 Abcam 
α-mouse-biotin, donkey ELISA 1:25,000 Jackson ImmunoResearch 
Streptavidin-HRP ELISA 1:500 Jackson ImmunoResearch 
α-HA tag, mouse (16B12) IF, EM 1:800 Covance 
α-mouse-10 nm gold, goat EM 1:50 British BioCell 
α-MV F, mouse (Y503) FC, IF 1:250 R. Cattaneo 
α-MV H, mouse (K83) FC, IF 1:10-20 J. Schneider-Schaulies 
α-mouse IgG2a AlexaFluor546, goat IF 1:250 Invitrogen 
α-mouse IgG1 AlexaFluor633, goat IF 1:250 Invitrogen 
α-mouse-PE, goat FC 1:20 Sigma-Aldrich 
α-MV H, mouse (L77) NA, FC variable J. Schneider-Schaulies 
α-MV H, mouse (Nc32) NA, FC variable J. Schneider-Schaulies 
α-MV H, mouse (K71) NA, FC variable J. Schneider-Schaulies 
α-MV H, mouse (K29) NA, FC variable J. Schneider-Schaulies 
α-Her2/neu-PE, mouse FC 1:20 BD Pharmingen 
α-EpCAM-PE, mouse FC 1:20 Miltenyi Biotec 
α-HA tag-PE FC 1:20 Miltenyi Biotec 
FcR blocking reagent, human FC 1:10 Miltenyi Biotec 
WB: western blot, ELISA: enzyme-linked immunosorbent assay, IF: immunofluorescence, EM: immunoelectron microscopy, 
FC: flow cytometry, NA: neutralization assay 
2.1.7 Oligonucleotides 
Oligonucleotides were synthesized by Eurofins MWG Operon or Sigma-Aldrich.  
Name Sequence (5’ – 3’) 
GFP-for  GCTACCCCGACCACATGAAG 
GFP-rev GTCCATGCCGAGAGTGATCC 
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luc-for TTCGGCTGGCAGAAGCTATG 
luc-rev GCTCGCGCTCGTTGTAGATG 
DARPin-for GGAAGGACCGGTATGGACCTGGGTAAGAAACTG 
DARPincorr-rev GTCCGAGCACTTGTACAGATTAAGCTTCGCCGCTTT 
His-for 
GGAAGGACCGGTATGCATCACCATCACCATCACATCGAGGG 
AAGGGACCTGGGTAAGAAACTGCTG 
Myc-for 
GGAAGGACCGGTATGGAACAAAAACTTATTTCTGAAGAAGA 
TCTGATCGAGGGAAGGGACCTGGGTAAGAAACTGCTG 
EpCAM-for 
TTAATAGGCGCGCCAGTCCTCCGACAGACTGAGTCGCCCGGG 
GGGGATCCACCGGTCGCCACCATGGCGCCCCCGCAGGTCCTCG 
EpCAM-rev GATGCACCGACTGACTAGTTAGTTATGCATTGAGTTCCCTATGC 
oIMR8744 CAAATGTTGCTTGTCTGGTG 
oIMR8745 GTCAGTCGAGTGCACAGTTT 
oIMR8558 TCAGATAAAGGAGATGGGTGAGA 
oIMR8559 GGCAGCTTTCAATCACAAATCAG 
2.1.8 Plasmids 
Name Description Source 
pCMVΔR8.91 HIV-1 packaging plasmid 
U. Blömer 
(Zufferey et al, 
1998) 
pSEW 
HIV-1 transfer vector encoding GFP under 
control of the SFFV promoter 
M. Grez 
(Demaison et al, 
2002) 
pS-luc2-W 
HIV-1 transfer vector encoding luciferase 
under control of the SFFV promoter 
(Abel et al, 
2013) 
pS-EGFP-I-puro-W 
Bicistronic HIV-1 transfer vector encoding 
GFP and puromycin 
Irene C. 
Schneider 
pS-hEpCAM-I-puro-W 
Bicistronic HIV-1 transfer vector encoding 
human EpCAM and puromycin 
This thesis 
pCMV6-AC-
EpCAMcDNA 
Human full-length TruClone™ with human 
EpCAM cDNA 
Origene 
pMD2.G Encodes the VSV glycoprotein D. Trono 
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pCG-FΔ30 
Encodes MV F with a truncated 
cytoplasmic tail of 30 aa under control of 
the CMV promoter 
(Funke et al, 
2008) 
pCG-HΔ18 
Encodes MV H with a truncated 
cytoplasmic tail of 18 aa under control of 
the CMV promoter 
(Funke et al, 
2008) 
pCG-HmutΔ18 
Encodes MV H with a truncated 
cytoplasmic tail of 18 aa and the four point 
mutations Y481A, R533A, S548L, F549S 
under control of the CM promoter 
(Funke et al, 
2008) 
pCG-H*mutΔ18 
Encodes MV H with a truncated 
cytoplasmic tail of 18 aa and the five point 
mutations F111N, Y481A, R533A, S548L, 
F549S under control of the CM promoter 
(Rasbach et al, 
2013)  
pCG-HmutΔ18-DARPin-
9.29 
Encodes MV Hmut18 fused to the Her2/neu-
specific DARPin 9.29 
(Münch et al, 
2011) 
pCR2.1-Helical Linker 
Contains the sequence for the helical linker 
HL7 flanked by NotI and SalI restriction 
sites 
Eurofins MWG 
Operon 
pDisplay-D9.29 
Encodes the Her2/neu-specific DARPin 
9.29 fused to the PDGFR TMD under 
control of the CMV promoter 
(Rasbach et al, 
2013) 
pDisplay-DG3 
Encodes the Her2/neu-specific DARPin G3 
fused to the PDGFR TMD under control of 
the CMV promoter 
(Rasbach et al, 
2013) 
pDisplay-D9.26 
Encodes the Her2/neu-specific DARPin 
9.26 fused to the PDGFR TMD under 
control of the CMV promoter 
This thesis 
pDisplay-D9.16 
Encodes the Her2/neu-specific DARPin 
9.16 fused to the PDGFR TMD under 
control of the CMV promoter 
This thesis 
pDisplay-D9.01 
Encodes the Her2/neu-specific DARPin 
9.01 fused to the PDGFR TMD under 
control of the CMV promoter 
This thesis 
25 
 
Material and Methods 
pDisplay-DH14R 
Encodes the Her2/neu-specific DARPin 
H14R fused to the PDGFR TMD under 
control of the CMV promoter 
This thesis 
pDisplay-HL7-D9.29 
Encodes the Her2/neu-specific DARPin 
9.29 fused to a helical linker and the 
PDGFR TMD under control of the CMV 
promoter 
This thesis 
pDisplay-HL7-DG3 
Encodes the Her2/neu-specific DARPin G3 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-D9.26 
Encodes the Her2/neu-specific DARPin 
9.26 fused to a helical linker and the 
PDGFR TMD under control of the CMV 
promoter 
This thesis 
pDisplay-HL7-D9.16 
Encodes the Her2/neu-specific DARPin 
9.16 fused to a helical linker and the 
PDGFR TMD under control of the CMV 
promoter 
This thesis 
pDisplay-HL7-D9.01 
Encodes the Her2/neu-specific DARPin 
9.01 fused to a helical linker and the 
PDGFR TMD under control of the CMV 
promoter 
This thesis 
pDisplay-HL7-DH14R 
Encodes the Her2/neu-specific DARPin 
H14R fused to a helical linker and the 
PDGFR TMD under control of the CMV 
promoter 
This thesis 
pDisplay-D57.2 
Encodes the CD4-specific DARPin 57.2 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-D29.2 
Encodes the CD4-specific DARPin 29.2 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
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pDisplay-D27.2 
Encodes the CD4-specific DARPin 27.2 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-D55.2 
Encodes the CD4-specific DARPin 55.2 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-HL7-D57.2 
Encodes the CD4-specific DARPin 57.2 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-D29.2 
Encodes the CD4-specific DARPin 29.2 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-D27.2 
Encodes the CD4-specific DARPin 27.2 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-D55.2 
Encodes the CD4-specific DARPin 55.2 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-DAc1 
Encodes the EpCAM-specific DARPin Ac1 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-DEc1 
Encodes the EpCAM-specific DARPin Ec1 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-HL7-DAc1 
Encodes the EpCAM-specific DARPin Ac1 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-DEc1 
Encodes the EpCAM-specific DARPin Ec1 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-scFvA5 
Encodes the CD105-specific scFv A5 fused 
to the PDGFR TMD under control of the 
CMV promoter 
(Rasbach, 2010) 
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pDisplay-HL7-scFvA5 
Encodes the CD105-specific scFv A5 fused 
to a helical linker and the PDGFR TMD 
under control of the CMV promoter 
This thesis 
pDisplay-scFvCD20 
Encodes the CD20-specific scFv fused to 
the PDGFR TMD under control of the 
CMV promoter 
(Rasbach, 2010) 
pDisplay-HL7-scFvCD20 
Encodes the CD20-specific scFv fused to a 
helical linker and the PDGFR TMD under 
control of the CMV promoter 
This thesis 
pDisplay-scFv141.7 
Encodes the CD133-specific scFv 141.7 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-scFvAC133 
Encodes the CD133-specific scFv AC133 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-HL7-scFv141.7 
Encodes the CD133-specific scFv 141.7 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-scFvAC133 
Encodes the CD133-specific scFv AC133 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-scFvCD30 
Encodes the CD30-specific scFv fused to 
the PDGFR TMD under control of the 
CMV promoter 
This thesis 
pDisplay-HL7-scFvCD30 
Encodes the CD30-specific scFv fused to a 
helical linker and the PDGFR TMD under 
control of the CMV promoter 
This thesis 
pDisplay-scFvCD8 
Encodes the CD8-specific scFv fused to the 
PDGFR TMD under control of the CMV 
promoter 
This thesis 
pDisplay-HL7-scFvCD8 
Encodes the CD8-specific scFv fused to a 
helical linker and the PDGFR TMD under 
control of the CMV promoter 
This thesis 
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pDisplay-nbs-14 
Encodes the Art2.2-specific nanobody s-14 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-nbl-17 
Encodes the Art2.2-specific nanobody l-17 
fused to the PDGFR TMD under control of 
the CMV promoter 
This thesis 
pDisplay-HL7-nbs-14 
Encodes the Art2.2-specific nanobody s-14 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pDisplay-HL7-nbl-17 
Encodes the Art2.2-specific nanobody l-17 
fused to a helical linker and the PDGFR 
TMD under control of the CMV promoter 
This thesis 
pXX6-80 
Adenoviral helper plasmid encoding E2A, 
E4 and VA 
H. Büning 
pscGFP-SFFV 
Self-complementary AAV transfer vector 
encoding GFP under control of the SFFV 
promoter 
(Münch et al, 
2013) 
pscluc2-SFFV 
Self-complementary AAV transfer vector 
encoding luciferase under control of the 
SFFV promoter 
(Münch et al, 
2013) 
pRC Encodes the AAV2 rep and cap proteins H. Büning 
pRC-VP2KO-HSGPmut 
Encodes the AAV2 rep and cap proteins 
with mutated VP2 start codon and the point 
mutations R585A and R588A 
H. Büning 
pDARPin-9.29-VP2 
Encodes the Her2/neu-specific DARPin 
9.29 fused to the N-terminus of the AAV2 
VP2 protein containing the point mutations 
R585A and R588A 
(Münch et al, 
2013) 
pDARPin-9.29Myc-VP2 
Encodes the Myc-tagged Her2/neu-specific 
DARPin 9.29 fused to the N-terminus of the 
AAV2 VP2 protein containing the point 
mutations R585A and R588A 
(Münch et al, 
2013) 
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pDARPin-Ec1-VP2 
Encodes the EpCAM-specific DARPin Ec1 
fused to the N-terminus of the AAV2 VP2 
protein containing the point mutations 
R585A and R588A 
This thesis 
pDARPin-Ec1Myc-VP2 
Encodes the Myc-tagged EpCAM-specific 
DARPin Ec1 fused to the N-terminus of the 
AAV2 VP2 protein containing the point 
mutations R585A and R588A 
This thesis 
pDARPin-Ec1His-VP2 
Encodes the His-tagged EpCAM-specific 
DARPin Ec1 fused to the N-terminus of the 
AAV2 VP2 protein containing the point 
mutations R585A and R588A 
This thesis 
pDARPin-Ac1-VP2 
Encodes the EpCAM-specific DARPin Ac1 
fused to the N-terminus of the AAV2 VP2 
protein containing the point mutations 
R585A and R588A 
This thesis 
2.1.9 Bacterial strains and mammalian cells  
Name Description Source 
E. coli Top10 Chemically competent bacterial strain 
Life 
Technologies 
E. coli SURE 
Chemically competent bacterial strain (Stop 
Unwanted Rearrangement Events) 
Stratagene 
HEK-293T 
Human embryonic kidney cell line, genetically 
engineered to express the SV40 T antigen 
ATCC 
CRL-11268 
SK-OV-3 Human ovarian carcinoma cell line 
ATCC 
HTB-77 
CHO-K1 Chinese hamster ovary cell line 
ATCC 
CCL-61 
CHO-Her2 
Chinese hamster ovary cell line genetically 
engineered to express Her2/neu 
(Münch et al, 
2011) 
MDA-MB-453 Human breast cancer cell line 
ATCC 
HTB-131 
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Name Description Source 
MCF-7 Human breast cancer cell line 
ATCC 
HTB-22 
LNT-229 Human glioblastoma cell line 
ATCC 
CRL-2611 
CHO-EpCAM 
Chinese hamster ovary cell line genetically 
engineered to express EpCAM 
This thesis 
CHO-EpCAM L1 
Chinese hamster ovary cell line genetically 
engineered to express EpCAM 
This thesis 
CHO-EpCAM M6 
Chinese hamster ovary cell line genetically 
engineered to express EpCAM 
This thesis 
CHO-EpCAM H1 
Chinese hamster ovary cell line genetically 
engineered to express EpCAM 
This thesis 
HMECs Human mammary epithelial cells Lonza 
2.1.10 Culture media 
Name Description Source 
Luria-Bertani (LB) 
broth 
1% tryptone, 0.5% yeast extract, 1% NaCl 
in H2O pH 7.2 
Paul-Ehrlich-Institut 
S.O.C. medium 
2% Tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, 20 mM glucose in H2O 
Invitrogen 
Dulbecco’s modified 
Eagle medium 
(DMEM) 
Supplemented with 10% FCS and 2 mM 
L-glutamine as culture medium for HEK-
293T, CHO-K1, MDA-MB-453, MCF-7, 
LNT-229 and all CHO-EpCAM cells  
Lonza 
McCoy’s medium 
Supplemented with 10% FCS and 2 mM 
L-glutamine as culture medium for SK-
OV-3 cells 
Sigma-Aldrich 
Mammary Epithelial 
Cell Growth Medium 
BulletKit™ 
Culture medium for HMECs Lonza 
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2.2 Methods of molecular biology 
2.2.1 Transformation of chemically competent bacteria 
For transformation, chemically competent E. coli Top10 or SURE bacteria were thawed on 
ice and 50 ng DNA or 5 µl ligation reaction mix were added. After 30 min incubation, 
bacteria were heat-shocked at 42°C for 45 seconds in a thermomixer and immediately cooled 
on ice. For initial recovery, cells were diluted with 500 µl S.O.C. medium and incubated for 
30 min at 37°C and 600 rpm. Transformed bacteria were then plated on LB agar plates 
containing the corresponding antibiotics and incubated over night at 37°C or for 3 days at 
25°C.  
2.2.2 Plasmid preparation 
Plasmid DNA from transformed bacteria was purified using the GeneJET Plasmid Miniprep 
Kit, EndoFree® Plasmid Maxi Kit or JETStar NoEndo Jetfilter Giga Kit according to the 
manufacturer’s instructions. These kits are based on the use of silica membranes binding 
DNA in the presence of high concentrations of chaotropic salts or anion-exchange columns. 
Thus, cellular components can be washed away prior to DNA elution with low-salt buffers.  
For purification of low, medium and high amounts of DNA, 5 ml, 200 ml or 2400 ml LB 
medium supplemented with the corresponding antibiotic were inoculated with a single 
bacteria clone and cultivated overnight at 37°C. The grown bacteria were pelleted by 
centrifugation at 2,000 × g (low amounts, Multifuge 3) or 6,000 rpm (medium and high 
amounts, Sorvall Rc26 plus) for 15 min at 4°C. The concentration of purified DNA was 
determined photometrically (NanoDrop 2000c). 
2.2.3 Restriction of DNA 
Analytical or preparative restrictions of DNA were performed using restriction endonucleases 
from New England Biolabs according to the manufacturer’s instructions. Standard restriction 
reaction mix was prepared as follows: 
 
 
32 
 
Material and Methods 
 Analytical Preparative 
DNA 1 µg 5 µg 
10x restriction buffer 3 µl 5 µl 
Enzyme(s) 5 U 20 U 
H2O ad 30 µl ad 500 µl 
Incubation time 1-2 hours 5-16 hours 
 
For digestions with two or more enzymes the optimal buffer conditions for all endonucleases 
were chosen. If different incubation temperatures were required, digestions were performed 
sequentially.  
2.2.4 DNA Ligation 
Ligation of double-stranded DNA fragments with either cohesive or blunt termini was carried 
out using the Rapid Ligation Kit (Fermentas) according to the manufacturer’s instructions. In 
total 50 ng – 200 ng DNA was used for each reaction in a molar ratio of 3:1 for 
insert/linearized vector DNA. The ligation mix, which contained Rapid Ligation buffer and 
the T4-DNA ligase to catalyze the formation of phosphodiester bonds, was incubated for 5-
15 min at room temperature. The ligated DNA was directly used for transformation of 
chemically competent bacteria or frozen at -20°C.  
2.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyze and separate DNA fragments of different 
sizes. This technique is based on the molecular sieve properties of polymerized agarose gels 
and the distinct migration behavior of negatively-charged DNA according to its size in the 
electrical field. Agarose gels with different concentrations were produced by adding the 
corresponding amount of agarose to 100 ml TAE buffer and heating until the agarose powder 
dissolved. After addition of 50 µg/ml ethidium bromide which intercalates into DNA strands 
and can be visualized under UV light, the solution was casted into a tray to allow 
polymerization. For separation of fragments > 1 kb, 0.7-1% agarose gels were prepared, 
whereas 1.5-2% agarose gels were used for smaller fragments.   
DNA samples were supplemented with 5x loading buffer and loaded into the gel pockets in a 
Bio-Rad WIDE MINI-SUB chamber. Electrophoresis was performed at 100-120 V until 
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fragments were sufficiently separated. Results were analyzed under UV light and compared to 
a 2-Log DNA ladder (New England Biolabs).  
2.2.6 Isolation of DNA from agarose gels 
DNA fragments of interest were cut out of the agarose gel and transferred into an Eppendorf 
tube. Purification of DNA was performed using the GeneJET Gel Extraction Kit according to 
the manufacturer’s instructions.   
2.2.7 Isolation of DNA from tissue and vector particles 
For the purification of total DNA from tissues or vector particles, the DNeasy Blood & Tissue 
Kit was used according to the manufacturer’s instructions. Subsequently, DNA obtained from 
0.5 cm mouse tail was used for genotyping transgenic mice by polymerase chain reaction. 
Genomic DNA obtained from 10 µl AAV preparations was used for determination of 
genomic titers by quantitative polymerase chain reaction.  
2.2.8 Polymerase chain reaction 
Polymerase chain reaction (PCR) allows amplification of specific DNA sequences using two 
or more primers. Additionally, primer-dependent extensions and mutations can be introduced 
into the amplified DNA sequences, emphasizing the importance of this powerful technique in 
molecular biology. A typical PCR reaction consists of several thermal cycles with multiple 
steps: (i) initial denaturation, (ii) annealing of the primers to the complementary DNA 
sequence and (iii) elongation of DNA by a DNA polymerase. The annealing and elongation 
temperatures have to be adjusted according to the primers, the amplicon length and the 
applied polymerase.   
For cloning purposes, the Phusion Hot Start II High Fidelity DNA polymerase was used, 
offering high proofreading capacity and fast elongation rates. Due to a reversible bound 
affibody inhibiting the DNA polymerase activity at room temperature, amplification of 
nonspecific products is prevented. The reaction mix was prepared as follows: 
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Component  
Template DNA 5-50 ng 
5x Phusion HF buffer 10 µl 
10 mM dNTPs 1 µl 
Primer for 0.5 µM 
Primer rev 0.5 µM 
Phusion Hot Start II HF DNA Polymerase (2 U/µl) 0.5 µl 
H2O ad 50 µl 
 
The PCR was performed using the manufacturer’s cycling instructions, repeating steps 2-4 
25-times: 
1. Initial denaturation   98°C      30 s 
2. Denaturation       98°C      5-10 s 
3. Annealing         52-72°C*   10-30 s 
4. Extension          72°C      15-30 s/kb 
5. Final Extension      72°C      5 min 
*depending on the primers 
For genotyping of human EpCAM transgenic mice, a Taq DNA polymerase PCR protocol 
was used: 
Component  
Template DNA (isolated from mouse tail) 7.5 µl 
10x DreamTaq Buffer 3 µl 
10 mM dNTPs 0.67 µl 
Primer oIMR8744 (100 µM) 0.75 µl 
Primer oIMR8745 (100 µM) 0.75 µl 
Primer oIMR8558 (100 µM) 1.5 µl 
Primer oIMR8559 (100 µM) 1.5 µl 
DreamTaq (5 U/µl) 0.25 µl 
H2O ad 30 µl 
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The PCR was performed using the manufacturer’s cycling instructions, repeating steps 2-4 
34-times: 
1. Initial Denaturation    95°C      3 min 
2. Denaturation        95°C      30 s  
3. Annealing          55°C      60 s 
4. Extension           72°C      60 s 
5. Final Extension       72°C      2 min 
Using two different primer pairs, a transgene-specific sequence of 383 bp and an internal 
positive control sequence of 200 bp can be amplified and detected simultaneously.  
2.2.9 Quantitative polymerase chain reaction  
Quantitative PCR (qPCR) was performed to determine the genomic titer of AAV vectors. Key 
feature of this method is a dye e.g. SYBR Green I which intercalates specifically into the 
double strand of the amplified PCR product. By measuring the increase of fluorescence after 
each cycle monitoring of the amplification is enabled. For the determination of genomic titers, 
the FastStart DNA MasterPLUS SYBR Green I kit was used according to the manufacturer’s 
instructions. DNA isolated from AAV vectors (2.2.7) served as template. Plasmid DNA 
containing the respective sequence was used as standard.  
Component  
H2O 14 µl 
Primer for (20 pmol/µl) 0.5 µl 
Primer rev (20 pmol/µl) 0.5 µl 
FastStart DNA MasterPLUS SYBR Green I (1a+1b) 4 µl 
Template DNA (isolated from AAV vectors) 1 µl 
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Depending on the packaged transgene, the primer pairs GFP-for/GFP-rev or luc-for/luc-rev 
were used and the qPCR program was adapted accordingly: 
1. Initial denaturation    95°C      10 min      slope: 20°C/s 
2. Quantification (40 cycles) 
a.              95°C      10 s        slope: 20°C/s 
b.              64°C      4 s*, 5 s#     slope: 20°C/s 
c.              72°C      7 s*, 10 s#    slope: 20°C/s 
3. Melting curve 
a.              95°C      0 s        slope: 20°C/s 
b.              67°C      10 s        slope: 20°C/s 
c.              95°C      0 s        slope: 0.1°C/s 
*for GFP transferring AAV vectors, #for luciferase transferring AAV vectors 
2.3 Protein biochemical methods 
2.3.1 SDS-polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a commonly used 
technique for separating proteins based on their molecular mass. The anionic detergent SDS 
denatures proteins thus removing secondary and tertiary protein structures. Additionally, SDS 
coats the proteins mostly proportional to their molecular weight conferring a negative charge 
to the linearized protein. When applied to an electrical field, the negatively charged proteins 
migrate to the anode and can be separated by the gel matrix of a polyacrylamide gel according 
to their molecular mass, analogous to agarose gel electrophoresis.   
Vector particles or flotation assay fractions were mixed with 2x urea sample buffer and 
incubated at 95°C for 10 min. Then, samples were loaded to 10% SDS polyacrylamide gels 
and separated using the Bio-Rad Mini Protein II chamber system. The Precision Plus 
Protein™ Standard Kaleidoscope™ marker, commercially available from Bio-Rad, was used 
as protein standard. SDS-PAGE was performed at 70 V until samples entered the resolving 
gel and then at 120 V until the desired marker protein reached the end of the gel.  
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 Resolving gel (10%) Stacking gel (5%) 
30% acrylamide 3.33 ml 0.83 ml 
1 M Tris, pH 8.8 3.9 ml - 
1 M Tris, pH 6.8 - 0.63 ml 
50% glycerine 0.82 ml - 
10% SDS 55 µl 25 µl 
Aqua bidest 1.9 ml 3.5 ml 
TEMED 13 µl 10 µl 
20% APS 26 µl 20 µl 
Food coloring - 20 µl 
2.3.2 Western blot analysis 
Following SDS-PAGE (2.3.1), the separated proteins can be transferred onto a protein-
binding surface e.g. a nitrocellulose membrane for subsequent visualization by 
immunostaining. This so-called western blot analysis was performed using the Bio-Rad 
Trans-Blot SD Semi-Dry transfer cell. Whatman filter papers, nitrocellulose membrane and 
the SDS polyacrylamide gel were shortly incubated in transfer buffer before they were 
carefully layered into the transfer cell. After blotting at 180 mA for 90 min, unspecific 
membrane binding sites were blocked with blocking buffer (TBS-T with 5% horse serum or 
5% milk powder) for one hour at room temperature. For specific detection of proteins, 
membranes were incubated with primary antibody diluted in blocking buffer over night at 
4°C. The next day, membranes were washed five times with TBS-T and then incubated with 
the respective secondary antibody conjugated to horseradish peroxidase (HRP). After a 
second washing step, detection was performed using the ECL Plus Western Blotting detection 
reagent. The reagent contains luminol which can be oxidized, a process catalyzed by HRP, 
resulting in an excited product emitting light with a wavelength of 425 nm. Signals were 
visualized using chemiluminescence films or the Fusion FX7 imager.  
2.3.3 Dot blot analysis 
Fractions collected during affinity chromatography of AAV vectors were analyzed by dot 
blot. This method is a simple way to detect the presence or absence of a protein in a sample 
without electrophoretic protein separation prior to analysis. For the detection of AAV2 capsid 
proteins, 25 µl of collected fractions were mixed with 1% SDS and incubated for 10 min at 
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95°C. Whatman filter papers and nitrocellulose membrane pre-incubated first in water and 
then PBS were layered into the dot blot apparatus and samples were transferred onto the 
membrane according to the manufacturer’s instructions. Subsequent, immunostaining and 
detection of chemiluminescence was performed as described for western blot analysis (2.3.2). 
2.3.4 Flotation assay 
Detergent-resistant membranes (DRMs) were isolated by flotation assay. This method is 
based on the specific properties of the sphingolipid- and cholesterol-rich detergent-resistant 
membranes. They are not solubilized by detergents under certain conditions and can therefore 
be separated from the rest of the cellular material using density centrifugation. For DRM 
isolation, vector particle-producing cells were scraped and lysed in ice-cold TNE buffer 
containing 0.5% Triton X-100. Lysates were homogenized through a 23-gauge needle and 
incubated with constant agitation for 30 min at 4°C. Then, they were mixed with 1 ml 
OptiPrep™, transferred to ultracentrifuge tubes and overlaid with an OptiPrep™ gradient 
(2 ml of 30% followed by 1 ml of 25, 20, 17.5, 15, 12.5 and 5% OptiPrep™ in TNE buffer). 
Centrifugation was performed for 16 h at 39,000 rpm and 4°C in a Beckman SW41 rotor. 
Gradient fractions were analyzed by SDS-PAGE and western blotting. 
2.3.5 Enzyme-linked immunosorbent assay 
The enzyme-linked immunosorbent assay (ELISA) is used to detect and quantify a substance 
in solution. Antigens or antibodies are adsorbed to a well-plate followed by blocking, washing 
and detection using enzyme-conjugated antibodies.  
Quantification of p24 gag in lentiviral vector particle preparations was performed using the 
RETROtek HIV p24 antigen ELISA kit according to the manufacturer’s instructions.  
For capsid titer determination, immunoplates (Nunc) were coated with serial dilutions of 
vector particles over night at 4°C. The next day, plates were washed three times with ELISA 
washing buffer and blocked with ELISA blocking buffer for 2 hours at room temperature. 
Primary antibody incubation with the α-AAV2 intact capsid antibody diluted in ELISA 
blocking buffer was performed for one hour at room temperature, followed by another 
washing step and incubation with the anti-mouse Biotin-conjugated secondary antibody for 
one hour at room temperature. Again, the plate was washed and then incubated with 
streptavidin-HRP diluted in ELISA blocking buffer. After final washing steps with ELISA 
washing buffer and water, coated capsids were detected using the TMB liquid substrate 
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system and a microplate reader according to the manufacturer’s instructions. Previously 
analyzed vector preparations were used as standard.   
For the detection of surface-exposed DARPins on AAV particles, immunoplates were coated 
with α-myc tag antibody diluted in PBS over night at 4°C. After washing and blocking, serial 
dilutions of AAV vector preparations were added for 2 hours at room temperature. Detection 
of captured AAV particles was performed as described for the capsid ELISA. 
2.3.6 Immobilized-metal affinity chromatography 
Immobilized-metal affinity chromatography (IMAC) is a method to separate proteins and 
molecules based on the interaction with metal ions. Proteins containing a polyhistidine tag can 
be retained in a HisTrap HP column (GE Healthcare) due to formation of chelat complexes 
between the tag and the nickel ions of the stationary phase. Then, bound proteins can be 
eluted by addition of the aromatic heterocycle imidazole.  
For IMAC purification of DARPin-displaying AAV vector particles a Knauer HPLC system 
was used according to the manufacturer’s instructions. Prior to sample loading, columns were 
washed with 15 column volumes water and equilibrated with 15 column volumes IMAC 
binding buffer. Vector particles were diluted in IMAC binding buffer and were loaded onto 
the column at a flow rate of 0.1 ml/min followed by washing with 10 column volumes. For 
elution of bound vector particles, columns were washed with another 3 column volumes 
IMAC binding buffer and then eluted with 5 column volumes IMAC elution buffer at a flow 
rate of 0.2 ml/min. A final elution step to clean the columns was performed with buffer 
containing 500 mM imidazole. During loading, washing and elution, flow through was 
collected by an autosampler.  
2.3.7 Dialysis 
Iodixanol density gradient- or IMAC-purified AAV vectors were dialyzed using Slide-A-
Lyzer® dialysis cassettes (7,000 Da molecular weight cut-off, Thermo Scientific) according to 
the manufacturer’s instructions. AAV preparations were injected into the cassettes with a 21-
gauge needle and dialyzed against 2 liters of PBS for 12 hours at 4°C.  
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2.3.8 Immunofluorescence microscopy 
For immunofluorescence microscopy, HEK-293T cells were seeded into a covered chamber 
of an 8-well LabTek plate and transfected with 0.25 µg pDisplay-D9.29, pCG-HmutΔ18 and 
pCG-FΔ30. After 24 hours, cells were washed with PBS and fixed with 4% formaldehyde for 
20 min at room temperature. Cells were permeabilized with 0.5% Triton X-100 in PBS for 
8 min before they were washed again and incubated with blocking solution (PBS, 5% chicken 
serum) for 45 min at room temperature. Subsequently, cells were incubated with α-MV H and 
α-HA tag antibody for one hour at 37°C. Secondary antibodies conjugated to Alexa Fluor 
dyes 546 and 633, respectively, were added and left for one hour at 37°C. Finally, cells were 
washed twice with PBS and were analyzed using a laser scanning microscope (LSM 510). 
Micrographs shown as false-color images were assembled using the LSM Image Browser 
(Zeiss, Jena, Germany).  
2.3.9 Electron microscopy 
For immunoelectron microscopy, lentiviral vector-producing HEK-293T cells were fixed with 
2% formaldehyde, washed three times with PBS and incubated with blocking solution (PBS, 
5% chicken serum). Primary antibody directed against HA tag was added to the cells and left 
for one hour at 37°C. After two additional washing steps, cells were incubated with secondary 
anti-mouse-10 nm gold antibody for one hour at 37°C following glutaraldehyde fixation, 
epoxy embedding and preparation of ultrathin sections. For this, detached cells were 
embedded in agarose, fixated with 1% osmium tetroxide and contrasted with 2% uranyl 
acetate. Stepwise dehydration of the samples was performed using 30%, 50%, 70%, 80%, 
90%, 96% and 100% ethanol. Finally, samples were embedded into epoxy, cut into ultrathin 
sections and mounted on Formvar-coated 200-mesh copper grids.   
For electron microscopy of AAV vector preparations, Formvar-coated 200-mesh nickel were 
placed on a suspension drop containing AAV2, Her2-AAV or EpCAM-AAV particles for 
10 min at room temperature. Then, the grids were washed three times with H2O and stained 
for 15 seconds in 2% uranyl acetate.  
All samples were analyzed using an EM109 transmission electron microscope.  
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2.4 Cell culture and virological methods 
2.4.1 Cultivation of cell lines 
Cells were cultivated in the appropriate medium (2.1.10) in a humidified incubator at 37°C, 
5% CO2 and 90% humidity. They were passaged twice a week. For this purpose, medium was 
aspirated and adherent cells were washed with PBS and then detached using trypsin for 5 min 
at 37°C. An appropriate fraction of the resulting suspension was seeded into a new culture 
flask with fresh medium.    
All cell lines were regularly checked for contaminations with mycoplasma by PCR.  
2.4.2 Freezing and thawing of cell lines 
Adherent cells were detached as described (2.4.1), resuspended in cell culture medium and 
centrifuged for 4 min at 800 rpm and 4°C. The cell pellet was resuspended in cold freezing 
medium (2.1.5), aliquoted into cryotubes and frozen at -80°C using a 5100 Cryo Freezing 
Container (Nalgene). 24 hours later, cells were transferred to the gas phase of liquid nitrogen 
for long-term storage at -155°C.   
Frozen cells were thawed in a 37°C water bath and immediately transferred to a cell culture 
flask containing pre-warmed medium. The next day, cell culture medium was exchanged.  
2.4.3 Transfection of cell lines 
Mammalian cells were transfected using the cationic polymer polyethylenimine (PEI). 
Positively-charged PEI/DNA complexes bind to the cell surface, are endocytosed and 
eventually released into the cytoplasm of a cell.   
For transfection of HEK-293T cells, 1.4 x 105 cells per cm2 cell culture vessel were seeded. 
The next day, cell culture medium was replaced with DMEM supplemented with 15% FCS 
and 3.2 mM glutamine. Then, 0.2 µg DNA/cm2 and 0.8 µl PEI/cm2 (2.1.5) were each diluted 
with DMEM and vortexed. Both solutions were combined and again vortexed thoroughly. 
After incubation for 20 min at room temperature, the transfection mix was added to the cells. 
Another medium exchange was performed 24 hours later to remove residual PEI/DNA 
complexes.   
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2.4.4 Cultivation of primary cells 
Primary cells are freshly derived from a living organism and resemble more closely the 
physiological state of cells in the body. They undergo only a predetermined number of cell 
divisions and are usually less robust than immortal cell lines. HMECs were cultivated in 
Mammary Epithelial Cell Growth Medium (2.1.10) according to the distributor’s instructions 
using supplied subculture reagents.  
2.4.5 Isolation of human peripheral blood mononuclear cells 
Human peripheral blood mononuclear cells (PBMCs) were isolated from freshly collected 
healthy donor blood or buffy coats (Blutspendedienst Hessen) by density centrifugation. For 
this purpose, either Vacutainer CPT Cell Preparation tubes (Becton Dickinson) were used 
according to the manufacturer’s instructions or Histopaque®-1077 gradients were prepared. 
After density centrifugation, erythrocytes and granulocytes were pelleted and the 
mononuclear cell layer (lymphocytes, monocytes and macrophages) was aspirated from the 
interphase. PBMCs were washed twice with PBS and remaining erythrocytes were 
subsequently lysed for 20 min at 37°C using 0.86% ammonium chloride. After two additional 
washing steps, PBMCs were counted and resuspended in cell culture medium.  
2.4.6 Vector production and concentration 
Lentiviral and AAV vector particles were generated by transient transfection of HEK-293T 
cells using the PEI transfection protocol (2.4.3). Production scales ranged from one 6-well up 
to 40 cell culture dishes à 147.8 cm2 growth surface.  
For production of lentiviral vector particles, co-transfection of pCG-FΔ30, pCG-HmutΔ18, 
pDisplay-D9.29, pCMVΔR8.91 and transfer vector in a ratio of 5:3:6:20:21 was performed. 
Two days after transfection, cell culture supernatant containing vector particles was filtered 
with a 0.45 µm PTFE syringe filter and concentrated over a 20% sucrose cushion by 
ultracentrifugation in a SW28 rotor (Beckman Coulter) for 3 hours at 28,000 rpm and 4°C or 
for 24 hours at 4,500 × g and 4°C. The pellet was resuspended in PBS and aliquots were 
stored at -80°C.   
AAV vector particles were produced using the adenovirus helper-free AAV packaging 
strategy (Xiao et al, 1998). The plasmids pRC-VP2KO-HSPGmut, pDARPin-VP2, pXX6-80 
and the transfer vector were co-transfected into HEK-293T cells in a ratio of 1:1:1:3. Two 
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days after transfection, cells were scraped off the cell culture dish and centrifuged for 7 min at 
1000 rpm. Cell pellets were resuspended in AAV lysis buffer (2.1.5) and subjected to three 
freeze/thaw cycles in liquid nitrogen and a 37°C water bath. After benzonase treatment 
(50 U/ml) for 30 min at 37°C, cell debris was removed by centrifugation for 20 min at 
3700 × g and 4°C. Vector particle containing supernatant was diluted with PBS M/K (2.1.5) 
and transferred to a Quick-Seal® ultracentrifugation tube (Beckman Coulter). Subsequently, a 
gradient of 9 ml 15%, 6 ml 25%, 5 ml 40% and 6 ml 60% OptiPrep™ was underlayered. 
Density gradient centrifugation was performed in a 70Ti rotor (Beckman Coulter) for 
two hours at 63,000 at 4°C. AAV vector particles were recovered from the 40% OptiPrep™ 
fractions, aliquoted and stored at -80°C.  
2.4.7 Transduction and titration 
For titration, serially diluted viral particle solutions were added to cells. At 72 h after 
transduction, the percentage of GFP-positive cells was determined by flow cytometry 
analysis. Dilutions with 2 to 20% of GFP-positive cells were used to calculate the titer in 
transducing units/ml.  
For transduction, 8 x 103 to 1.2 x 104 cells were seeded into a single well of a 96-well plate. 
The next day, vector particle dilutions were added to the cells, from which in advance 
medium was aspirated.   
For spinfection experiments, cells and vector dilutions were centrifuged at 700 × g and 4°C 
for 1 h. After 72 h, titers were calculated based on the percentage of green fluorescent cells 
determined by flow cytometry. 
2.4.8 Flow cytometry und fluorescence-activated cell sorting 
Flow cytometry is a laser-based technique to measure and analyze characteristics of cells. 
Single cells flow in a sheath fluid through a beam of light and properties such as relative size, 
granularity, or fluorescence intensity can be determined based on scattered and emitted light.  
For flow cytometry analysis of cells, medium was aspirated and cells were washed with 
FACS washing buffer and then detached using trypsin. After centrifugation at 800 rpm for 
4 min, cells were either stained with antibodies or directly fixed with FACS fix.  
For fluorescence-activated cell sorting (FACS) of CHO-EpCAM cells, cells were detached as 
described above. After centrifugation at 800 rpm for 4 min, cells were stained with anti-
EpCAM-PE antibody and washed again. Cells were resuspended in FACS sorting buffer and 
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filtered through a 50 µm cell strainer. EpCAM-positive single cells were sorted into 96-wells 
and cultivated in conditioned medium.  
2.4.9 Neutralization assay 
Lentiviral vector particles were incubated with or without H-specific MAbs (0.001 µg, 
0.01 µg, 0.1 µg or 1 µg in 100 µl) for 1 h at room temperature and then added to SK-OV-3 
cells at an MOI of 0.3. The percentage of GFP-positive cells was determined after 72 h by 
flow cytometry.  
2.4.10 Binding assay 
Vector particles (0.14 µg p24) were incubated with 1 µg MAbs for 1 h at room temperature. 
Subsequently, 1.5×105 SK-OV-3 cells were added following 1 h of incubation at 4°C. Cell-
particle complexes were then stained with anti-HA tag PE-coupled antibody, fixed and 
analyzed by flow cytometry. 
2.4.11 Competition assay 
For the competition of EpCAM-AAV with soluble recombinant protein, vector particles were 
incubated with increasing amounts (0, 0.001, 0.01, 0.1, 1 or 10 µg/ml) of the extracellular 
domain of human or murine EpCAM for 1 h at 4°C. Then, samples were used to transduce 
EpCAM-positive cells. Analysis of GFP expression was performed 72 h post transduction.  
2.4.12 Detection of tumor cells in whole blood samples 
Mimicking the conditions of circulating tumor cells in blood samples derived from patients, 
MDA-MB453 tumor cells were mixed with 7.5 ml blood of healthy donors. PBMCs were 
purified as described in chapter 2.4.5, plated in a 10 cm² cell culture dish and 3×1010 vector 
genomes EpCAM-AAV were added. After 48 h, cells were completely removed from the cell 
culture dish using trypsin, washed, incubated with human FcR blocking reagent for 15 min on 
ice (20 µl per 107 cells) and stained with anti-CD326-PE (diluted 1:10) and anti-CD45-APC 
(diluted 1:5) for another 15 min. Samples were washed again, fixed with 1% formaldehyde in 
PBS and analyzed by flow cytometry. A gating strategy to exclude debris, doublets and high 
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CD45+ cells was performed. Remaining GFP+/EpCAM+ cells were analyzed using version 
4.07 of the FCS Express software (De Novo). 
2.5 Experimental mouse work 
2.5.1 Injection of tumor cells 
SK-OV-3 cells were cultured and detached as described (2.4.1), centrifuged for 4 min at 
800 rpm and washed with PBS. After an additional centrifugation step, cells were 
resuspended in PBS and counted. Then, CB17 SCID female mice (6 to 8 weeks old; Harlan 
Laboratories, Eystrup, Germany) were anaesthetized with 2.5% isoflurane. The cell 
suspension was briefly vortexed and 5 x 106 cells in 100 µl were injected subcutaneously 
using a 23 gauge needle into the right flank of the mice.  
2.5.2 Injection of vector particles 
For intravenous injection (i.v.) of vector particles, mice were transferred to a restrainer and 
200 µl vector particles diluted in PBS were injected into a lateral tail vein using a 30 gauge 
needle.   
For intraperitoneal injection (i.p.), mice were restrained and tilted so that the head was facing 
downwards and 200 µl vector particles diluted in PBS were injected into the abdomen using a 
30 gauge needle.   
2.5.3 In vivo imaging 
The in vivo imaging technology allows non-invasive visualization of bioluminescence signals 
in small animals. In order to detect luciferase expression, mice were injected i.p. with 150 mg 
D-Luciferin/kg body weight (2.1.5). After 5 min, mice were anaesthetized with 2.5% 
isoflurane in a XGI-8 induction chamber for 2 min and placed into the IVIS Spectrum 
imaging chamber. Imaging data were obtained 10 - 20 min after substrate injection. Data were 
analyzed using the software Living Image 4.2 (Caliper Life Sciences).  
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3 Results 
This thesis describes the generation and characterization of two types of receptor-targeted 
viral vectors for the application in basic research as well as potentially in cancer treatment and 
diagnosis. A lentiviral vector pseudotyped with the measles virus (MV) glycoproteins was 
used to separate the receptor attachment and fusion-helper function provided by the MV H 
protein. It was shown that H is still able to perform its fusion-helper function without 
attaching to the receptor. The resulting vector particles achieved specific and efficient gene 
transfer in vitro and in vivo. Furthermore, AAV vectors targeted to the human epithelial cell 
adhesion molecule (EpCAM) were developed. Fusion of a designed ankyrin repeat protein 
(DARPin) to the N-terminus of the VP2 capsid protein did not affect vector particle integrity 
and resulted in high specificity for EpCAM-positive cells. Since EpCAM-positive cells play a 
major role in metastases initiation and can be an indicator of the efficacy of cancer therapy, 
the vector’s ability to detect rare tumor cells in blood was assessed.  
3.1 Using MV-pseudotyped lentiviral vectors to separate the fusion-helper 
function from receptor attachment 
3.1.1 Setting up the system 
To separate the receptor attachment function from H, three transmembrane proteins had to be  
incorporated into the envelope membrane of LV particles: i) the cytoplasmic tail-truncated F 
protein variant FΔ30, ii) the cytoplasmic tail-truncated H variant HmutΔ18 which is in addition 
mutated in its natural receptor binding sites, and iii) an artificial transmembrane protein 
composed of the transmembrane domain (TMD) of the platelet-derived growth factor receptor 
(PDGFR) and a targeting ligand mediating attachment to the receptor of choice (pDisplay-TL) 
(Figure 11). Different types of targeting ligands were applied including DARPins and scFvs. 
Figure 11 provides an overview on the design and elements present in the different plasmids, 
also including a number of control constructs and variants. Among these are the plasmids 
encoding the unmutated HΔ18 variant, the H*mutΔ18 additionally harboring the F111N 
mutation, a conventional HmutΔ18 fused with a targeting ligand and the glycoprotein of the 
vesicular stomatitis virus (VSV).  
Initially, the coding sequence of DARPin 9.29, which is specific for Her2/neu, a receptor 
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tyrosine kinase overexpressed on cancer cells, was fused to the PDGFR TMD resulting in 
pDisplay-D9.29 (Figure 11) (Rasbach, 2010).  
 
Figure 11: Schematic drawing of constructs used for the generation of lentiviral vectors. A targeting ligand (TD) is 
fused between the HA and myc-tag of the pDisplay (Invitrogen). Resulting proteins are presented on the platelet-derived 
growth factor receptor (PDGFR) transmembrane domain (TMD). The signal peptide (SP) sequence at the N-terminus targets 
the protein to the secretory pathway. The construct pDisplay-HL7-TD contains an additional sequence coding for a helical 
linker (HL7) between the TL and myc-tag. Asterisks mark mutations introduced to ablate natural receptor recognition of H 
(Hmut) or the F111N glycosylation site (H*mut). For retargeting the H protein to a cell surface marker of choice, a TL was 
fused in frame in construct pCG-Hmut∆18-TL. In order to generate control vectors pseudotyped with VSVG, the plasmid 
pMD2.G was used. The transfer vector pSEW or pS-luc2-W encoding the GFP or luciferase reporter genes and the packaging 
construct pCMV∆R8.91 are shown.   
In order to generate D9.29-LV particles having incorporated D9.29, Hmut∆18 and F∆30, 
cotransfection of five plasmids into HEK-293T cells was performed. The plasmids pDisplay-
D9.29, pCG- Hmut∆18, pCG- F∆30 as well as the GFP encoding transfer vector plasmid pSEW 
(Münch et al, 2011; Demaison et al, 2002) and the packaging construct pCMV∆R8.91 
(Zufferey et al, 1997) are required for production and release of the respective vector particles 
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into the supernatant (Figure 11, Figure 12). Supernatants of transfected cells were collected 
after 48 hours and subsequently purified and concentrated by centrifugation over a sucrose 
cushion. 
 
Figure 12: Principle of virus particle generation by transfection of HEK-293T cells. Transfection with the five plasmids 
shown gives rise to D9.29-LV particles pseudotyped with Hmut∆18 (red), F∆30 (dark blue) and D9.29 (light gray and blue). 
Proteins can only become incorporated into the LV particle envelope if they are efficiently 
expressed at the cell surface of producer cells. Fluorescence microscopy of cells expressing 
HmutΔ18 and D9.29 had revealed that both proteins were well expressed on the surface of 
HEK-293T cells (Rasbach, 2010), meeting the critical prerequisite for efficient incorporation 
into LVs. Moreover, Hmut∆18 and D9.29 colocalized (Figure 13A). 
 
Figure 13: D9.29 colocalizes with MV glycoproteins. (A) Hmut∆18 and D9.29 coimmunostaining one day after HEK-293T 
cells were transfected with 0.25 µg of pCG-Hmut∆18, pCG-F∆30, and pDisplay-D9.29. Fixed and permeabilized cells were 
stained with anti-H and then with anti-HA antibody. Secondary antibodies conjugated with Alexa Fluor dyes 546 and 633 
were used for detection. Scale bar, 10 µm. Modified from (Rasbach, 2010). (B) D9.29 resides within the same membrane 
fractions as the MV glycoprotein complex. Detergent-resistant membranes (DRM) from HEK-293T cells transfected with 
pCMVR8.9, pSEW, pCG-Hmut∆18, pCG-F∆30, and pDisplay-D9.29 were separated by flotation assay. The distribution of 
proteins within fractions (fraction 1 represents the top of the gradient) and the pellet (P) was assessed by immunoblotting 
with antibodies specific for H, F, the HA tag of D9.29, the DRM marker flotillin 1, and the non-DRM marker CD46. (Rasbach 
et al, 2013) 
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It is known that H and F form a tight complex already within the endoplasmic reticulum 
(Plemper et al, 2001) and are then transported together to the cell surface. Supposedly, they 
do not distribute randomly within the membrane but are enriched in detergent-resistant 
membranes (DRM) (Avota et al, 2004; Vincent et al, 2000). Therefore, it was evaluated 
whether D9.29 can also be found in these distinct membrane populations together with Hmut∆18 
and F∆30 by membrane flotation assay and subsequent western blot analysis.   
For this assay, vector particle producing HEK-293T cells were lysed in TNE buffer which 
only disrupts membrane parts that are not cholesterol-rich and therefore not detergent-
resistant. In an OptiPrep™ step gradient DRMs were separated from soluble components by 
ultracentrifugation and resulting fractions were analyzed for their protein content. The DRMs 
were present in fractions 5-10 as determined by use of the DRM marker flotillin-1 (Langhorst 
et al, 2005), with the soluble membranes in fractions 11 and 12 as indicated by use of the non-
DRM marker CD46 (Hogue et al, 2011). F∆30 as well as a significant amount of Hmut∆18 
were detected in the DRM fractions (Figure 13B). Although the MV H protein alone has not 
been described to be sorted into DRMs, it is known that it is associated up to 30% with DRMs 
upon coexpression with MV F (Vincent et al, 2000). The modifications in the F and H 
cytoplasmic tails thus did not alter their DRM association. Interestingly, the vast majority of 
D9.29 was also found in the DRM fractions, thus suggesting a colocalization with 
F∆30/Hmut∆18 at the cell membrane. 
3.1.2 Characterization of vector particles 
Besides incorporation into the virus membrane, a proper display of the DARPin 9.29 and the 
efficient release of functional viral particles are crucial for evaluating whether cell entry was 
still possible although receptor attachment had been uncoupled from H. To assess the quality 
of vector preparations, the particles were analyzed for their protein content, accessibility of 
the D9.29, transduction performance as well as infectivity.  
3.1.2.1 D9.29 is incorporated into the viral membrane and accessible 
In addition to D9.29-LV, a series of particles was generated as control: by omitting one of each 
of the three plasmids encoding Hmut∆18, F∆30, or D9.29 and replacing the DNA with an empty 
plasmid called pCG-1, particles with only two of the three transmembrane proteins were 
generated (Figure 14). Moreover, a Hmut∆18 variant (H*mut∆18) was used in which F93 
(correlates to position 111 in the untruncated H protein) was replaced by an asparagine to 
50 
 
Results 
introduce an additional N-glycosylation site (Figure 11, Figure 14). This mutation has been 
described to interfere with H/F complex formation (Paal et al, 2009) and was shown to be 
well expressed in HEK-293T cells (Rasbach, 2010). As positive control conventional 9.29-LV 
particles were generated where the DARPin 9.29 has been fused to the C terminus of Hmut∆18 
(Figure 11) (Münch et al, 2011) thereby integrating the tasks of receptor attachment and 
fusion helper function to H (Figure 14).  
 
Figure 14: Schematic drawing of D9.29-LV and its variants. D9.29-LV contains F∆30 (dark blue) and Hmut∆18 (red) and the 
DARPin (light blue) presented on the PDGFR TMD (gray) in its envelope. The conventional targeting vector 9.29-LV 
displays the DARPin as fusion protein with H. Control vectors w/o F∆30, w/o Hmut∆18, w/o D9.29 or with the H*mut∆18 
variant characterized by an additional N-glycosylation site (yellow) are shown. 
All particles were analyzed by western blotting for the presence of H, F1, which is a subunit 
of F linked to the smaller subunit F2 by a disulfide bond after cleavage of the F0 precursor 
protein, and D9.29 (HA tag) as well as the HIV-1 gag protein p24. For D9.29-LV, all three types 
of transmembrane proteins, i.e. D9.29, Hmut∆18 and F∆30, were found to be efficiently 
incorporated. Notably, Hmut∆18 and F∆30 were incorporated at similar levels to those in the 
conventional 9.29-LV vector (Figure 15A, lanes 1 and 2). H*mut∆18 was also detected in the 
particles (Figure 15, lane 6) and migrated below the 9.29-Hmut∆18 protein due to the smaller 
size of the Hmut∆18 variants compared to the DARPin-H fusion protein. Consistent with the 
omission of one plasmid encoding for each one transmembrane protein during production, no 
F1∆30, Hmut∆18 or D9.29 were detected in the respective samples (Figure 15A, lanes 3-5).   
To further confirm the presence and accessibility of D9.29 on the surface of released particles, 
immunoelectron microscopy was performed. HEK-293T producer cells were fixed, stained 
against the HA tag of D9.29, embedded in epoxy and ultrathin sectioned. It was expected that 
mature viral particles were not only released from the cells but that they were displaying the 
DARPin protein on their surface as indicated by gold labelling (arrow head) (Figure 15B). 
Thus, viral vectors exhibited the expected protein composition, had HIV-1 like morphology 
and had incorporated the additional D9.29 protein. 
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Figure 15: MV-pseudotyped virus incorporates D9.29. (A) Western blot analysis for incorporation of F∆30, D9.29, p24, and 
Hmut∆18 or 9.29-Hmut∆18 in vector particles 9.29-LV, D9.29-LV, and variants of D9.29-LV in which F∆30 (w/o F∆30), 
Hmut∆18 (w/o Hmut∆18), or D9.29 (w/o D9.29) was omitted, respectively, or Hmut∆18 was replaced by H*mut∆18 (w/ H*mut∆18). 
(B) Immunoelectron microscopy of ultrathin sections of HEK-293T producer cells releasing D9.29-LV vector particles. D9.29 
was detected with a primary antibody directed against the HA tag and secondary anti-mouse antibody conjugated with 10-nm 
gold particles (arrow heads) following epoxy embedding and ultrathin sectioning. Scale bar, 200 nm. (Rasbach et al, 2013) 
3.1.2.2 D9.29-LV is able to enter Her2/neu-positive cells 
As demonstrated in the previous chapter, D9.29-LV particles were successfully produced and 
revealed the expected physical properties. But the key question was whether these particles 
will be able to bind to Her2/neu-positive cells via the D9.29 protein and, more importantly, 
then fuse with the cell membrane to enter the cytoplasm.   
To address this question, Her2/neu-positive SK-OV-3 cells were incubated with D9.29-LV and 
its control vectors. D9.29-LV was able to enter the cells which was indicated by strong GFP 
fluorescence and transduced even more cells than the conventional vector 9.29-LV where the 
DARPin was fused to H (Figure 16A). None of the control particles lacking one of the three 
transmembrane proteins or particles containing H*mut∆18 were able to mediate any significant 
transfer of the egfp gene (Figure 16A). Upon performance of transduction experiments in 
serial dilutions to titrate the vectors it could be shown that an almost 10-fold-higher 
transduction efficiency was achieved with D9.29-LV than with 9.29-LV (8.5×106 t.u./ml 
compared to 8.9×105 t.u./ml) (Figure 16B). One possible explanation for the increase in 
transduction efficiency and titer upon presentation of the DARPin 9.29 on the PDGFR 
transmembrane domain instead of H was that more particles were released from D9-29-LV 
producing cells eventually leading to higher concentrated vector stocks. 
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Figure 16: D9.29-LV mediates efficient gene delivery. Equal amounts of egfp gene-delivering virus particles 9.29-LV, D9.29-
LV, and variants of D9.29-LV in which F∆30 (w/o F∆30), Hmut∆18 (w/o Hmut∆18), or D9.29 (w/o D9.29) was omitted, 
respectively, or Hmut∆18 was replaced by H*mut∆18 (w/ H*mut∆18) were added to SK-OV-3 cells. (A) Representative pictures 
and flow cytometry dot plots of SK-OV-3 cells 3 days after addition of virus. Scale bar, 100 µm. (B) Titers on SK-OV-3 cells 
as determined by flow cytometry analysis. Arrows indicate titers of < 1×104 transducing units (t.u.)/ml. (C) Infectivity 
determined as ratio of transducing units (t.u.) per µg p24 for 9.29-LV, D9.29-LV, and MV-LV (n = 4; mean±standard 
deviations [SD] are shown; *, P < 0.01; n.s., not significant by unpaired t test). (Rasbach et al, 2013) 
To determine the amount of particles, the HIV-1 capsid protein p24 was used as an indicator. 
Calculations of titers and quantification of p24 by ELISA for four different virus stocks 
revealed a 26-fold-higher infectivity-to-particle-number ratio (n = 4, P < 0.01) for D9-29-LV 
than for 9.29-LV and a ratio similar to that for the nontargeted MV-LV (Figure 16C). These 
findings ruled out that better transduction performance was due to higher concentrated D9.29-
LV stocks but rather suggested that less particles were produced compared to 9.29-LV. It is 
well known that not all LVs released from producer cells are infectious and functional but it 
seemed that D9.29-LV particles were significantly more infectious than the conventional 
targeting vector and comparable to MV-LV.  
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3.1.2.3 Different targeting ligands can be used as receptor binding domain 
To validate that these findings were not just DARPin 9.29 specific, the whole panel of 
Her2/neu-specific DARPins, that were already described to work for redirecting lentiviral 
vector particles, were applied (Münch et al, 2011). In total five other DARPins, namely G3, 
H14R, 9.26, 9.16 and 9.01, were used (Table 1). Except for DARPin G3 which was selected 
and affinity-maturated using ribosome display (Zahnd et al, 2006; Zahnd et al, 2007), all other 
Her2-specific DARPins were selected from a large phage library by using signal recognition 
particle (SRP) phage display (Steiner et al, 2008). In contrast to conventional phage display, a 
signal sequence directs the proteins to the SRP translocation pathway. This route enables 
translocation of proteins cotranslationally and thus results in much higher display levels of 
stable and fast-folding proteins (Steiner et al, 2008; Steiner et al, 2006).  
Table 1: Applied Her2/neu-specific DARPins 
 9.29c,e G3d,e H14Rc 9.26c,e 9.16c 9.01c 
KD (nmol/l)a 3.83 0.09 0.20 1.36 6.90 N/A 
DARPin typeb N3C N2C N3C N3C N3C N3C 
Her2/neu binding I IV IV I I-III N/A 
a Dissociation constant, b Number of ankyrin repeats; N represents the N-capping repeat, internal binding repeats are indicated 
by numbers, C represents the C-capping repeat, c (Steiner et al, 2008), d (Zahnd et al, 2007), e (Jost et al, 2013) 
In a first experiment, particles displaying the DARPin G3 on the PDGFR transmembrane 
domain were generated (DG3-LV). This DARPin binds the membrane-proximal Her2/neu 
domain IV, whereas DARPin 9.29 is directed against the membrane-distal domain I (Jost et 
al, 2013). Compared to particles presenting the DARPin G3 directly fused to H (G3-LV), 
DG3-LV revealed lower transduction efficiency. Only 16% SK-OV-3 cells were GFP-positive, 
whereas G3-LV transduced up to 30% of the cells (Figure 17A, left and middle).    
Since one of the main differences between G3 and 9.29 is their Her2/neu binding domain, this 
could be the reason for the efficiency drop. Therefore, the distance between DARPin and 
Her2/neu domain IV was compensated by inserting a helical linker (HL) between the PDGFR 
transmembrane domain and the DARPin G3.   
The coding sequence for the helical linker RGSGA-(EAAAK)7-ALGS was synthesized 
(pRC2.1-Helical Linker) and inserted into the NotI/SalI digested pDisplay-DG3. The resulting 
pDisplay-HL7-DG3 (Figure 11) was used for production of DHL7-G3-LV particles. Remarkably, 
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titers increased dramatically and resulted in more than 80% positive SK-OV-3 cells (Figure 
17A, right).  
 
Figure 17: Panel of Her2/neu-specific DARPins as alternative targeting ligands. (A) SK-OV-3 cells were transduced 
with particles presenting the Her2/neu-specific DARPin G3 fused to H (G3-LV), to the PDGFR transmembrane domain 
(DG3-LV), or to the PDGFR transmembrane domain connected by a helical linker (DHL7-G3-LV). Representative pictures of 
GFP-expressing cells were taken 72 h after transduction, and the percentage of GFP-positive cells was determined by flow 
cytometry. Scale bar, 100 µm. (B) SK-OV-3 cells were transduced with particles presenting the DARPin G3, 9.26, 9.16, 9.01 
or H14R either fused to the PDGFR transmembrane domain (white bars) or to the PDGFR transmembrane domain connected 
by a helical linker (black bars). Titers as determined by flow cytometry are shown and fold changes are indicated. (Rasbach 
et al, 2013) 
After production of all five DX-LV and DHL7-X-LV (X stands for the respective Her2/neu-
specific DARPin) variants, titers were determined on SK-OV-3 cells. Consistently, for 
particles presenting a DARPin directed against domain IV, titers increased 72-fold for DHL7-
G3-LV and 5.7-fold for DHL7-H14R-LV compared to DG3-LV and DH14R-LV. In contrast, the 
helical linker did neither increase nor decrease titers of particles presenting DARPins 9.26 and 
9.16. The strongest fold-change was observed for the vector pair D9.01-LV/DHL7-9.01-LV. 
Although the Her2/neu binding domain of this specific DARPin is not known, it can be 
speculated that it is sterically not favorable when the DARPin is presented directly on the 
PDGFR transmembrane domain.   
Regardless of their size, binding domain or Her2/neu affinity, all five DARPins could be 
successfully used for generating particles that were able to enter cells although receptor 
attachment was uncoupled from H. Interestingly, it could be shown that the distance between 
receptor attachment domain and membrane influences the transduction efficiency.   
In a next step, other receptor types than Her2/neu were addressed. CD4- and EpCAM-specific 
DARPins (Schweizer et al, 2008; Stefan et al, 2011), single-chain variable fragments (scFv) 
directed against CD105, CD20, CD133, CD30 and CD8 (Abel et al, 2013; Funke et al, 2008; 
Anliker et al, 2010; Friedel et al; Zhou et al, 2012) and nanobodies binding to rat ADP-
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ribosyltransferase (Art2.2) (Koch-Nolte et al, 2007) were tested as targeting ligands without 
and with helical linker in this system (Table 2).  
Table 2: Summary of targeting ligands used for pDisplay constructs and vector particles. 
 
Different designed ankyrin repeat proteins (DARPins), single-chain variable fragments (scFv) or nanobodies were cloned 
into pDisplay (w/o linker) or pDisplay-HL7 (w/linker) using SfiI/NotI restrictions enzymes. Vector particles generated using 
the respective plasmids were titrated on receptor-positive cell lines. a(Schweizer et al, 2008), b(Stefan et al, 2011), c(Völkel et 
al, 2004; Abel et al, 2013), d(Funke et al, 2008), e(Anliker et al, 2010), f(Friedel et al) , g(Zhou et al, 2012), h(Koch-Nolte et 
al, 2007), #(Rasbach, 2010) 
After cloning of all the respective plasmid constructs and production of the vector particles, 
titers were determined on receptor-positive cell lines. Whereas gene transfer into CD4-
positive cells could not be observed at all, moderate transduction was detected on EpCAM-
positive cells using DARPin Ac1 as targeting ligand. Interestingly, not only DARPins could 
be used as targeting proteins but also scFvs. Gene transfer into human CD105-positive 
endothelial cells as well as into cells expressing the stem cell marker CD133 was successful. 
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On the other hand, lymphocyte cell marker CD20, CD30 and CD8 failed to work as cell entry 
receptors for the respective LVs. As third class of targeting domains, nanobodies selected to 
bind to rat ADP ribosyltransferase 2.2 (Art2.2) expressed exclusively by mature rat T cells 
was used. All four resulting vector particle variants were able to transfer the gfp transgene 
into target cells with DHL7-s-14-LV exhibiting the highest titer.   
Although some targeted receptors did not mediate entry, it was clearly shown that several 
different receptors can be used as cell entry portals. Transduction efficiency varied depending 
on the target and the targeting ligand and with no other targeting ligand were higher or 
comparable titers achieved than with the Her2/neu-specific DARPins. Consequently, further 
experiments and characterization was carried out using D9.29-LV.  
3.1.3 Characterization of D9.29-LV cell entry 
Having shown that D9.29-LV is able to fuse with the cell membrane and to transfer the gfp 
gene very efficiently, a panel of experiments was performed to characterize the molecular 
prerequisites for its cell entry. First, the dependence on Her2/neu was assessed to clarify that 
receptor binding was indeed mediated via the D9.29 protein. Second, the function of the MV 
fusion machinery was tested. 
3.1.3.1 Her2/neu binding is required for cell entry 
To confirm that Her2/neu binding is necessary for efficient transduction, a spinfection 
experiment was performed. Here, D9.29-LV and its control vectors were centrifuged onto SK-
OV-3 cells. This way, viruses and cells were artificially brought into close contact, potentially 
circumventing the need for high-affinity receptor binding.   
Without centrifugation the same transduction pattern was observed as in Figure 16A, 
strengthening the fact that transduction only occurred after addition of 9.29-LV or D9.29-LV, 
but not when the MV glycoprotein complex was not intact or when D9.29 was missing (Figure 
18A). The spinfection increased transduction by D9.29-LV and 9.29-LV, whereas still no 
remarkable transduction was observed for the control vectors (Figure 18B). Although this 
experiment shows that one can enhance the transduction using spinfection, it clearly 
demonstrates that high-affinity receptor binding is needed and close contact of virus and cell 
is not enough for cell entry of D9.29-LV. 
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Figure 18: High-affinity receptor binding is needed for virus entry. SK-OV-3 cells were incubated with equal amounts of 
egfp gene-delivering virus particles 9.29-LV, D9.29-LV, and variants of D9.29-LV in which F∆30 (w/o F∆30), Hmut∆18 (w/o 
Hmut∆18), or D9.29 (w/o D9.29) was omitted, respectively, or Hmut∆18 was replaced by H*mut∆18 (w/ H*mut∆18) either without 
centrifugation (A) or with additional centrifugation at 700 × g for 1 h (B). Flow cytometry analysis was performed 72 h after 
transduction. (Rasbach et al, 2013) 
As described in chapter 3.1.1, the vector particles generated were adapted from the targeting 
system using MV-pseudotyped lentiviral vector particles first described by Funke et al.  
(Funke et al, 2008). One key to retarget these particles was to ablate the natural receptor 
binding by introducing several point mutations in H (Nakamura et al, 2005; Vongpunsawad et 
al, 2004). This was shown to be sufficient to prevent binding to the MV receptors SLAM, 
CD46 or Nectin-4. However, upon presentation of the attachment domain on a third protein 
and thereby potentially taking away a shielding effect from H, residual recognition of a so far 
unidentified MV receptor might be present. If this was true, receptor attachment and fusion 
helper function would not have been completely uncoupled.  
To assess whether D9.29-LV cell entry occurred also in absence of the MV receptors, CHO 
cells stably expressing Her2/neu (Münch et al, 2011) were transduced. While the parental 
CHO-K1 cells which expressed neither Her2/neu nor any of the natural MV receptors 
remained untransduced, CHO-Her2 cells were readily transduced by D9.29-LV (Figure 19). 
Although the percentage of GFP-positive CHO-Her2 cells was lower than that of transduced 
SK-OV-3 cells, which is likely due to the lower susceptibility of rodent cells to LVs 
compared to that of human cells, the data demonstrate that cell entry of D9.29-LV is Her2/neu 
dependent. Hence, receptor binding in D9.29-LV particles must have been uncoupled from H 
while still mediating efficient cell entry. 
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Figure 19: Cell entry is Her2/neu dependent. Parental CHO-K1, CHO-Her2 cells stably expressing Her2/neu or SK-OV-3 
cells were transduced with D9.29-LV. After 72 h cells were stained with anti-Her2/neu-PE antibody and analyzed by flow 
cytometry for receptor and GFP expression. (Rasbach et al, 2013)  
3.1.3.2 Cell entry relies on the MV membrane fusion mechanism 
D9.29-LV particles have been proven to enter cells upon high-affinity receptor binding in a 
Her2/neu-dependent manner. Furthermore, these particles could enter cells in absence of MV 
receptors confirming that cell entry was not due to recognition of an unidentified natural 
receptor. 
To assess whether D9.29-LV cell entry relies on F-mediated membrane fusion, acidification of 
endosomes was blocked with chloroquine to prove that virus particle entry was pH 
independent. Besides 9.29-LV, MV-LV virus particles pseudotyped with F∆30/H∆18 entering 
into cells pH independently via CD46 or Nectin-4 (Funke et al, 2008), as well as LV particles 
pseudotyped with the glycoprotein G of vesicular stomatitis virus (VSV), which enter cells 
pH dependently (Hernandez et al, 1996), were used as controls (Figure 20A). 
 
Figure 20: Membrane fusion is MV F dependent. (A) SK-OV-3 cells (1×104) were treated with 150 µM chloroquine 
before the indicated virus particles were added. Relative transduction rates compared to that for cells transduced in the 
absence of chloroquine were determined by flow cytometry analysis. (B) MV-pseudotyped LV particles (0.07 µg p24) and 
VSVG-LV (0.008 µg p24) were incubated with (+ FIP) or without (control) 200 µM FIP for 1 h at room temperature and 
then added to SK-OV-3 cells at an MOI of 0.3. The percentages of GFP-positive cells were determined by flow cytometry 
after 72 h and transduction rates relative to that obtained with untreated particles were calculated (n = 3; means ± SD are 
shown; *, P < 0.05; **, P < 0.01; ***, P < 0.0001; n.s., not significant by unpaired t test). (Rasbach et al, 2013) 
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As expected, chloroquine treatment of SKOV-3 cells reduced the transduction rate mediated 
by VSVG-LV substantially (Figure 20A). In contrast, the transduction mediated by D9.29-LV 
and MV-LV was slightly but significantly enhanced in presence of chloroquine. The strongest 
effect was observed for 9.29-LV, were the relative transduction rate reached 200% after 
chloroquine treatment (Figure 20A). Possibly, blocking endocytosis allowed more virus 
particles to enter cells at the plasma membrane.  
In order to show that F is actively taking part in the fusion process, the fusion inhibitory 
peptide (FIP) (Norrby, 1971; Richardson & Choppin, 1983) was applied to specifically block 
F. While FIP did not influence VSVG-LV-mediated gene transfer, which was expected since 
FIP cannot bind to any VSVG-LV component, it almost completely inhibited gene transfer of 
all three MV-pseudotyped particles (Figure 20B). These experiments clearly demonstrated 
that F is required for cell entry proving that at least one component of the MV glycoprotein 
complex is actively taking part in the fusion process.  
One important question remained: Why is H needed although receptor attachment is mediated 
by a third protein? It has been shown in chapter 3.1.2.2 that w/o Hmut∆18-LV was not able to 
transduce cells implying that presence of H is essential. Possible explanations could be that H 
is required as passive stabilizer of the MV glycoprotein complex or that it fulfills a 
mechanistic function during the fusion process. Therefore, the role of H in D9.29-LV cell entry 
was assessed by applying neutralizing H-specific monoclonal antibodies (MAbs). The 
selected MAbs recognize conformational epitopes on H which have been roughly mapped by 
competition assays and mutational analysis of MV escape variants (Liebert et al, 1994; 
Moeller et al, 2001). Putative MAb binding sites as well as the mutations introduced in 
Hmut∆18 to ablate the natural receptor usage are localized on the dimeric globular head 
domain of the H protein. MV-LV particles, which served as a positive control for the 
neutralizing activities of the MAbs, were completely neutralized in the presence of 0.1 µg of 
K71 or L77 and 1 µg of Nc32 or K29 (Figure 21A). In contrast, VSVG-LV was not affected 
by any of the four MAbs, thus excluding any interference with virus particle cell entry in 
general (Figure 21A). The strongest effect on D9.29-LV was exerted by L77, whereas MAbs 
Nc32 and K29 impaired gene delivery of D9.29-LV or 9.29-LV moderately. Remarkably, one 
of the MAbs, K71, was unable to neutralize both Her2/neu-targeted viruses (Figure 21A) 
which could be due to the ablation of its epitope in Hmut∆18. 
60 
 
Results 
 
Figure 21: Neutralization of D9.29-LV by H-specific monoclonal antibodies. (A) MV-pseudotyped LV (0.1 µg p24) and 
VSVG-LV (0.004 µg p24) particles were incubated with or without H-specific MAbs K71 (top left), L77 (top right), Nc32 
(bottom left), and K29 (bottom right) for 1 h at room temperature and then added to SK-OV-3 cells at an MOI of 0.3. The 
percentages of GFP-positive cells were determined by flow cytometry after 72 h, and transduction rates relative to that 
obtained in the absence of MAbs were calculated (n = 3; means ± SD are shown). (B) HEK-293T cells (1×106) transiently 
transfected with pCG-H∆18, pCG-Hmut∆18, or pCG-Hmut∆18-DARPin-9.29 were stained with K29, K71, Nc32, or L77. 
Secondary anti-mouse-PE was used for detection in flow cytometry. (C) Binding of virus particles to SK-OV-3 cells. D9.29-
LV was incubated with 1 µg K29, K71, Nc32, or L77 for 1 h at room temperature, and then SK-OV-3 cells were added and 
left for another hour. Samples were stained against the HA tag of particles using an anti-HA PE-coupled antibody. Cells 
incubated only with virus or virus displaying an attachment domain unable to bind to Her2/neu (DX-LV) were used as 
positive and negative controls, respectively. Fluorescence of cell-particle complexes was analyzed using flow cytometry. 
(Rasbach et al, 2013) 
To confirm that the inability of K71 to neutralize D9.29-LV and 9.29-LV relies on the 
disruption of the antibody epitope in Hmut∆18, cells expressing H∆18, Hmut∆18 or 9.29- 
Hmut∆18 were stained with all four MAbs and flow cytometry was performed to determine 
potential differences in avidity.   
As expected, only cells transfected with H∆18 were recognized by K71. The mutated H 
variants showed signals comparable to that of untransfected cells (Figure 21B). K29, Nc32 
and L77 bound all three H proteins with similar efficiencies whether it was mutated, fused to 
the DARPin or in its native form. These data prove that cell entry and transduction of D9.29-
LV can be inhibited by presence of H-specific neutralizing MAbs. But conceivably, this 
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neutralization could simply be due to interference with receptor attachment because of steric 
hindrance upon antibody binding. That in turn would not prove an active role of H in the virus 
cell fusion. To rule out steric hindrance as neutralization cause, a binding assay of D9.29-LV to 
SK-OV-3 cells in presence of the MAbs was performed. None of the four MAbs impaired 
binding of D9.29-LV particles to Her2/neu-expressing cells (Figure 21C). The fluoresecence 
signals were comparable to that of D9.29-LV binding cells in absence of MAbs and clearly 
stronger than that of the negative control, cells incubated with virus displaying an attachment 
domain unable to bind to Her2/neu (DX-LV). Thus, three of four tested MAbs neutralized 
D9.29-LV to at least some extent without interfering with virus receptor attachment. Hmut∆18 
must therefore fulfill an essential role during cell entry of D9.29-LV particles.  
3.1.4 D9.29-LV as a gene transfer vector 
For the safe and successful use of viral vectors in gene therapy, the design of the vector has to 
meet a set of strict requirements. Ideally for in vivo applications, the transgene of choice is 
delivered precisely and efficiently into a target organ or cell population upon systemic 
administration. That MV-pseudotyped lentiviral vectors are able to target not only specific 
tissues but cells defined by a single surface marker in vitro and in vivo, as for example CD8+ 
T lymphocytes, CD105+ endothelial cells or Her2/neu+ tumor cells, has been reported (Zhou 
et al, 2012; Abel et al, 2013; Münch et al, 2011).   
In chapter 3.1.2.2 it was shown that D9.29-LV was even more infectious and transduced 
Her2/neu cells more efficiently than 9.29-LV. Therefore, the potential of D9.29-LV as a novel 
type of cell entry-targeted vector for gene transfer was assessed. First, vector production was 
optimized and then the ability to mediate stable gene transfer evaluated in vitro. Finally, 
targeting tumor cells in vivo was tested in a xenograft mouse model.  
3.1.4.1 Optimizing D9.29-LV production 
One prerequisite for the application of viral vectors in in vivo gene therapy is to have high 
titers. Funke et al. (Funke et al, 2008) showed that the ratio of H and F-encoding plasmids in 
packaging cells can be optimized to increase LV titers. It is known that after infection with 
MV, cells produce less H than F mRNA (Cattaneo et al, 1987), suggesting that once 
production conditions are adjusted accordingly the release of infectious particles would be 
optimal. Moreover, LV particles displaying three different transmembrane proteins had not 
been described before.   
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Therefore, vector particle production was optimized in two consecutive steps. First, the 
amounts of F- and H-encoding plasmids were varied, and then, based on one of the optimal F-
to-H ratios (5:3) (Figure 22A), the amount of pDisplay-D9.29 plasmid was varied. In general, it 
was beneficial to transfect more pDisplay-D9.29 than pCG-Hmut∆18 (Figure 22B), thus a ratio 
of 5:3:6 for F-, H-, and D9.29-encoding plasmids was used for further vector production. 
 
Figure 22: Optimizing D9.29-LV production. Titers of D9.29-LV stocks were optimized by (A) keeping the amount of 
pDisplay-D9.29 constant and varying that of pCG-F∆30 to pCG-Hmut∆18 or (B) keeping the amounts of pCG-F∆30 and pCG- 
Hmut∆18 constant and varying that of pDisplay-D9.29 for transfection of HEK-293T cells along with pCMV∆8.91 and pSEW. 
For each ratio, pseudotyped vectors were titrated on SK-OV-3 cells and their relative titer normalized to that obtained after 
transfection of a 1:1 plasmid ratio (100%) is shown (n = 3; means ± SD are shown). (Rasbach et al, 2013) 
3.1.4.2 D9.29-LV mediates stable gene transfer 
D9.29-LV showed high titers on SK-OV-3 as well as CHO-Her2 cells. To confirm that gene 
transfer was long lasting and to exclude that observed titers were attributable to 
pseudotransduction, which means GFP protein transfer from the producer to the target cells, 
the sensitivity of D9.29-LV and its control vector VSVG-LV towards a reverse transcriptase 
inhibitor was tested (Liu et al, 1996). A contribution of protein transfer to titers was well 
possible since it is known and was also observed for D9.29-LV that during production of MV 
pseudotyped vector particles syncytia are formed. These multinucleated cells result from cell 
fusion and are prone to enhanced vesicle production and release. Formation of syncytia and, 
in late stages of vector production, cell death was especially pronounced for D9.29-LV 
compared to 9.29-LV.  In contrast to protein transfer which would be unaffected by reverse 
transcriptase inhibitors, treatment with 3’-azido-3’-deoxythymidine (AZT) inhibits the reverse 
transcription of the transfer vector in transduced cells and thereby prevents GFP expression.  
SK-OV-3 cells were transduced with D9.29-LV or as positive control VSVG-LV either in 
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presence or absence of 10 µM AZT. After three days cells were analyzed by flow cytometry 
and transduction was compared. In the presence of AZT, gene transfer rates dropped 
substantially to extents that were similar for both D9.29-LV and VSVG-LV (Figure 23A). 
 
Figure 23: D9.29-LV mediates stable gene transfer. (A) SK-OV-3 cells were transduced with D9.29-LV or VSVG-LV in the 
presence or absence of 10 µM reverse transcriptase inhibitor azidothymidine (AZT) to verify that vectors mediated transgene 
integration. Relative transduction efficiency is shown (n = 3; means ± SD are shown; P < 0.001 by unpaired t test). (B) In 
order to demonstrate stable transduction, SK-OV-3 cells were cultivated for 20 days after transduction with D9.29-LV at an 
MOI of 0.4 or 0.1. The percentage of EGFP-positive cells was determined at the indicated time points by flow cytometry 
analysis. (Rasbach et al, 2013) 
To further verify that gene expression was stable, SK-OV-3 cells were transduced with D9.29-
LV at MOI 0.1 or 0.4 and the number of GFP-positive cells was determined over a period of 
20 days. Constant levels of 10% or 40% GFP-positive cells were detected over the whole 
observation period.   
Because D9.29-LV was sensitive towards reverse transcriptase inhibition and able to mediate 
long lasting GFP expression, the data demonstrate stability of gene integration and that 
pseudotransduction was not the cause for observed high titers. 
3.1.4.3 Tumor targeting of D9.29-LV in a xenograft mouse model 
After having demonstrated that D9.29-LV transfers genes stably into receptor-positive cells, its 
in vivo targeting potential was assessed in a xenograft mouse model carrying a subcutaneously 
growing SK-OV-3 tumor. To follow tumor targeting by in vivo imaging and enabling the 
analysis of the distribution after systemic administration, vector particles were equipped with 
a luciferase reporter gene. CB17 SCID mice were subcutaneously injected with the Her2/neu-
positive human cell line SK-OV-3 that has been proven to be susceptible for D9.29-LV 
(chapter 3.1.2.2). Tumor growth was monitored until tumors had reached a volume of about 
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50 mm3. Subsequently, D9.29-LV or control particles pseudotyped with F∆30 and Hmut∆18 but 
devoid of D9.29 (w/o D9.29-LVluc) were injected systemically through the lateral tail vein. 
Several time points after vector administration, mice were analyzed by in vivo imaging. D9.29-
LVluc resulted in luciferase activity already 3 days after vector administration, which steadily 
increased over time in the SK-OV-3 tumor (Figure 24A). In contrast, even after 2 weeks no 
luciferase signals could be detected in the tumor tissue of w/o D9.29-LVluc-injected mice 
(Figure 24B). 
 
Figure 24: D9.29-LV selectively targets Her2/neu-positive tumors in vivo. CB17 SCID mice were injected with 5×106 SK-
OV-3 cells into the right flank (arrowheads). Once tumors had reached a volume of about 50 mm3, D9.29-LVluc (8 µg p24) or 
w/o D9.29-LVluc (15 µg p24) was injected into the tail vein, and luciferase signals were analyzed by in vivo imaging 1 week 
later. Luciferase signal intensity is expressed as photons/second/square centimeter/steradian. (Rasbach et al, 2013) 
Thus, it is clear that D9.29-LV is directed to the tumor cells by D9.29 and that in its absence an 
MV-pseudotyped lentiviral vector containing a receptor-blinded H is not able to specifically 
target SK-OV-3 cells in vivo. 
3.2 Adeno-associated viral vector targeted to EpCAM-positive tumor cells 
The human epithelial cell adhesion molecule (EpCAM) is a surface marker of normal 
epithelia, but it is also highly overexpressed in primary tumors and metastases of many 
epithelial tumors (Simon et al, 2013). In addition to its role in cell adhesion, EpCAM is a 
signaling molecule described to be involved in oncogenic pathways activating and engaging 
c-myc and Wnt signaling (Litvinov et al, 1994; Yamashita et al, 2007; Münz et al, 2004; 
Maetzel et al, 2009). In recent years, it has attracted a lot of attention in biomedical research 
due to reports that it is also expressed on cancer stem cells (CSCs) and ciruculating tumor 
cells (CTCs) (Dalerba et al, 2007; Pantel et al, 2008). These rare cell populations are difficult 
to track, modify and eventually destroy. Therefore, a viral vector directed against EpCAM 
65 
 
Results 
could be useful in basic research as well as therapeutic settings.   
To this end, the recently described strategy to generate receptor-targeted AAV2-derived 
vector particles was employed (Münch et al, 2013). AAVs displaying EpCAM-specific 
DARPins were generated, characterized and tested for their capacity to detect rare tumor cells.  
3.2.1 Generation and characterization of EpCAM-AAV 
The successful incorporation of the Her2/neu-specific DARPin 9.29 into the AAV capsid was 
previously shown by Münch et al (Münch et al, 2013). Here, a fusion of the DARPin to the 
VP2 capsid protein of AAV2 was chosen. This site was selected because EGFP-VP2 fusion 
proteins were already described to be tolerated and did not interfere with viral assembly, 
packaging efficiency of the genome or infectivity (Lux et al, 2005). The same was true for 
Her2-AAV particles combined with an unprecedented capacity to target Her2/neu-positive 
tumor cells and to mediate safe gene transfer in vitro and in vivo (Münch et al, 2013).  
Producing receptor-targeted AAV relies on an adenovirus helper free, four-plasmid 
transfection system. Naturally, a plasmid encoding the DARPin-VP2 fusion protein is 
essential. The sequence of the EpCAM-specific DARPin Ec1 (Stefan et al, 2011) was 
amplified by PCR using the primers DARPin-for and DARPincorr-rev. Then, the PCR product 
was inserted into the AgeI/BsrGI digested pDARPin-9.29-VP2, thereby replacing the 
sequence of the Her2/neu-specific DARPin and resulting in pDARPin-Ec1-VP2, coding for 
Ec1 N-terminally fused to VP2. In this construct, the start codon for the VP2 protein was 
mutated to prevent expression of the unmodified VP2 protein (Figure 25). For expression of 
the other two capsid proteins VP1 and VP3 as well as the nonstructural proteins Rep78, 
Rep68, Rep52, Rep40 and AAP, the plasmid pRC-VP2ko was used. Of course, the same 
mutation as in pDARPin-VP2 disrupting the VP2 start codon was present in this construct. 
Additionally, both plasmids harbor mutations resulting in exchange of arginines 585 and 588 
for alanines which prevent binding to the natural receptor HSPG (Kern et al, 2003; Opie et al, 
2003; Boucas et al, 2009; Münch et al, 2013) (Figure 25).  
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Figure 25: Schematic drawing of constructs used for AAV production. The transfer vector, the AAV2 plasmid pRC-
VP2KO-HSPGmut, the adenoviral helper plasmid pXX6-80 and a pDARPin-VP2 construct shown here are required for 
production of targeted AAV vectors. Unmodified VP2 expression was prevented by mutating the VP2 start codons in 
pDARPin-VP2 and pRC-VP2KO-HSPGmut (labeled by stars). For ablation of HSPG binding, two point mutations (R585A 
and R588A) were introduced (labeled by triangles). The unmodified pRC plasmid which is used for production of AAV2 
encodes the AAV2 rep and cap proteins. Plasmid pXX6-80 provides the sequences for the essential adenoviral helper genes 
E2A, E4 and VA RNA necessary for AAV production. All transgenes were placed under control of the SSFV promoter and 
flanked by inverted terminal repeats (ITR). Immunological tags (myc and 6x His) of pDARPinmyc-VP2 or pDARPinHis-VP2 
are indicated. 
A minimal set of adenoviral helper genes are described to be sufficient for AAV production 
(Xiao et al, 1998). Transfection of HEK-293 or HEK-293T cells with pXX6-80 provides the 
required early adenoviral proteins E2A, E4 and VA RNA (Figure 25). As fourth plasmid, the 
transfer vector encoding the transgene under control of the SFFV promoter in self-
complementary format (McCarty, 2008, Münch 2013) is needed. Upon co-transfection of 
these plasmids, AAV vector particles are produced and can be harvested and purified using 
iodixanol gradient purification.  
3.2.1.1 EpCAM-specific DARPin can be incorporated into AAV particles 
Besides particles presenting the EpCAM-specific DARPin Ec1 (EpCAM-AAV) (Stefan et al, 
2011), Her2-AAV and AAV2 particles were generated as controls. In contrast to AAV2 
particles, Her2-AAV is thought to present up to five DARPin molecules protruding from the 
five-fold symmetry axis. If Ec1 was successfully incorporated, resulting particles are assumed 
to look similar (Figure 26A).  
One of the crucial prerequisites for gene transfer activity of receptor-targeted AAVs is the 
integrity of the virus capsid. Only if the fusion of DARPin-VP2 is not affecting virus 
assembly, infectious particles with high titers can be produced. Therefore, particles were 
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purified by iodixanol gradient centrifugation and then coated onto Nickel200 grids and 
stained with uranyl acetate to analyze virus morphology (Figure 26B). All three vector 
preparations revealed structurally intact particles in typical AAV shape. More importantly, not 
only empty vector particles which can be distinguished by the dark circle in their center but 
also genome-packaged (full) AAV particles were detected which indicates that infectious 
particles have been produced. In general, empty particles were overrepresented (data not 
shown) which is in accordance with data published for the Her2-AAV (Münch et al, 2013) as 
well as reports of a ten-fold excess of empty over genome-packaged AAV2 (Grimm et al, 
1999; Drittanti et al, 2001; Sommer et al, 2003; Park et al, 2006). 
 
Figure 26: Incorporation of DARPins does not alter virus morphology. (A) Schematic illustration of AAV2, Her2-AAV 
and EpCAM-AAV particles. For surface exposure of the DARPin molecules (pink or green), the N-terminus of the VP2 
protein has to be located at the pore complex. Illustrations were created using Pymol and PDB files 1LP3 (Xie et al, 2002) 
and 2XEE (Kramer et al, 2010) without exact modeling of the DARPin-AAV particle (Münch et al, 2013). (B) Electron 
micrographs of AAV particles. AAV2, Her2-AAV or EpCAM-AAV were coated on Ni200 grids and negative stained with 
uranyl acetate. Full and empty capsids are marked by black and white arrow heads, respectively. Micrographs were taken on 
a Zeiss EM109. Scale bar, 50 nm. 
After having demonstrated that EpCAM-AAV exhibited AAV2-like morphology, vector 
particles were analyzed for their protein composition by western blot analysis. Capsid proteins 
of unmodified AAV2, Her2-AAV or EpCAM-AAV vector preparations were detected using 
the capsid-specific antibody B1. AAV2 structural proteins migrated according to their 
expected molecular weights of 90 kDa (VP1), 72 kDa (VP2) and 60 kDa (VP3) (Rose et al, 
1971) (Figure 27A). Interestingly, vector particles harboring the two point mutations to 
abolish HSPG binding are described to migrate slower than the non-mutated proteins (Boucas 
et al, 2009; Münch et al, 2013) which was also true for Her2-AAV and EpCAM-AAV vector 
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preparations. The unmodified VP2 protein was absent in both targeting vector particles as a 
consequence of the mutated start codon. Instead, the DARPin-VP2 protein shifted to 89 kDa 
which overlaps with the VP1 protein. That the DARPin-VP2 band migrated at the same height 
as VP1 was demonstrated by western blot analysis of cell lysates from cells transfected with 
the plasmid encoding either VP1/Ec1-VP2/VP3 (Figure 27B, lane 1) or Ec1-VP2/VP3 (Figure 
27B, lane 2). 
 
Figure 27: Western blot analysis of AAV vector particles and cell lysates. (A) Iodixanol gradient-purified vector particles 
were analyzed by western blot. Structural proteins of AAV2, Her2-AAV or EpCAM-AAV were detected using the capsid-
specific antibody B1 recognizing a common epitope at the C-terminus of all three capsid proteins. (B) HEK-293T cells were 
transfected with pXX6-80, pscGFP-SFFV and the indicated plasmids. After 48 hours, cell lysates were prepared and 
analyzed by western blotting in co-operation with Prof. Dr. H. Büning (Köln). Structural proteins were detected using the 
capsid-specific antibody B1. VP variants with R585A and R588A mutations are marked by asterisks.  
To show that EpCAM-VP2 was not only incorporated into vector particles but that the 
DARPin was also surface exposed, a myc-tag was fused to the N-terminal end of the Ec1 
coding sequence using the primers Myc-for/DARPincorr-rev. The amplified PCR product was 
inserted into the pDARPin-9.29-VP2 plasmid via AgeI/BsrGI replacing the Her2/neu-specific 
DARPin and resulting in the plasmid pDARPin-Ec1Myc-VP2 (Figure 25). Subsequently, 
EpCAMMyc-AAV particles were generated by replacing plasmid pDARPin-Ec1-VP2 with 
pDARPin-Ec1Myc-VP2 for transfection.   
EpCAMMyc-AAV, Her2Myc-AAV and AAV2 particles were incubated on ELISA plates pre-
coated with anti-myc antibody and after several washing steps, bound particles were detected 
with the capsid specific antibody A20. Both, EpCAMMyc-AAV and Her2Myc-AAV, led to clear 
ELISA signals correlating with the number of applied vector particles (Figure 28). In contrast, 
no signals above background were detectable for the negative control AAV2. This assay 
proved that the myc-tag was accessible from outside the particle indicating that the DARPin 
was surface exposed as well.  
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Figure 28: DARPin Ec1 displayed on the surface of AAV vector particles is accessible. Iodixanol gradient-purified 
AAV2, Her2Myc-AAV or EpCAMMyc-AAV vector preparations were bound to ELISA plates pre-coated with anti-myc 
antibody. After several washing steps, bound vector particles were detected using the capsid-specific antibody A20. AAV2 
particles (not displaying a DARPin) served as negative control, Her2Myc-AAV as positive control (n = 3; means ± SD are 
shown). (Münch et al, 2015) 
After having demonstrated that AAVs presenting the EpCAM-specific DARPin were of 
AAV-like morphology and protein composition, one of the remaining concerns was the 
influence of the Ec1-VP2 fusion protein on the vector particle production. It was already 
shown in Figure 26 that genome-packaged AAVs were produced, but it was still unclear 
whether genomic titers were affected. Even small alterations in the AAV capsids are 
described to alter capsid to genome ratios und thus potentially impair packaging efficiency 
(Wu et al, 2000; Wu et al, 2006a).   
For the analysis of EpCAM-AAV preparations, the number of genome packaged AAVs 
(genomic titer) was determined by qPCR as described previously (Theiss et al, 2003) using a 
primer pair specific for an egfp gene sequence (0.71 kbps) (Münch et al, 2013). As standard 
for quantification, defined copy numbers of the transfer vector pscGFP-SFFV were used. 
Genomic titers of EpCAM-AAV proved to be in the same range as that of unmodified AAV2 
and were even slightly higher than that of Her2-AAV (Figure 29A).  
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Figure 29: Ec1-VP2 fusion protein does not disturb particle production. (A) Genomic titers of AAV2, Her2-AAV and 
EpCAM-AAV were determined by qPCR detecting the egfp gene (n = 3; means ± SD are shown). (B) The number of vector 
particles was determined by capsid ELISA using the capsid-specific antibody A20 which recognizes a conformational 
epitope of assembled particles. The ratio between empty and genome-packaged (full) particles is shown (AAV2 n = 1; 
EpCAM-AAV n = 3; means ± SD are shown). (Münch et al, 2015) 
To analyze the influence on the packaging efficiency, capsid titers were determined by 
sandwich ELISA (Grimm et al, 1999). Then, the ratio of total particles and genome-packaged 
particles reflecting the packaging efficiency can be determined. A ratio above 1 indicates an 
excess of empty over full particles, which is expected for recombinant AAV. The ratio for 
EpCAM-AAV was increased compared to AAV2 (Figure 29B). But it had been described 
previously that ratios below or equal to 50 are considered to be wild-type phenotype (Kern et 
al, 2003) suggesting that mutation of the HSPG-binding site as well as the Ec1-VP2 fusion 
protein had negligible effects on the capsid structure. 
3.2.2 EpCAM-AAV is specific for human EpCAM 
As demonstrated in the previous chapter, capsid integrity was not affected by the 
incorporation of the Ec1-VP2 fusion protein. Particles displayed the EpCAM-specific 
DARPin as described before for the Her2/neu DARPin.  
AAV vector preparations were evaluated for their capacity to target receptor-positive cells. 
For this, the absence of off-targeting by ablation of the natural tropism as well as effective 
redirection and binding to the receptor of choice are essential.  
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3.2.2.1 Selective transduction of receptor-positive cells by EpCAM-AAV 
To assess if the incorporation of the DARPin in combination with introduction of the two 
point mutations to ablate HSPG binding equipped the EpCAM-AAV with a restricted tropism 
for EpCAM+ cells, transduction of receptor-positive and -negative cell lines was performed.   
As EpCAM-positive cells the breast cancer cell lines MDA-MB-453 and MCF-7 were used. 
The glioblastoma cell line LNT-229 served as negative control. The EpCAM expression 
pattern was confirmed by flow cytometry (Figure 30A). 
 
Figure 30: EpCAM-AAV specifically transduces EpCAM-positive cells. (A) EpCAM expression level of the indicated 
cell lines was determined by flow cytometry using the EpCAM-specific antibody anti-CD326-PE. (B) EpCAM-positive 
(MDA-MB-453 and MCF-7) and EpCAM-negative cells (LNT-229) were transduced with EpCAM-AAV or AAV-2 (GOI = 
70,000). 48 h after transduction cells were analyzed by fluorescence microscopy. (Münch et al, 2015) 
Two days after transduction of all three cell lines with either EpCAM-AAV or the unmodified 
AAV2 as control vector, GFP expression was assessed by fluorescence microscopy. EpCAM-
AAV exclusively transduced MDA-MB-453 and MCF-7 cells but not the receptor-negative 
LNT-229 cells, whereas transduction with AAV2 resulted in GFP expression in all three cell 
lines (Figure 30B). In general, AAV2 transduced cells more efficiently than EpCAM-AAV 
when the same GOI was applied. This might be due to the fact, that not all genome-packaged 
EpCAM-AAVs necessarily incorporated the Ec1-VP2 fusion protein. It is described that only 
VP1 and VP3 capsid proteins can give rise to intact AAV particles. If this holds true for 
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EpCAM-AAV preparations, particles not able to bind to EpCAM or HSPG were present 
during transduction but do not contribute to gene transfer.  
These data confirm that EpCAM-AAV exhibits the desired receptor specificity.  
3.2.2.2 EpCAM-AAV binds to human but not mouse EpCAM 
In chapter 3.2.2.1 the specificity of EpCAM-AAV for receptor-positive human cells has been 
proven. But among different species, the amino acid sequence of EpCAM is highly 
conserved. Antibodies raised against the human EpCAM protein showed cross-reactivity 
against the homologous proteins in mice, rats and non-human primates (Zaloudik et al, 1997). 
The murine EpCAM shows 81% homology to its human counterpart as determined by 
alignment of protein sequences using Clustal Omega (Sievers et al, 2011; Goujon et al, 2010; 
McWilliam et al, 2013), which makes it a good candidate as DARPin Ec1 binding partner. To 
evaluate whether EpCAM-AAV was not only EpCAM-specific but also restricted to bind 
only the human protein, competition experiments were performed using the soluble form of 
the extracellular domains of human und murine EpCAM. AAV2 or EpCAM-AAV particles 
were incubated with increasing concentrations of recombinant protein and subsequently used 
to transduce MDA-MB-453. Transduction by EpCAM-AAV decreased only in presence of 
human but not mouse EpCAM, while no effect was observed for AAV2 particles pre-
incubated with both forms of the soluble receptor (Figure 31). Competition with the 
extracellular domain was clearly dose-dependent 
 
Figure 31: Transduction mediated by EpCAM-AAV is human EpCAM dependent. EpCAM-AAV (GOI=10,000) was 
incubated for 1 h at 4°C with increasing amounts of the entire extracellular domain of human (hEpCAM) or murine EpCAM 
(mEpCAM) as competitor. Following incubation, MDA-MB-453 cells were transduced and analyzed for GFP expression by 
flow cytometry 72 h post transduction. AAV-2 (not displaying a DARPin) (GOI 350) served as control. Data are normalized 
to the transduction efficiency measured without preincubation with recombinant protein (n = 3; means ± SD are shown). 
(Münch et al, 2015) 
73 
 
Results 
Accordingly, EpCAM-AAV was able to distinguish between the human and murine EpCAM 
protein. Its specificity for human EpCAM and the selective transduction was further 
confirmed by this competition experiment.  
3.2.2.3 Transduction efficiency is receptor density-dependent 
In the previous chapters, EpCAM-AAV has been proven to specifically transduce receptor-
positive cells. But transduction of cells is not an experiment with a simple binary outcome. 
The efficiency may be dependent on vector properties such as titer or avidity for its receptor 
but it might also be influenced by cell characteristics as for example the receptor density. That 
efficient transduction mediated by receptor-targeted vectors depends on the target receptor 
density was not only shown for Her2/neu-targeted LVs (Münch et al, 2011) but also for 
Her2/neu-targeted AAVs (Münch et al, 2013), using a panel of CHO cells expressing the 
human Her2/neu protein with different densities. 
Therefore, the cDNA sequence of human EpCAM (NCIB reference sequence NM_002354) 
was cloned into the pS-EGFP-I-puro-W transfer vector resulting in the bicistronic plasmid pS-
hEpCAM-I-puro-W. In this construct both reading frames are linked by an internal ribosome 
entry site (IRES) which allows protein synthesis of the second gene product from a translation 
initiation site within the messenger RNA.   
A VSVG-pseudotyped lentiviral vector packaging the hEpCAM-I-puro sequence was 
produced. After transduction of CHO-K1 cells, cells were put under selection pressure using 
puromycin for two weeks. The resulting CHO-EpCAM bulk cell population was stained for 
EpCAM expression and single cells were sorted. Screening of 30 single clones revealed cells 
expressing low, medium and high levels of EpCAM (Figure 32A).  
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Figure 32: Receptor density influences transduction efficiency of EpCAM-AAV. (A) EpCAM expression of stably 
transduced CHO-EpCAM cell clones. CHO-K1 cells were transduced with a VSVG-pseudotyped lentiviral vector 
transferring the genes for human EpCAM and puromycin resistance. After selection of puromycin resistant cells, the bulk 
population was stained using an anti-EpCAM-PE antibody and single clones were obtained by fluorescence-activated cell 
sorting. After cultivation and fluorescence cytometry, a low (L1), medium (M6) and high (H1) EpCAM-expressing cell clone 
was chosen. Histograms are shown. Parental CHO-K1 cells (black) were used as negative control. (B) CHO-EpCAM clones 
L1, M6 and H1 were transduced with EpCAM AAV (GOI=80.000) and analyzed 72 h later for EGFP expression and 
EpCAM expression. Untransduced and unstained cells are shown as control.  
The single cell clones CHO-EpCAM L1, M6 and H1 were transduced by EpCAM-AAV 
particles and analyzed for GFP and EpCAM expression three days later. Although all three 
clones were 100% EpCAM-positive and readily transduced, the strongest transduction 
efficiency was observed on CHO-EpCAM H1 cells, representing the highest target receptor 
expression of all three cell lines (Figure 32B). Here, almost all cells were GFP-positive 
whereas only 73% CHO-EpCAM M6 and 32% CHO-EpCAM L1 cells were transduced. 
These data prove that transduction mediated by EpCAM-AAV is clearly dependent on 
receptor density. 
3.2.3 DARPin usage is flexible 
In the previous chapters it was shown that the generation of EpCAM-targeted AAV vector 
particles was successful. Transduction of cell lines exclusively relied on the attachment of the 
EpCAM-specific DARPin Ec1 to its receptor. Ec1 evolved from the DARPin EPh1 which 
was selected by SRP phage display from a library using the biotinylated extracellular domain 
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of EpCAM as target (Stefan et al, 2011). Another available EpCAM-specific DARPin called 
Ac1 was selected by ribosome display and descended from DARPin C9 (Winkler et al, 2009) 
(Table 3). Both parental DARPins were subjected to directed evolution using error-prone PCR 
followed by new rounds of off-rate selection using ribosome display in solution to improve 
their affinities (Stefan et al, 2011). Additionally, a C-cap designed to be more stable 
(Interlandi et al, 2008) was introduced.   
 
Table 3: Applied EpCAM-specific DARPins. 
 Ec1c Ac1c 
KD (nmol/l)a 0.068 0.12 & 75d 
DARPin typeb N3C N3C 
Selection method SRP phage display Ribosome display 
a Dissociation constant, b Number of ankyrin repeats; N represents the N-capping repeat, internal binding repeats are indicated 
by numbers, C represents the C-capping repeat, c (Stefan et al, 2011), d biphasic dissociation 
The Ac1 coding sequence was amplified by PCR using the primer pair DARPin-
for/DARPincorr-rev and was subsequently inserted into the AgeI/BsrGI digested pDARPin-
Ec1-VP2 plasmid, thereby replacing the Ec1 coding sequence. The resulting pDARPin-Ac1-
VP2 and pDARPin-Ec1-VP2 were used to produce three independent Ac1-AAV and Ec1-
AAV (elsewhere termed EpCAM-AAV) small scale vector preparations. Vector particles 
were not iodixanol gradient-purified and instead cleared lysates were used for analysis of 
genomic titers and transduction efficiency.   
Genomic titers for both vector types were in the same range of about 108 genome copies/µl 
but titers of Ac1-AAV were slightly but significantly lower than Ec1-AAV titers (Figure 
33A).  
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Figure 33: Ec1 is better suited as targeting ligand for AAVs than Ac1. (A) Genomic titers of AAVs displaying the 
EpCAM-specific DARPin Ec1 (Ec1-AAV) or Ac1 (Ac1-AAV) were determined by qPCR detecting the egfp gene (n = 3; 
means ± SD are shown). (B) CHO-EpCAM bulk cells were transduced with Ec1-AAV or Ac1-AAV (GOI = 62.5000) and 
percentage of GFP-positive cells was determined by flow cytometry 72 h later (n = 3; means ± SD are shown; *, P < 0.05; 
****, P < 0.0001; by unpaired t test). 
For the evaluation of the gene transfer efficiency, CHO-EpCAM cells were transduced with 
equal genomic copy numbers of Ec1-AAV or Ac1-AAV and analyzed three days later by 
flow cytometry. Remarkably, Ec1-AAV transduced up to 75% of all cells whereas Ac1-AAV 
was only able to mediate gene transfer into 20% CHO-EpCAM cells (Figure 33B). This result 
was highly significant and indicated that DARPin Ec1 was better suited for retargeting AAVs 
than DARPin Ac1.   
Nevertheless, DARPin Ac1 can be used to retarget AAV vector particles although Ec1-AAV 
performed better. For this reason, Ec1-AAV was used in all further experiments.  
3.2.4 Affinity purification of EpCAM-AAV 
As a result of an expanded application and a growing selection of viral vectors in biomedical 
research and gene therapy, sophisticated purification methods need to be implemented to 
ensure quality, efficacy and safety of the product. Chromatography-based methods such as gel 
filtration, ion-exchange and affinity chromatography have become well-established in the 
field of AAV vector development. These techniques enable purification of large-scale 
productions but are also used to remove possible contaminants or byproducts.   
In order to separate DARPin-displaying from -deficient AAV particles, the DARPin-VP2 has 
to have a His tag at the N-terminus of the DARPin to allow immobilized metal ion affinity 
chromatography (IMAC). The principle of this purification method is based on the formation 
of chelate complexes between the hexa-histidine tag of the vector particle and the nickel ions 
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of the stationary phase. This interaction results in retention of DARPin-displaying AAVs and 
flow through of DARPin-deficient particles. By competition of binding to the nickel ions 
using the aromatic heterocycle imidazole, the DARPin-displaying vector particles can then be 
eluted. The combination of iodixanol gradient purification to remove empty particles and 
subsequent IMAC to enrich DARPin-displaying AAVs (Figure 34) is the key to not only 
prevent off-targeting in vivo but also to enhance gene delivery efficiency (Münch, 2013).  
 
Figure 34: Separation of DARPin-displaying from DARPin-deficient vector particles. Schematic drawing of the two-
step procedure including density gradient centrifugation followed by immobilized metal ion affinity chromatography 
(IMAC), which separates DARPin-displaying AAV particles carrying a hexa-histidine-tag at the N-terminus of the DARPin 
from DARPin-deficient particles. (Münch et al, 2015) 
The same two-step purification procedure was applied to EpCAM-AAV and its transferability 
as well as potency of purified particles was evaluated.  
3.2.4.1 Analysis of IMAC-purified EpCAM-AAV 
In order to affinity purify EpCAM-AAV, the Ec1-VP2 fusion protein had to be equipped with 
a hexa-histidine tag. Therefore, the Ec1 coding sequence was amplified by PCR using the 
primers His-for and DARPincorr-rev. The PCR product was inserted into the AgeI/BsrGI 
digested plasmid pDARPin-Ec1-VP2, resulting in the plasmid pDARPin-Ec1His-VP2. This 
construct gives rise to the Ec1-VP2 fusion protein with the His tag fused to the N-terminal 
end of the DARPin molecule (Figure 25). The same position was used for the myc tag in 
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chapter 3.2.1.1 indicating that this was well tolerated for capsid assembly. For the production 
of EpCAMHis-AAV particles the already described production system (3.2.1) was used.   
To set up the IMAC purification of EpCAMHis-AAV, several parameters had to be 
determined such as binding conditions, flow rate and retention time. The purification protocol 
for Her2His-AAV particles was used as starting point (Münch, 2013). Iodixanol gradient-
purified EpCAMHis-AAV particles were diluted in binding buffer containing 20 mM 
imidazole to prevent unspecific binding to the HisTrap column. Loading of vector particles to 
the equilibrated column was performed at 0.1 ml/min using a HPLC system to allow slow 
binding and complex formation. Monitoring of absorbance at 280 nm revealed a high peak 
upon vector particle loading and subsequent decline during washing phase (Figure 35A). The 
elution conditions of EpCAMHis-AAV were determined by performing a linear elution 
gradient from 20-500 mM imidazole. Analysis of collected fractions revealed that functional 
EpCAMHis-AAV vector particles started to elute at an imidazole concentration of 250 mM 
(data not shown). To stringently elute DARPin-displaying particles within only a few 
fractions, a step gradient was used. After loading of particles and subsequent washing with 
20 mM imidazole, a single elution step with 300 mM imidazole for five column volumes 
followed by washing with 500 mM imidazole was performed (Figure 35B). Unfortunately, the 
imidazole used in these experiments was UV-active, resulting in strong absorbance upon 
increase of imidazole concentration to 300 or 500 mM. Eventually, signals arising from eluted 
vector particles could be superimposed by imidazole signals. Thus, further analysis of 
collected fractions for content of AAVs was obligatory.  
 
Figure 35: Step gradient affinity purification of EpCAMHis-AAV. (A) Vector particles were diluted in binding buffer 
containing 20 mM imidazole and loaded onto a HisTrap column (min 15-30) using a HPLC system. The column was washed 
with 15 column volumes binding buffer. (B) AAV vector particles were eluted from the column using buffer containing 
300 mM imidazole (min 15-40) followed by final elution with buffer containing 500 mM imidazole (min 40-60). 
Representative absorbance profiles of vector particle loading (A) and elution (B) are shown.  
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Collected fractions were analyzed by dot blot using the capsid-specific antibody B1. Strong 
signals were detected for the loading fractions which was well in accordance with the loading 
profile. The most prominent signal intensities were observed for fractions 7-10 (Figure 36A). 
In contrast, no capsid signals were detected in the washing fractions and only 3 dots (51-53) 
appeared in the elution fractions. Although these signals were comparably weak and faint, it 
seemed that eluted particles were at least concentrated in only a few fractions (Figure 36A) 
and correlated with the corresponding elution profile.  
 
Figure 36: IMAC purification of EpCAMHis-AAV. (A) 80 fractions collected during column loading (1-10), washing (11-
49) and elution (50-80) were analyzed by dot blot using the capsid protein specific antibody B1. Fractions were loaded in 
alternating order from top-left to bottom-left. Elution fractions (51-53) with the strongest signals are indicated. (B) Genomic 
titers of corresponding fractions were determined by qPCR detecting the egfp gene. Loading (7-10) and elution (51-53) 
fractions with the strongest signals are indicated.  
Based on the dot blot results, a few fractions were selected and genomic titers were 
determined by qPCR using egfp-specific primers. Pre-loading fraction 3 was used to 
determine the background of the experiment which was around 103 genome copies/µl. Only 
slightly higher values resulted from washing fractions indicating that they did not contain a 
relevant number of AAV particles. Loading fractions 7-10 revealed to have the highest titers 
whereas elution fractions 51-53 had at least 10-fold lower genomic titers (Figure 36B). This 
discrepancy was expected since dot blotting already revealed a vast excess of capsids in the 
loading fractions.   
Due to very high imidazole concentrations in higher number fractions and the fact that this 
was not very well tolerated by cells (data not shown), only fractions 1-65 were used to 
transduce CHO-EpCAM cells. Flow cytometry analysis revealed, that similar if not higher 
transduction was achieved when the same volume of elution fractions 51-53 was used to 
transduce cells than with loading fractions 7-10 (Figure 37A). Combined with data obtained 
from qPCR, this clearly showed that eluted particles were more infectious although they had 
significantly lower titers. In accordance with previous AAV IMAC experiments, it is safe to 
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assume that particles in fractions 51-53 were displaying the Ec1 DARPin and therefore bound 
to the HisTrap column and were able to specifically transduce EpCAM-positive cells. A 
considerable amount of AAVs in loading fractions 7-10 contained a genome but were most 
likely DARPin-deficient and could not transduce CHO-EpCAM cells.  
 
Figure 37: IMAC-purified EpCAMHis-AAV transduces receptor-positive cells. 20 µl of the collected fractions of 
EpCAM-AAV IMAC purification were used to transduce (A) CHO-EpCAM or (B) CHO-K1 cells. Cells were analyzed 72h 
later for EGFP expression. Only the first 65 fractions were included to avoid to high imidazole concentrations killing the 
cells. Eventually, only in fractions 1-53 were enough cells alive to analyze EGFP expression. Loading fractions 7-10 and 
elution fractions 51-53 are indicated.  
Nevertheless, the transduction that was observed for loading fractions 7-10 was either based 
on unspecific transduction of VP1/VP3-only particles or these fractions still contained 
EpCAMHis-AAV, implying that not all vector particles were able to bind to the HisTrap 
column. For clarification, receptor-negative CHO-K1 cells were transduced with 20 µl of the 
same fractions as before. In case transduction was due to unspecific VP1/VP3-only particle 
cell entry, the same transduction efficiency as on CHO-EpCAM cells would be observed on 
CHO-K1 cells. But EGFP expression 72 hours after transduction was negligible for all 
fractions. If at all, slightly higher transduction efficiency in the range of 0.5% was observed 
for loading fractions 7-10 (Figure 37B). Thus, transduction of CHO-EpCAM cells with 
loading fractions must have been caused by DARPin-displaying EpCAMHis-AAV particles 
that were not able to bind to the column. This indicates that although it was possible to purify 
EpCAMHis-AAV using IMAC, the procedure was still not as efficient as described for 
Her2His-AAV (Münch, 2013). One possible explanation might be, that the His tag interacts 
with the modified C-cap or the ankyrin repeats of the Ec1 DARPin preventing efficient 
binding to the HisTrap column. To further improve the purification, column binding 
conditions could be modified to be less stringent and to allow more AAV particles to bind.  
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3.2.4.2 Enhanced transduction of purified EpCAMHis-AAV 
Analysis of IMAC-purified EpCAMHis-AAVs had demonstrated that particles were able to 
bind the column material and were still infectious and specifically transduced EpCAM-
positive cells. Although AAV vector particles are inherently more stable and less affected by 
storage conditions such as pH, salt concentrations and temperature compared to the enveloped 
lentiviral vectors, downstream processes of AAV IMAC purification must ensure their 
integrity. In addition, buffer conditions were already shown to be critical for transduced cells 
which might be especially pronounced for primary material and in vivo applications. 
Therefore, respective elution fractions were pooled and dialyzed against PBS to get rid of 
high salt and imidazole concentrations. In parallel, the same procedure was performed for 
EpCAMHis-AAV that was only iodixanol-gradient but not IMAC purified.   
Resulting vector particle suspensions were analyzed by qPCR and an equal number of 
genome copies were used to transduce MDA-MB-453 or CHO-EpCAM cells. In general, 
transduction efficiency on MDA-MB-453 cells was higher than on CHO-EpCAM cells 
(Figure 38).  
 
Figure 38: IMAC purification enhances EpCAM-AAV-mediated transduction. (A) MDA-MB-453 or (B) CHO-EpCAM 
cells were transduced with conventionally purified EpCAMHis-AAV or IMAC-purified EpCAM-AAV (GOI 60,000, each) or 
were left untransduced. Transgene expression was analyzed by flow cytometry 72 h post transduction as a measure of 
transduction. (Münch et al, 2015) 
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Remarkably, transduction was strongly enhanced with IMAC-purified EpCAMHis-AAV. 
Percentage of GFP-expressing cells increased from 63% to 99% and the same tendency was 
true for the mean fluorescent intensity of MDA-MB-453 cells. Transduction with 
conventionally purified EpCAMHis-AAV resulted in only 5% of GFP-positive CHO-EpCAM 
cells but increased more than 10-fold with IMAC-purified EpCAMHis-AAV (Figure 38). 
These data clearly show that IMAC-purified AAV vector particles are superior in transduction 
of receptor-positive cells due to the depletion of genome-packaged but DARPin-deficient 
vector particles.  
3.2.5 Non-malignant epithelial cells are less susceptible for EpCAM-AAV than 
tumor cells 
The results described in the previous chapters prove that AAV vectors can be designed to 
specifically and efficiently target EpCAM-positive tumor cells. But EpCAM is not only 
abundantly expressed on primary tumors and metastases of most epithelial malignancies, it is 
also expressed in normal epithelial tissues (Simon et al, 2013).   
Therefore, non-malignant epithelial cells could potentially be a target for EpCAM-AAV. 
Depending on the application of the vector this might be critical. In a therapeutical setting 
with the aim of targeting and killing tumor cells in vivo it may cause severe side effects if 
healthy cells were affected as well. To verify the susceptibility of non-malignant EpCAM-
positive cells to EpCAM-AAV, primary epithelial cells were transduced. Additionally, gene 
transfer into mice transgenic for human EpCAM was monitored.  
3.2.5.1 Transduction of primary human mammary epithelial cells 
To determine whether EpCAM-AAV would be able to transduce normal epithelial cells, 
primary cells were obtained and cultivated. Since breast cancer derived tumor cell lines 
MDA-MB-453 and MCF-7 were shown to be susceptible for EpCAM-AAV (3.2.2.1 and 
3.2.2.2), human mammary epithelial cells (HMECs) isolated from adult female breast tissue 
were chosen for this experiment.   
Expression of EpCAM as well as Her2/neu was confirmed by staining against both antigens 
and subsequent flow cytometry analysis.  The whole cell population was positive for both cell 
surface marker, although Her2/neu expression seemed to be a bit more homogenous (Figure 
39A). In general, expression was moderate compared to expression levels observed on tumor 
cell lines.  
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Figure 39: Transduction of human mammary epithelial cells (HMECs) using AAV vectors. (A) Primary HMECs 
isolated from adult female breast tissue were obtained from LONZA and cultivated as recommended. After passaging twice, 
cells were stained with anti-Her2-PE or anti-EpCAM-PE antibody and analyzed for respective surface expression. (B) 
HMECS were either transduced with AAV2 (GOI 7.200) or with one of the targeted vectors Her2-AAV or EpCAM-AAV 
with high (upper panel) or low (lower panel) GOI. After three days, cells were analyzed for GFP expression by flow 
cytometry.  
Primary HMECs were then transduced with AAV2, Her2-AAV or EpCAM-AAV. Analysis of 
GFP expression 72 h later revealed a strong transduction of cells that were incubated with 
AAV2. In contrast, transduction with either Her2-AAV or EpCAM-AAV at a GOI of 36.000 
resulted in only a few GFP-positive cells. Even when a 25-fold higher GOI than with AAV2 
was used to transduce HMECs, only 2-4% of cells were GFP-positive. These data 
demonstrate that while HMECs are generally susceptible for AAV transduction, they were 
only poorly transduced by EpCAM-AAV. 
3.2.5.2 Administration of EpCAM-AAV into mice transgenic for hEpCAM 
One of the challenges of developing medical products targeting human proteins is the lack of 
relevant in vivo models to study biodistribution, efficacy and side effects. A way to avoid 
these problems is the use of transgenic animals. McLaughlin et al. generated a mouse model 
expressing the human EpCAM epithelial-specifically in a pattern very similar to that observed 
in humans (McLaughlin et al, 2001). These mice were bred and analyzed for transgene 
expression and then used to evaluate gene transfer by EpCAM-AAV into normal epithelial 
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tissue in vivo. For this purpose, EpCAM-AAV was equipped with the luciferase transgene to 
allow non-invasive monitoring of gene transfer.  
 
Figure 40: In vivo administration of EpCAM-AAV. EpCAM-AAV transferring the luciferase gene (2×1010 vector 
genomes) was i.p. injected into C57BL/6 or C57BL/6-Tg EpCAM mice. Three days after vector administration luciferase 
signals were analyzed by in vivo imaging. Luciferase signal intensity is expressed as photons/second/square 
centimeter/steradian.  
Three days after i.p. vector administration into C57BL/6 wildtype and C57BL/6 Tg EpCAM 
transgenic mice, weak luciferase signals were detected in the abdomen of both mice (Figure 
40). Further analysis revealed that the signals originated from the intestines but that they did 
not significantly differ in intensity from another. This indicates that normal epithelial tissue 
expressing human EpCAM may not be susceptible for EpCAM-AAV in vivo but that the 
observed signals were rather due to minimal unspecific uptake of the vector particles in 
wildtype and transgenic animals.  
3.2.6 Detection and modification of tumor cells using EpCAM-AAV 
EpCAM is a surface marker of human epithelial tissue and derived cancer cells but 
intriguingly it is also described to be expressed on cancer stem cells (CSCs) and circulating 
tumor cells (CTC) of various histotypes (Visvader & Lindeman, 2008; Gires et al, 2009; 
Pantel et al, 2008). CTCs are tumor cells that have disseminated from the primary tumor and 
circulate in the peripheral blood. To fathom whether EpCAM-AAV could be useful in CTC 
research and diagnosis, its capacity to find its target cells even when they are strongly 
underrepresented was evaluated.  
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3.2.6.1 EpCAM-AAV specifically detects strongly underrepresented tumor cells 
One of the prerequisites for this approach was that even a few tumor cells could be detected 
when they were strongly underrepresented in a cell mixture. To verify whether EpCAM-AAV 
could be used to detect and modify tumor cells in patient samples, a number of preliminary 
experiments were performed.  
Therefore, healthy human donor blood was used to purify PBMCs by density gradient 
centrifugation. PBMCs were then mixed in different ratios with MDA-MB-453 cells 
following transduction with EpCAM-AAV. Expression of GFP as well as the tumor surface 
marker EpCAM was analyzed two days later by flow cytometry (Figure 41A).   
 
Figure 41: EpCAM-AAV specifically detects strongly underrepresented tumor cells mixed with human PBMC. (A) 
Schematic drawing of the experimental outline. Human PBMCs were purified by density gradient centrifugation (30 min, 
1800 rpm) using Histopaque. Remaining erythrocytes were subsequently lysed (20 min, 37°C, 0.86% ammonium chloride) 
and cells were washed with PBS. PBMCs alone or mixed in the indicated ratios with MDA-MB-453 cells were transduced 
with EpCAM-AAV (GOI=1,500). After 48 h cells were analyzed by flow cytometry for EpCAM and GFP expression (as a 
measure of transduction). (B) Samples were analyzed for EpCAM using an anti-EpCAM-PE antibody and GFP expression. 
Representative flow cytometry data are shown. (Münch et al, 2015) 
A sample exclusively containing PBMCs was transduced with EpCAM-AAV as control. And 
as expected, neither EpCAM nor GFP expression could be detected demonstrating that no 
unspecific antibody staining or transduction of PBMCs occurred. In PBMC/MDA-MB-453 
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mixtures, EpCAM-AAV basically tracked all of the tumor cells, even when these made up 
only 0.3% of all cells. The fluorescence intensity of these cells was at least 100-fold above 
that of EpCAM-negative cells (Figure 41B). Thus, EpCAM-AAV was able to specifically 
detect strongly underrepresented tumor cells with remarkable efficiency.  
3.2.6.2 EpCAM-AAV detects low numbers of tumor cells in human blood 
As shown in the previous chapter, EpCAM-AAV was able to discriminate between EpCAM-
positive and -negative cells within a cell mixture. But in this experiment, mononuclear cells 
were already purified and separated from whole blood before they were mixed with tumor 
cells. Eventually, blood samples of cancer patients with circulating tumor cells are a greater 
challenge. Not only are tumor cells usually very rare, but the whole sample is more complex. 
Therefore, this situation was mimicked by mixing MDA-MB-453 tumor cells into whole 
human blood of healthy donors (Figure 42A). Density gradient centrifugation was performed 
as described above before addition of EpCAM-AAV and 48 h cultivation. Subsequently, 
samples were stained with anti-EpCAM-PE and anti-CD45-APC antibody, fixed and analyzed 
by flow cytometry. Debris, doublets and high CD45+ cells (marker for hematopoietic cells) 
were excluded. Whereas no transduction by EpCAM-AAV was observed when no tumor cells 
were present, the vector detected more than 90% of tumor cells (constituting between several 
thousand down to a few hundred cells) present in several million blood cells (Figure 42B). 
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Figure 42: EpCAM-AAV detects low numbers of tumor cells in human blood. (A) Workflow of the experimental 
procedure. Varying numbers of MDA-MB-453 tumor cells were mixed with 7.5 ml whole human donor blood and 
mononuclear cells were separated via density gradient centrifugation. The cell mixture was then transduced with EpCAM-
AAV, cultivated for 48 h and analyzed by flow cytometry for EpCAM and GFP expression. (B) FACS data of a sample 
containing whole blood without addition of MDA-MB-453 cells (left) or sample 3 (middle) and 4 (right) also shown in Table 
4. Representative dot plots are shown. The number of events in each of the two gates containing EpCAM-positive cells is 
indicated. (Münch et al, 2015) 
Remarkably, even when less than 100 tumor cells were present, most of these were tracked by 
EpCAM-AAV (Table 4). Interestingly, in control samples without tumor cells a few EpCAM-
positive cells were detected by the anti-EpCAM antibody but none of these events were GFP-
positive, suggesting that this approach may be less prone to false-positive signals than 
available detection systems that rely on antibodies.  
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Table 4: Data overview of seven samples and controls.  
 total cells 
EpCAM+ 
cells 
EpCAM+GFP+ 
cells 
EpCAM-
GFP+ cells 
transduced 
EpCAM+ 
cells  [%] 
sample 1 5,689,640 44,078 41,777 250 94.78 
sample 2 5,974,121 11,577 11,042 12 95.38 
sample 3 6,252,561 9,470 9,050 24 95.56 
sample 4 5,818,601 157 144 3 91.72 
sample 5 4,001,921 92 79 1 85.87 
sample 6 6,611,121 17 12 10 70.59 
sample 7 3,603,443 7 6 17 85.71 
control 1 5,690,000 4 0 8 0 
control 2 4,004,080 17 0 5 0 
control 3 6,318,040 2 0 18 0 
Samples 1-7 contained decreasing numbers of MDA-MB-453 tumor cells. Control 1 and 2 contained no tumor cells but were 
incubated with EpCAM-AAV, while control 3 contained neither tumor cells nor vector. (Münch et al, 2015) 
These data clearly indicate, that EpCAM-AAV is able to detect and modify a few tumor cells 
present in a complex blood sample. Although many parameters have yet to be optimized, the 
newly generated and characterized EpCAM-AAV could be a useful tool in CTC research.  
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4 Discussion 
Viral vectors have evolved to powerful tools in research and development and have proven to 
be indispensable in gene therapy. Nowadays, increasing efforts are being made to design and 
engineer these vectors to meet the requirements of researchers, clinicians and patients. 
Guaranteeing safe and efficacious gene transfer remains one of the main challenges in 
vectorology, driving the development of selective receptor-targeted viral vectors. The general 
concept of redirecting viruses to a receptor of choice is based on two simple principles: i) 
ablation of natural receptor recognition and ii) introduction of a targeting ligand to alter the 
viral tropism. Using this strategy, lentiviral and AAV vectors targeting cell surface receptors 
of choice were developed in this thesis. Lentiviral vectors pseudotyped with the MV 
glycoproteins and a third receptor attachment protein were generated as tool to challenge the 
MV membrane fusion model for a better understanding of the MV biology and as potential 
gene therapy vectors. The novel EpCAM-targeted AAV was generated for the detection and 
modification of rare cell populations.  
4.1 Implications for the mechanism of measles virus-triggered membrane 
fusion 
Attachment to cellular receptors and entry into the host cell are the first steps in viral 
infection. Cell entry by enveloped viruses depends on fusion of the viral envelope with the 
host cell membrane either directly at the cell surface or following virus internalization. This 
critical event is mediated by viral glycoproteins which are highly regulated to ensure proper 
timing and localization of the fusion. Membrane fusion involving two different viral 
glycoproteins is especially complex and less well understood than that of viruses having 
receptor attachment and membrane fusion combined in a single protein. As representatives of 
the first group, MV H and F are known to act concertedly to mediate cell entry. It is assumed 
that fusion is triggered upon binding of H to one of the three MV receptors, leading to 
conformational changes in H that are passed on to F (fusion-helper function of H). This thesis 
describes the generation of lentiviral vectors pseudotyped with engineered MV envelope 
protein complexes in which receptor attachment and fusion-helper function of H have been 
separated onto two transmembrane proteins to study the MV fusion mechanism.   
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4.1.1 Lentiviral particles as core for the MV glycoproteins 
For engineering the MV glycoprotein complex and eventually separating the receptor 
attachment function from H, the MV-pseudotyped LV targeting system established by Funke 
et al. (Funke et al, 2008) was modified. HIV-1-derived lentiviral vectors were pseudotyped 
with cytoplasmic tail-truncated variants of F and H. The latter harbored the four point 
mutations Y481A, R533A, S548L and F549S to ablate natural receptor recognition 
(Vongpunsawad et al, 2004) and thereby remove receptor attachment function from H. 
Instead of presenting a targeting ligand fused to H, the system was complemented by an 
artificial third transmembrane protein binding to Her2/neu. Vectors pseudotyped with this 
envelope triad conferring receptor attachment, fusion-helper and fusion function transduced 
Her2/neu-positive cells efficiently and even revealed higher or equal infectivity compared to 
the convential targeting vector or unmodified MV-LV. This is the first demonstration that in 
such a setting a paramyxovirus protein complex mediates cell entry equally well as in the two-
transmembrane-protein-based setting. Transfer of receptor attachment to a third 
transmembrane protein has been described for a totally different enveloped virus, i.e. the 
alphavirus Sindbis virus. Also in this case, lentiviral vectors were pseudotyped. Though 
receptor attachment was mediated by membrane-bound CD20-specific antibody (Yang et al, 
2006), vector particle cell entry relied on endocytic uptake and, more importantly, was 
triggered by low pH and not receptor contact. Moreover, substantial background transduction 
was observed even in the absence of the target receptor due to a residual receptor recognition 
of the Sindbis E2 protein (Zhang et al, 2010) clearly revealing the differences between both 
systems.   
The decision to use MV-pseudotyped lentiviral vectors instead of the virus itself was based on 
rational considerations: i) LVs can be more easily engineered and generated from plasmid 
DNA and ii) the modified MV glycoproteins used for pseudotyping exhibit a receptor usage 
identical to that of unmodified MV glycoproteins (Funke et al, 2008; Frecha et al, 2008). 
Because of alterations required for incorporation of H and F into the lentiviral envelope, one 
could argue that these proteins behave differently in the LV setting. But cytoplasmic tail-
truncated variants F∆30 and H∆18 have been successfully used for the retargeting of lentiviral 
vectors (Funke et al, 2008; Anliker et al, 2010). Previous studies demonstrated that the 
cytoplasmic tail of F is not required for cell surface expression and membrane fusion (Moll et 
al, 2002). Likewise, H can be truncated by 20 amino acids without losing its fusion-helper 
function (Moll et al, 2002) . A recombinant MV with F∆30 and H∆20 was fully infectious and 
replication-competent, although glycoprotein incorporation rates were reduced upon 
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cytoplasmic tail truncation (Moll et al, 2002; Cathomen et al, 1998b). Interestingly, it has also 
been suggested that these truncations enhance the fusogenicity of F and H (Cathomen et al, 
1998b) implying that the MV glycoprotein complex in D9.29-LV particles may be in a 
preactivated state. It is, however, evident from data in this thesis that the fusion-helper 
function of H is required for D9.29-LV cell entry and that close contact of cells and vector 
particles is not sufficient for fusion initiation. Identical to MV characteristics, D9.29-LV cell 
entry was pH-independent and sensitive towards the F protein-specific fusion inhibitory 
peptide (FIP) as well as neutralizing antibodies. In addition, the H/F fusion machinery of 
D9.29-LV was active only in presence of the target receptor Her2/neu.  
4.1.2 Do further receptors for MV exist? 
Generally, these data could also be explained by the existence of a so far unidentified MV 
coreceptor. Since D9.29-LV transduced both human and hamster Her2/neu-positive cells, such 
a coreceptor must be expressed in both species. All data available cannot explicitly exclude 
this possibility but data supporting the idea of a MV coreceptor have not been published 
except for a report in 2007 in which neurokinin-1 was proposed as potential coreceptor for F 
on neurons (Makhortova et al, 2007). In 2010, Watanabe et al. reported that cyclophilin B, 
among others serving as CD147 ligand, was incorporated into the membranes of MV virions 
(Watanabe et al, 2010). They demonstrated that the binding partner CD147 is involved in MV 
infection of HEK-293 cells, since CD147-specific antibodies significantly reduced MV 
infectivity. Furthermore, MV infectivity was slightly increased on CHO cells stably 
expressing CD147 in comparison to parental CHO cells. Initially, they suggested that CD147 
could be the up to that time unidentified MV receptor on epithelial cells. Although this was 
later contradicted by the identification of nectin-4 (Mühlebach et al, 2011; Noyce et al, 2011), 
the cyclophilin B/CD147 interaction can possibly be seen as a natural counterpart of the 
D9.29/Her2/neu interaction. One of the main differences in both settings are the protein-protein 
interaction affinities, which are high for D9.29 and Her2/neu (Zahnd et al, 2007; Steiner et al, 
2008) and presumably orders of magnitudes lower for cyclophilin B and CD147 (Pakula et al, 
2007). Consequently, D9.29-LV particles were substantially more active in entering cells in the 
absence of natural receptor attachment. In concordance with a putative F coreceptor as well as 
data presented by Watanabe et al. and in this thesis, one can conclude that attachment of 
particles to cells is sufficient to trigger MV fusion without a need for H itself binding to a 
receptor.  
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4.1.3 The H/F interaction 
In recent years, many groups worked on understanding the structural and molecular interplay 
of H and F as well as H and its receptors. Structural analysis of H head domains bound to 
SLAM revealed new insights into the mechanism of fusion triggering. Two discrete forms of 
the H/SLAM tetrameric assembly were identified and were suggested to represent a prefusion 
form of H immediately after receptor binding and a postfusion receptor-bound form 
(Hashiguchi et al, 2011b). The reorganization that takes place from form I to form II is 
interpreted as shift of the noncovalent H dimer-dimer interface while the dimer structure itself 
remains intact (Hashiguchi et al, 2011b; Plemper et al, 2011). Still, it is widely assumed that 
the H heads are not responsible for the direct interplay between H and F but rather a H-stalk/F 
interaction (Ader et al, 2012; Apte-Sengupta et al, 2013; Navaratnarajah et al, 2012; Paal et al, 
2009). Biochemical and mutational analyses mapped the so-called central fusion activation 
segment to stalk residues 84-117 (Navaratnarajah et al, 2012; Navaratnarajah et al, 2014). 
Data of this thesis show that conformational and/or structural changes can be triggered even if 
receptor binding is carried out not by H but by an additional protein. The fact that D9.29-LV 
was not able to enter cells in the absence of H or when the H/F complex formation was 
impaired (H*mut∆18) indicates a need for H to interact with F in order to achieve membrane 
fusion.  
This was corroborated by neutralization experiments shown in Figure 21. D9.29-LV cell entry 
was blocked by three out of four MV H-specific monoclonal antibodies. Putative epitopes of 
all four antibodies can be mapped on the globular head domain of H. According to this model, 
K71 and K29 bind in close proximity to the natural receptor binding sites and correspondingly 
to the introduced mutations in Hmut, whereas Nc32 and L77 epitopes are located more 
distantly (Figure 43). Furthermore, the MAbs L77 and K71 have recently been shown to 
neutralize MV-LV vectors (Kneissl et al, 2012). Steric hindrance effects and thus prevention 
of Her2/neu binding by the antibodies were excluded. Interestingly, Tahara et al. identified 
the so-called antigenic site vi, which is located at the bottom, membrane-proximal site of the 
H blade and acts as effective neutralization epitope (Figure 43). In contrast to many 
neutralizing antibodies inhibiting the receptor binding, antibodies binding to the vi site seem 
to interfere with H/F interaction (Tahara et al, 2013). The epitope of L77, which was most 
efficient in neutralizing D9.29-LV, is in spatial proximity to the vi site. This indicates and 
supports the idea that H plays an active and indispensable role in the membrane fusion 
process of D9.29-LV.  
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Figure 43: Putative antibody epitopes on the H globular head domains. (A) Sphere representation of the H dimer crystal 
structure (Hashiguchi et al, 2007). The stalk, transmembrane, and cytoplasmic regions are depicted as vertical lines, with two 
horizontal lines indicating disulfide bonds. Putative antibody binding sites are indicated in orange, red, green, and blue. 
Residues mutated in Hmut∆18 to ablate natural receptor tropism are shown in yellow. Antigenic site vi is shown in purple 
(Tahara et al, 2013). The virus membrane is illustrated as a light gray box. Protein Data Bank [PDB] ID 2ZB5; modified with 
PyMOL. 
4.1.4 Conformational changes to activate membrane fusion 
Currently, two alternative conformations for the H head domains shape new MV fusion 
mechanism concepts. The so-called “heads-up” conformation with heads located above the 
stalks is derived from soluble H heads cocrystallized with their receptor (Hashiguchi et al, 
2011b). The relatively new idea of a “heads-down” conformation relies on structures obtained 
from entire hemagglutinin-neuraminidase (HN) ectodomains of the cognate Newcastle disease 
virus (NDV) and the parainfluenza virus 5 (PIV5) (Yuan et al, 2011; Welch et al, 2013). In 
this conformation, the heads of both or only one HN dimer, respectively, are tilted and form 
interactions with the sides of the stalks. According to the stalk exposure model described for 
other paramyxoviruses (Yuan et al, 2011; Bose et al, 2014), the heads-down conformation 
blocks HN-stalk/F interactions. Upon receptor binding, the heads move up and uncover 
residues in the HN stalks that can interact with and ultimately activate F. But it has been 
noted, that unlike other paramyxoviruses, MV glycoproteins already form a complex within 
the cell which would require at least a one head-up/one head-down configuration to allow the 
association of H and F (Navaratnarajah et al, 2014; Mateo et al, 2014). Thus, further 
rearrangements would be necessary for MV fusion triggering. Similarly, the so-called three-
step safety-catch model describes the pre-fusion complex in a heads-down conformation 
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(Brindley et al, 2014). The crucial difference to the first model is that despite the heads-down 
conformation, the F interaction site in the H stalk is accessible. After assembly of H/F0 
complexes in the endoplasmic reticulum, the F protein is proteolytically matured which in 
turn reduces the strength of the H/F interaction. This is assumed to prepare the complex for 
physical separation upon fusion triggering. The H heads act as safety catch to suppress 
spontaneous reorganization of the central stalk region. Only after receptor binding and 
transition into the heads-up conformation the central stalks are unwinded triggering refolding 
of F (Brindley et al, 2014).   
The absolute necessity of H binding to one of its receptors for fusion triggering is challenged 
by data described in this thesis but also by a report of a recombinant MV incorporating a 
headless H (Brindley et al, 2013). It was shown that the stabilized H-stem was sufficient for 
triggering membrane fusion although the virus was severely growth impaired. Here, 
spontaneous rearrangements of the central stalk region seemed to serve as molecular trigger. 
Altogether, it is not direct binding of an MV receptor to H that induces fusion and, possibly, 
also heads-down to heads-up transition, but rather short-range changes in the 
microenvironment of H and F (Plemper et al, 2011), such as the close proximity of the target 
cell membrane mediated by binding of D9.29 to Her2/neu (Figure 44). These then drive 
irreversible changes and ultimately membrane fusion. 
 
Figure 44: MV fusion mechanism model with separated receptor attachment and fusion-helper function. H (red), F 
(dark blue) and D9.29 (light blue and gray) reside in close proximity in the viral membrane. Upon attachment of D9.29 to its 
receptor (dark grey), viral and cellular membranes are in close contact and the microenvironment of the MV glycoprotein 
complex changes. This leads to rearrangements in the central stalk region of H (depicted in yellow) which ultimately triggers 
F, release of the fusion peptide and membrane fusion.  
Taking the colocalization of D9.29 with the MV glycoproteins into account, D9.29 possibly 
replaces one of the H dimers physically and functionally or closely associates with the MV 
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complex, thereby transcomplementing the receptor binding-deficient Hmut∆18. This is 
reminiscent of work by Brindley et al. demonstrating transcomplementation of the MV fusion 
complex by combining an H dimer deficient for F triggering but able to bind to MV receptors 
with an H dimer competent for F triggering but lacking receptor binding function (Brindley et 
al, 2012).  
4.2 Targeting AAVs by protein display 
Even before AAV crystal structures had become available, several groups aimed at modifying 
the viral capsid to alter its tropism or equip it with desirable features such as enhanced 
transduction or evasion of neutralizing antibodies. Already in 1999, Girod et al. demonstrated 
that insertional mutagenesis at position 587 can lead to transduction of cells that are normally 
resistant to AAV2 (Girod et al, 1999). Insertion of the 14-amino-acid peptide L14 containing 
an RGD motif resulted in vector particles binding to cellular integrin receptors. Although 
many other positions have been experimentally tested, peptide ligands inserted at position 
587/588 dominated due to their location at the apex of the second highest peak of the AAV 
capsid (Xie et al, 2002). Only position 453, which is even more exposed on the viral capsid, 
proved to be equivalent or superior when an RGD-containing peptide was inserted (Boucas et 
al, 2009). Peptide ligands of up to 34 amino acids incorporated into the capsid have been 
shown to be tolerated and to enhance transduction levels in endothelial cells, tumor cell lines, 
cardiomyoblasts and several other cell types (Schaffer et al, 2008). However, the limitation of 
peptide length as well as the absence of secondary and tertiary structures often resulted in 
only low affinity peptides and thus a weak receptor-ligand interaction.    
Consequently, the display of whole proteins may open up new possibilities leading to more 
versatile AAV retargeting systems. First reports of a scFv directed against CD34 fused to the 
N-terminus of VP2 (Yang et al, 1998) proved that this position can be used to incorporate 
large proteins. However, intact viral particles were only produced in the presence of 
unmodified VP1, VP2 and VP3 in addition to scFv-VP2, titers were severely compromised 
compared to wildtype AAV2 and natural receptor binding sites were still present (Yang et al, 
1998). Similarly, others were not able to efficiently re-direct AAV with scFv-VP2 fusion 
proteins. AAV2 incorporating anti-GluRD, anti-CD30, anti-CA19 or anti-CEA scFv-VP2 
were not able to specifically transduce targets cells (Boucas, Jorge Miguel Martins, 2008; 
Reul, 2013). One possible explanation could be that scFv fused to VP2 cannot properly fold 
due to the fact that AAV capsid assembly takes place in the nucleus which does not allow the 
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formation of disulfide bonds usually required for scFv folding (Reul, 2013).   
Extending this approach, Lux et al. fused GFP to the VP2 N-terminus in order to enable 
visualization of AAV trafficking through the cell (Lux et al, 2005). Contrary to what had been 
published before (Yang et al, 1998; Warrington et al, 2004), they were able to show that 
particles incorporating GFP-VP2 did not require unmodified VP2 complementation and that 
GFP-tagged virions were fully infectious. Since all of these studies reported that large 
proteins can be incorporated into the AAV capsid using the VP2 N-terminus, if only 
physically and not functionally as seen for scFvs, Münch et al. chose this position for the 
fusion with a Her2/neu-specific DARPin in combination with capsid mutations to ablate 
HSPG-binding (Münch et al, 2013). DARPins are ideal alternative binding proteins in the 
context of AAV retargeting because they are of small size, highly stable, lack disulfide bonds 
and can be selected using high-throughput library screens to become a high affinity binder to 
a given antigen (Stumpp & Amstutz, 2007). The resulting Her2-AAV was the first fully 
retargeted AAV with high affinity and selectivity for Her2/neu-positive tumor cells in vitro 
and in vivo.    
In this thesis, the same retargeting strategy was employed to develop AAV vectors that 
specifically transduce EpCAM-positive cells. For this purpose, two different DARPins, 
namely Ec1 and Ac1, which were previously selected to bind to EpCAM, were used. They 
were selected by two different methods and were also shown to differ in affinities. While Ec1 
binds to EpCAM with picomolar affinity, association and dissociation of Ac1 is rather 
biphasic and lies in the nanomolar range (Table 3). It was speculated that Ac1 recognizes an 
epitope on EpCAM which is present in two different conformations and is bound with two 
different affinities (Stefan et al, 2011). In contrast, only Ec1 competed for binding with the 
anti-EpCAM antibody MOC31 proving that epitopes of these two DARPins were not 
overlapping. Thus, it was expected that they behaved differently as targeting ligands for AAV 
vectors. And indeed, Ec1-AAV produced slightly higher titers and, more importantly, 
transduced EpCAM-positive cells more efficiently. Possible explanations for these differences 
include, but are not limited to, the higher affinity of Ec1 to EpCAM or its binding epitope. It 
might be that efficient uptake of the AAV only occurs when binding to EpCAM is extremely 
stable. Alternatively, the Ac1 epitope could be less accessible for a whole virus particle. Since 
EpCAM is a highly glycosylated protein, binding of Ac1-AAV could be sterically deterred. 
Of course the superiority of Ec1-AAV could also rely on effects inherent to AAV vector 
particle production. It was shown in chapter 3.2.1.1 that Ec1-VP2 did not affect packaging 
efficiency in general. But what remains unknown is the percentage of genome packaged 
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versus empty DARPin-presenting particles. Eventually, it could be that incorporation of Ac1-
VP2 is more prone to result in empty particles than incorporation of Ec1-VP2. In this case, 
less functional EpCAM-targeted particles would be present in Ac1-AAV preparations leading 
to lower transduction efficiencies. Interestingly, when used as targeting ligand in the lentiviral 
vector context, DARPin Ac1 results in higher titer vectors than Ec1 (Bender and Buchholz, 
unpublished). This clearly demonstrates, that characteristics of targeting ligands in soluble 
form or even in combination with another viral vector may not reflect  its potential in the 
AAV retargeting system.   
An alternative approach to retarget AAVs relies on indirect coupling of the targeting ligand 
(Figure 45). In contrast to strategies described above, the targeting ligand itself is not 
genetically fused to the AAV capsid but interacts and associates with the viral vector and the 
cell surface receptor.  
 
Figure 45: AAV protein display retargeting strategies. Retargeting of AAV vectors can be achieved by either genetic 
(left) or indirect (right) coupling of the targeting ligand with the capsid.  
Bartlett et al. demonstrated that a bispecific F(ab’γ)2 antibody directed against the αIIbβ3 
integrin and the AAV capsid mediated attachment to and transduction of megakaryocytes 
(Bartlett et al, 1999). Additionally, two groups reported that the high affinity avidin-biotin 
interaction can be used as molecular bridge between the AAV capsid and the targeting ligand 
(Ponnazhagan et al, 2002; Arnold et al, 2006). The main advantages of the indirect coupling 
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are that (i) there is no need for a detailed structural understanding of the AAV or the AAV 
fusion proteins, (ii) that the maximal number of targeting ligands is not limited by the number 
of VP2 proteins and (iii) that one AAV vector batch can easily be combined with several 
different targeting ligands. However, this retargeting approach relies on a reversible and 
maybe even transient interaction of capsid and targeting ligand which may be a limiting factor 
for vector uptake and in vivo administration (Büning et al, 2003; Kwon & Schaffer, 2008).  
Possibly, the future of AAV retargeting will benefit from combining the best features of 
different strategies. Post-translational but covalent coupling of a targeting ligand to the AAV 
capsid could be achieved by so-called copper-free click chemistry. This strain-promoted 
azido-alkyne cycloaddition has recently been used to couple fluorescent dyes to the plant 
virus cowpea chlorotic mottle virus (Hommersom et al, 2014) and to functionalize DARPin 
molecules (Simon et al, 2012). Therefore, this method may be suitable to team up AAV and 
DARPin in an even more flexible way.  
4.3 Applications of receptor-targeted viral vectors 
In this thesis, receptor targeting of lentiviral and AAV vectors for different applications has 
been demonstrated, proving the versatility of this approach. While both vector types are 
promising tools, possible limitations, drawbacks and comparisons to other systems will be 
discussed. 
4.3.1 D9.29-LV and derivatives as gene therapy vector 
D9.29-LV has proven to be a valuable tool to investigate the MV fusion mechanism, but 
vectors pseudotyped with such an envelope triad may also represent a novel targeting concept 
for lentiviral vectors. D9.29-LV mediated stable gene transfer and exhibited a 26-fold better 
infectivity-to-particle ratio than the conventional 9.29-LV, where the targeting ligand is fused 
directly to H. Explanations for this enhanced gene transfer activity include, but are not limited 
to, an increased stability of the MV glycoprotein complex, improved conformation and/or 
presentation of the targeting ligand, or establishment of a more suitable distance between LV 
and target cell membrane (Buchholz et al, 1996). It is known that the biophysical properties of 
the targeting ligand can influence and decrease transport of the H-targeting ligand fusion 
protein to the plasma membrane (Friedel et al). Likewise, the H protein type-II 
transmembrane protein topology could disturb the binding capability of some targeting 
ligands. Circumventing the need for a direct modification of H may therefore be beneficial. 
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As proof of concept for the applicability of D9.29-LV for in vivo gene transfer, the vector 
transferring the luciferase gene was systemically injected into mice xenografted with a 
subcutaneously growing SK-OV-3 tumor. Bioluminescence signals were exclusively detected 
in the tumor tissue, proving its targeting potential. While replication-competent vectors and 
oncolytic viruses are the weapons of choice in tumor therapy, D9.29-LV may prove useful for 
functional genomics studies in tumor biology.  
One drawback of this targeting system is that targeting ligands don’t seem to be universally 
exchangeable. Transduction of cells expressing CD4, CD20, CD30 or CD8 using the 
respective vector particles was not successful. In some cases, titers improved upon insertion 
of a linker between transmembrane domain and targeting ligand. This helix-forming peptide 
linker designed to compensate the distance of the 9.29 to G3 Her2/neu binding sites consists 
of A(EAAAK)nA repeats and was already described to effectively separate bifunctional 
fusion proteins (Arai et al, 2001). Assuming that the length of helix per residue corresponds to 
1.5 Å (Brändén & Tooze, 1991) and that one helical turn consists of 3.6 residues (Berg et al, 
2007), a helical linker with seven repeats results in round about 10 turns and has a length of 
55 Å. At that time, it was only known that DARPin 9.29 was directed against domain I, II or 
III  (Steiner et al, 2008) but not yet the exact binding site. If binding occurred somewhere 
along domain III or II, the distance to the G3 binding domain IV would be in the range of 50-
60 Å (using Pymol and PDB file 1N8Z, (Cho et al, 2003)). Consequently, the DARPin G3 
was one of the targeting ligands benefitting the most, proving that vectors based on this 
targeting concept can be optimized by altering the length of the linker between PDGFR 
transmembrane domain and the targeting ligand.  
4.3.2 EpCAM-AAV in CTC research 
EpCAM is a surface marker of human epithelial tissue and derived cancer cells but 
intriguingly it is also described to be expressed on cancer stem cells (CSCs) and circulating 
tumor cells (CTC) of various histotypes (Visvader & Lindeman, 2008; Gires et al, 2009; 
Pantel et al, 2008). CTCs are tumor cells that have disseminated from the primary tumor and 
circulate in the peripheral blood. Equipped with the capacity to initiate new tumors and strong 
invading potential, a subpopulation of CTCs is responsible for the formation of metastases 
and their presence is believed to be an indicator of poor prognosis (Baccelli et al, 2013; Pantel 
et al, 2008). Understandably, the detection and characterization of these cells has gained 
considerable attention in recent years. One of the problems in this field is that CTCs are 
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usually present only in low numbers in the blood of many cancer patients and that extremely 
sensitive and reliable techniques are required. The most commonly used methods rely on 
antibody-mediated detection of EpCAM-positive CTCs. One of the systems, an automated 
immunomagnetic enrichment and staining system called CellSearch, was already approved by 
the US Food and Drug Administration for monitoring treatment effectiveness of patients with 
metastatic breast, colon and prostate cancer (Hayes et al, 2006; Cohen et al, 2008; de Bono, 
Johann S et al, 2008). However, these techniques only allow staining of CTCs via binding of 
fluorophore-coupled antibodies to the cell surface. As a viral vector, EpCAM-AAV provides 
antibody-like specificity combined with the possibility to modify these cells either to express 
a fluorescence protein of choice or any other desired transgene that can be packaged. Proof of 
principle experiments demonstrated that EpCAM-AAV specifically and efficiently detected 
tumor cells strongly underrepresented in human blood at a high signal-to-noise ratio. 
However, this has to be confirmed with patient material in direct comparison to state of the art 
methods to make a realistic assessment of the vector. If necessary, several parameters can still 
be further optimized. These include use of single-stranded AAV vectors which may offer a 
second layer of specificity. The second strand synthesis prior to transgene expression is 
hampered in cells of the hematopoietic system, but proceeds efficiently in tumor cells (Hacker 
et al, 2005; Schuhmann et al, 2010). Additionally, further optimizing the affinity purification 
for EpCAM-AAV and thereby increasing the yield of DARPin-displaying particles will be 
beneficial.  
One source for false-positive signals in CTC detection may arise from transduction of non-
malignant epithelial cells present in the blood sample. With the exception of epidermal 
keratinocytes, gastric parietal cells, hepatocytes, thymic cortical epithelial and myoepithelial 
cells, epithelial cells throughout the body are EpCAM-positive and can be stained using an 
anti-EpCAM antibody in immunohistochemical studies (Momburg et al, 1987; Schmelzer & 
Reid, 2008). Nevertheless, the expression profile of EpCAM in non-malignant and malignant 
tissues is different. Variable levels are found in normal epithelial cells, whereas EpCAM is 
usually highly overexpressed in tumor cells (Spizzo et al, 2011). Moreover, the distribution of 
EpCAM molecules at the surface of tumor cells seems to be homogenous, while it is only 
found at the basolateral membrane in normal tissues (Balzar et al, 1999; McLaughlin et al, 
2001). The resulting limited in vivo accessibility of non-malignant tissues was confirmed by 
i.v. administration of the EpCAM-specific monoclonal antibody MOC31 into tumor bearing 
mice (McLaughlin et al, 2001). Similar observations were made with the EpCAM-AAV 
presenting the DARPin Ec1 which is directed against the same epitope as MOC31. The fact 
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that transduction mediated by EpCAM-AAV was clearly receptor density-dependent and that 
primary human mammary epithelial cells as well as mice transgenic for human EpCAM were 
less susceptible for EpCAM-AAV argues that a strong preference for tumor cells is inherent 
to the vector particles.   
It has been suggested that in some cases characterization of CTCs by EpCAM is not sufficient 
to detect the real metastases initiating cells (Baccelli et al, 2013). In part, this could be 
accounted for by a possible epithelial-to-mesenchymal transition (EMT) of carcinoma cells 
which can result in at least a partial downregulation of EpCAM (Kalluri & Weinberg, 2009; 
Yu et al, 2013). This further highlights the potential of EpCAM-AAV in CTC research 
because permanent labelling of EpCAM-positive CTCs without the need for fixation, as 
required for other methods such as the CellSearch system, could be useful in functional EMT 
studies as well.     
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6 Abbreviations 
α             anti 
AAV           adeno-associated virus  
APS           ammonium persulfate  
ATCC          American Type Culture Collection  
bp             base pair  
BSA           bovine serum albumin  
°C             degree Celsius 
cap            capsid protein  
CHO           Chinese hamster ovary  
CMV           cytomegalovirus  
Δ             delta 
DARPin         designed ankyrin repeat protein  
DMEM         Dulbecco’s modified Eagle medium  
DMSO         dimethyl sulfoxide  
DNA           deoxyribonucleic acid   
E. coli          Escherichia coli    
EDTA          ethylenediaminetetraacetic acid  
EGFP          enhanced green fluorescent protein  
ELISA          enzyme-linked immunosorbent assay  
EM            electron microscopy  
Env            envelope protein  
EpCAM         epithelial cell adhesion molecule  
et al.           and others  
F             fusion protein  
FACS          fluorescence-activated cell sorting  
FCS           fetal calf serum  
FIP            fusion inhibitory peptide  
for            forward  
g              gram 
GFP           green fluorescent protein 
GOI           genomes per cell  
H             hemagglutinin 
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Abbreviations 
HCl            hydrochloride  
HEK           human embryonic kidney  
Her2/neu        human epidermal growth factor receptor 2  
his            hexa-histidine motif   
HIV           human immunodeficiency virus  
HMEC         human mammary epithelial cell  
HN            hemagglutinin-neuraminidase 
HPLC          high-performance liquid chromatography 
HRP           horseradish peroxidase  
HSPG          heparan sulfate proteoglycan   
ITR            inverted terminal repeat  
K             potassium 
kDa            kilo Dalton  
kg             kilogram  
l              liter  
LB            Luria-Bertani  
luc            luciferase  
LTR           long terminal repeat  
LV            lentiviral vector  
µ             micro 
MAb           monoclonal antibody  
Mg            Magnesium 
MOI           multiplicity of infection  
mRNA         messenger RNA  
MV            measles virus  
nb             nanobody 
n.s.            not significant 
NDV           Newcastle disease virus  
ORF           open reading frame  
PBMC          peripheral blood mononuclear cells 
PBS           phosphate buffered saline  
PBS M/K        PBS supplemented with Mg/K   
PCR           polymerase chain reaction  
PIV5           parainfluenza virus 5  
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Abbreviations 
rep            viral regulatory proteins  
rev            reverse 
RNA           ribonucleic acid  
rpm            rounds per minute  
scAAV         AAV vector with self-complementary genome  
scFv           single chain Fragment variable 
SDS           sodium dodecyl sulfate   
SDS-PAGE      SDS polyacrylamide gel electrophoresis  
SFFV          spleen focus forming virus  
SLAM          signaling lymphocyte activation molecule  
TEMED         tetramethylethylenediamine  
Tris            tris(hydroxymethyl)aminomethane  
t.u.            transducing unit 
U             unit  
V             volt  
VP            viral protein 
VSV           vesicular stomatitis virus 
VSVG          envelope glycoprotein of VSV  
wt             wildtype 
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